Mutual Fund Series Trust NCSRS Certified semi-annual shareholder report (management investment company)

united states
securities and exchange commission
washington, d.c. 20549

form n-csr

certified shareholder report of registered management
investment companies

Investment Company Act file number 811-21872

Mutual Fund Series Trust

(Exact name of registrant as specified in charter)

225 Pictoria Drive, Suite 450, Cincinnati, Ohio 45246

(Address of principal executive offices) (Zip code)

CT CORPORATION SYSTEM

1300 EAST NINTH STREET, CLEVELAND, OH 44114

(Name and address of agent for service)

Registrant's telephone number, including area code: 631-470-2619

Date of fiscal year end: 6/30

Date of reporting period: 12/31/20

ITEM 1. REPORTS TO SHAREHOLDERS.

(EVENTIDE LOGO)

Semi-Annual Report	December 31, 2020

	Eventide Core Bond Fund

	Eventide Dividend Opportunities Fund
	(formerly, the Global Dividend Opportunities Fund)

	Eventide Exponential Technologies Fund

	Eventide Gilead Fund

	Eventide Healthcare & Life Sciences Fund

	Eventide Limited-Term Bond Fund

	Eventide Multi-Asset Income Fund



























	Eventide Asset Management, LLC
	One International Place, Suite 4210
	Boston, MA 02110
	1-877-771-3836

E V E N T I D E		1

S E M I - A N N U A L R E P O R T

December 31, 2020

Shareholder Letter

Dear Eventide shareholders,

We started Eventide by asking ‘how do we love our neighbors through the way we invest?’ and we have never stopped asking this question. Instead of profiting from company activities that create harm, we seek to embrace companies that are serving the deepest needs of our world.

In a year where the market experienced some of the greatest upheaval in modern times, we saw this purpose hold strong. In 2020, Eventide’s investors allocated over $7 billion dollars of capital toward advances in medical treatment for unmet health needs, safer transportation, clean energy, and cybersecurity. In addition, we added two funds to our fund family and experienced significant growth throughout the firm.

This summer, we launched the Eventide Exponential Technologies Fund (ETIEX, ETNEX, ETAEX, ETCEX) and Eventide Core Bond Fund (ETIRX, ETNRX, ETARX, ETCRX).

A concentrated mutual fund, the Eventide Exponential Technologies Fund seeks long-term capital appreciation by investing in technology companies, including companies in the information technology, communications, and healthcare technology and devices industries. By focusing on small and mid-sized companies with a highly concentrated investment approach, this fund seeks to produce compelling value by targeting large-scale unmet technological needs in society.

The Eventide Core Bond Fund seeks to invest in income-producing securities such as corporate bonds and preferred stocks. We intend that the use of capital by the issuers of these bonds and preferred stocks will have a positive impact on the world. A part of the Core Bond Fund is invested in green bonds (i.e., bonds that allow issuers to use proceeds for environmental projects), social bonds (i.e., bonds that allow issuers to use proceeds for social projects), and sustainable bonds (i.e., bonds that are a combination of green and social bonds).

At Eventide, we seek to invest in companies positioned within the long-term trends that also promote human flourishing–we call these “themes.” Our investment themes heading into the year played out well even through the global pandemic. One such area of focus for us has been cybersecurity. As more and more people started to work remotely in 2020, cyber threats increased and are expected to increase significantly over the next few years. In fact, according to an article published on November 13, 2020 in Cybersecurity Ventures and Cybercrime Magazine, global cybercrime costs are expected to grow by 15 percent per year over the next five years, reaching $10.5 trillion annually by 2025. As protecting sensitive data becomes more of a focus for corporations and governments, we see considerable opportunity for investors to benefit from new and innovative technologies related to this sector.

COVID-19 headlines continued to dominate the second half of 2020. In particular, all eyes were on the vaccine developers and the results of their clinical trials. Because of the high interest, even startup biotech companies related to COVID-19 vaccines received a great deal of attention with immature data. This overflowed to a large increase in funding for biotech in general, and a high degree of speculation about which startups might emerge as winners. These forces came together to create a frothy environment of IPOs and pre-revenue companies.

E V E N T I D E		2

S E M I - A N N U A L R E P O R T

December 31, 2020

While the anticipation of the end of COVID-19 was driving a rally, cyclical growth companies (as opposed to secular growth) generally outperformed during 2020. Our funds generally performed well since they were positioned for market recovery. However, the second half of 2020 was uneven due to periods of secular growth lagging cyclical growth.

In order to help investors to think rationally and strategically about concerns presented by COVID-19, we began a series of special webinar updates in March 2020, communicating regularly about our views of the rapidly evolving pandemic. In these special updates, our CIO, Finny Kuruvilla, MD, PhD, sought to educate others on the virus as well as its implications on market performance. From perspectives related to COVID-19 herd immunity and vaccine efficacy to our views on long-term investing opportunities which could emerge, we committed ourselves to regular communication with financial advisors and investors through this uncertain season.

In the midst of a difficult 2020, Eventide has sought to remain a faithful lighthouse, shining light on investments we believe bring benefit to a world in need of hope. Our commitment to our mission and excellence in our work did not waiver through the pandemic; in fact, our mission has never been so clear. And in a season with much uncertainty, we boldly launched two new funds, an expression of our confidence in the markets and our hope for future flourishing. Our investors responded by allocating more capital into our mutual funds. We started the year with about $4 billion of assets under management, and we ended the year with over $7 billion of assets under management.

As we move into this new year, we remain committed to investing shareholder capital into companies that are innovating and creating value for the global common good. We also remain committed to our employees. Since our office closure on March 13, 2020, Eventide leadership, employees and their families have navigated the nuance and blessing of our new work-from-home lives, together.

We are grateful for your partnership in this mission of “investing that makes the world rejoice^®!” I welcome you to visit our website to read stories about how your investments are impacting the world. The way you invest makes a difference!

Robin John

Co-founder & CEO, Eventide Asset Management

This report is intended for the Funds’ shareholders. It may not be distributed to prospective investors unless it is preceded or accompanied by the current Funds prospectus. To obtain a prospectus or other information about the Funds, please visit www.eventidefunds.com or call 1-877-771-EVEN (3836). Please read the prospectus carefully before investing.

4202-NLD-2/1/2021

E V E N T I D E		3

S E M I - A N N U A L R E P O R T

December 31, 2020

Eventide Core Bond Fund

Portfolio Review (Unaudited)

December 31, 2020

Average Annual Total Return	Since
Through December 31, 2020, ¹ as compared to its benchmark	Inception²
Class N	(0.36)%
Class A without load	(0.35)%
Class A with 5.75% load	(6.08)%
Class C	(0.58)%
Class I	(0.29)%
Bloomberg Barclays U.S. Aggregate Bond Index³	(0.20)%

The performance data quoted here represents past performance. Current performance may be lower or higher than the performance data quoted above. Investment return and principal value will fluctuate, so that shares, when redeemed, may be worth more or less than their original cost. The returns shown do not reflect the deduction of taxes that a shareholder would pay on Fund distributions or on the redemptions of Fund shares. Past performance is no guarantee of future results. Performance figures for periods greater than 1 year are annualized. The Fund’s manager has contractually agreed to waive fees and/or reimburse expenses of the Fund to the extent necessary to limit operating expenses (excluding front-end or contingent deferred loads, taxes, leverage interest, brokerage commissions, expenses incurred in connection with any merger or reorganization, dividend expenses on securities sold short, underlying fund fees and expenses or extraordinary expenses such as litigation) at 0.83%, 1.58%, 0.78% and 0.58% for Class A shares, Class C shares, Class N shares and Class I shares, respectively, through October 31, 2021. Per the Fund’s most recent prospectus, total annual Fund estimated expenses before waiver are 1.50%, 2.25%, 1.45% and 1.25% for Class A, Class C, Class N, and Class I, respectively. Class A shares are subject to a maximum sales charge of 5.75% imposed on purchases and have a maximum deferred sales charge of 1.00% on purchases of $1 million or more made without an initial sales charge and applies to shares sold within 18 months. Class C shares are subject to a maximum deferred sales charge of 1.00% on shares sold within 12 months. For performance information current to the most recent month-end, please call toll-free 1-877-771-3836.

Eventide Core Bond Fund commenced operations on July 31, 2020.

The Bloomberg Barclays U.S. Aggregate Bond Index is a broad-based flagship benchmark that measures the investment grade, US dollar-denominated, fixed-rate taxable bond market. The index includes Treasuries, government-related and corporate securities, MBS (agency fixed-rate pass-throughs), ABS and CMBS (agency and non-agency). Investors cannot invest directly in an index.

Holdings by Industry	% of Net Assets
Agency Fixed Rate		24.0	%
Electric Utilities		18.6	%
Government Owned		11.7	%
Banking		8.9	%
Real Estate Investment Trusts		8.6	%
Electrical Equipment		4.2	%
Insurance		4.1	%
Institutional Financial Services		3.6	%
Technology Services		3.3	%
Government Sponsored		1.9	%
Other / Cash & Cash Equivalents		11.1	%
		100.0	%

Please refer to the Portfolio of Investments in this semi-annual report for a detailed listing of the Fund’s holdings.

E V E N T I D E		4

S E M I - A N N U A L R E P O R T

December 31, 2020

Eventide Dividend Opportunities Fund

Portfolio Review (Unaudited)

December 31, 2020

Average Annual Total Return			Since
Through December 31, 2020,¹ as compared to its benchmarks	Six Month	1 Year	Inception²
Class N	27.28%	25.09%	12.19%
Class A without load	27.29%	25.06%	12.11%
Class A with 5.75% load	20.00%	17.87%	10.09%
Class C	26.71%	24.15%	11.32%
Class I	27.43%	25.35%	12.42%
Russell Midcap Value Total Return Index³	28.14%	4.96%	6.68%
Russell Midcap Total Return Index⁴	28.86%	17.10%	12.67%

The performance data quoted here represents past performance. Current performance may be lower or higher than the performance data quoted above. Investment return and principal value will fluctuate, so that shares, when redeemed, may be worth more or less than their original cost. The returns shown do not reflect the deduction of taxes that a shareholder would pay on Fund distributions or on the redemptions of Fund shares. Past performance is no guarantee of future results. Performance figures for periods greater than 1 year are annualized. The Fund’s manager has contractually agreed to waive fees and/or reimburse expenses of the Fund to the extent necessary to limit operating expenses (excluding front-end or contingent deferred loads, taxes, leverage interest, brokerage commissions, expenses incurred in connection with any merger or reorganization, dividend expenses on securities sold short, underlying fund fees and expenses or extraordinary expenses such as litigation) at 1.20%, 1.95%, 1.15% and 0.95% for Class A shares, Class C shares, Class N shares and Class I shares, respectively, through October 31, 2021. Per the Fund’s most recent prospectus, total annual Fund estimated expenses before waiver are 1.55%, 2.30%, 1.50% and 1.30% for Class A, Class C, Class N, and Class I, respectively. Class A shares are subject to a maximum sales charge of 5.75% imposed on purchases and have a maximum deferred sales charge of 1.00% on purchases of $1 million or more made without an initial sales charge and applies to shares sold within 18 months. Class C shares are subject to a maximum deferred sales charge of 1.00% on shares sold within 12 months. For performance information current to the most recent month-end, please call toll-free 1-877-771-3836.

Eventide Dividend Opportunities Fund commenced operations on September 29, 2017.

The Russell Midcap Value Total Return Index measures the performance of the mid-capitalization U.S. equities that exhibit value characteristics. It includes those Russell Midcap Index companies with higher price-to-book ratios and higher forecasted growth values. Investors cannot invest directly in an index.

The Russell Midcap Total Return Index measures the performance of the mid-cap segment of the US equity universe. It is a subset of the Russell 1000 Index. It includes approximately 800 of the smallest securities based on a combination of their market cap and current index membership, representing approximately 31% of the total market capitalization of the Russell 1000 companies. It is constructed to provide a comprehensive and unbiased barometer for the mid-cap segment. The index is completely reconstituted annually to ensure larger stocks do not distort the performance and characteristics of the true mid-cap opportunity set. Investors cannot invest directly in an index.

Holdings by Industry	% of Net Assets
Real Estate Investment Trusts (REITs)		14.3	%
Electric Utilities		10.3	%
Medical Equipment & Devices		8.7	%
Semiconductors		8.2	%
Banking		7.2	%
Electrical Equipment		5.6	%
Software		5.6	%
Automotive		5.0	%
Diversified Industrials		4.9	%
Technology Services		4.7	%
Other / Cash & Cash Equivalents		25.5	%
		100.0	%

Please refer to the Portfolio of Investments in this semi-annual report for a detailed listing of the Fund’s holdings.

E V E N T I D E		5

S E M I - A N N U A L R E P O R T

December 31, 2020

Eventide Exponential Technologies Fund

Portfolio Review (Unaudited)

December 31, 2020

Average Annual Total Return
Through December 31, 2020,¹ as compared to its benchmarks	Six Month	Inception²
Class N	57.97%	57.97%
Class A without load	57.97%	57.97%
Class A with 5.75% load	48.88%	48.88%
Class C	57.57%	57.57%
Class I	58.17%	58.17%
S&P 500 Total Return Index³	22.16%	22.16%
S&P North American Technology Sector Industry Index⁴	25.80%	25.80%
Eventide Exponential Technologies Blended Index⁵	30.70%	30.70%

The performance data quoted here represents past performance. Current performance may be lower or higher than the performance data quoted above. Investment return and principal value will fluctuate, so that shares, when redeemed, may be worth more or less than their original cost. The returns shown do not reflect the deduction of taxes that a shareholder would pay on Fund distributions or on the redemptions of Fund shares. Past performance is no guarantee of future results. Performance figures for periods greater than 1 year are annualized. The Fund’s manager has contractually agreed to waive fees and/or reimburse expenses of the Fund to the extent necessary to limit operating expenses (excluding front-end or contingent deferred loads, taxes, leverage interest, brokerage commissions, expenses incurred in connection with any merger or reorganization, dividend expenses on securities sold short, underlying fund fees and expenses or extraordinary expenses such as litigation) at 1.68%, 2.43%, 1.63% and 1.43% for Class A shares, Class C shares, Class N shares and Class I shares, respectively, through October 31, 2021. Per the Fund’s most recent prospectus, total annual Fund estimated expenses before waiver are 2.75%, 3.50%, 2.70% and 2.50%for Class A, Class C, Class N, and Class I, respectively. Class A shares are subject to a maximum sales charge of 5.75% imposed on purchases and have a maximum deferred sales charge of 1.00% on purchases of $1 million or more made without an initial sales charge and applies to shares sold within 18 months. Class C shares are subject to a maximum deferred sales charge of 1.00% on shares sold within 12 months. Redemptions within 180 days of purchase are subject to a redemption fee of 1.00%. For performance information current to the most recent month-end, please call toll-free 1-877-771-3836.

Eventide Exponential Technologies Fund commenced operations on June 30, 2020.

The S&P 500 Total Return Index, a registered trademark of McGraw-Hill Co., Inc., is a market capitalization-weighted index of 500 widely held common stocks. Investors cannot invest directly in an index.

The S&P North American Technology Sector Index provides investors with a benchmark that represents U.S. securities classified under the GICS® information technology sector as well as the internet & direct marketing retail, interactive home entertainment, and interactive media & services sub-industries. Investors cannot invest directly in an index.

The Eventide Exponential Technologies Blended Index is comprised of 50% of the S&P North American Technology Software Index, 20% of the S&P Technology Hardware Select Industry Index, 20% of the Philadelphia Stock Exchange Semiconductor Index and 10% of the S&P500 Communications Services Sector. The Eventide Exponential Technologies Blended Index rebalances its weightings on a monthly frequency. Investors cannot invest directly in an index.

Holdings by Industry	% of Net Assets
Software		45.3	%
Semiconductors		21.7	%
Internet Media & Services		10.4	%
Advertising & Marketing		8.7	%
Short-Term Investments		7.1	%
Technology Services		6.1	%
Food		3.0	%
Asset Management		0.5	%
Put Options Purchased		0.2	%
Other / Cash & Cash Equivalents		(3.00	)%
		100.0	%

Please refer to the Portfolio of Investments in this semi-annual report for a detailed listing of the Fund’s holdings.

E V E N T I D E		6

S E M I - A N N U A L R E P O R T

December 31, 2020

Eventide Gilead Fund

Portfolio Review (Unaudited)

December 31, 2020

Average Annual Total Return					Since	Since	Since
Through December 31, 2020,¹ as compared to its benchmarks	Six Month	1 Year	5 Year	10 Year	Inception²	Inception³	Inception⁴
Class N	34.98%	55.11%	22.08%	18.94%	17.72%	N/A	N/A
Class A without load	34.97%	55.06%	22.02%	18.88%	N/A	20.22%	N/A
Class A with 5.75% load	27.22%	46.15%	20.58%	18.18%	N/A	19.59%	N/A
Class C	34.43%	53.85%	21.10%	17.98%	N/A	19.31%	N/A
Class I	35.15%	55.42%	22.33%	19.17%	N/A	N/A	19.12%
S&P 500 Total Return Index⁵	22.16%	18.40%	15.22%	13.88%	11.37%	14.49%	14.22%
Russell Midcap Growth Total Return Index⁶	30.18%	35.59%	18.66%	15.04%	13.06%	16.80%	16.26%

Class N commenced operations on July 8, 2008.

Class A and Class C commenced operations on October 28, 2009.

Class I commenced operations on February 2, 2010.

The Russell Midcap Growth Total Return Index measures the performance of the mid-cap growth segment of the U.S. equity universe. It includes those Russell Midcap Index companies with higher price-to-book ratios and higher forecasted growth values. Investors cannot invest directly in an index.

Holdings by Industry	% of Net Assets
Software		23.7	%
Biotechnology & Pharmaceuticals		12.1	%
Medical Equipment & Devices		8.9	%
Electrical Equipment		7.3	%
Advertising & Marketing		6.9	%
Semiconductors		5.0	%
Electric Utilities		4.0	%
Commercial Support Services		3.9	%
Automotive		2.7	%
Internet Media & Services		2.2	%
Other / Cash & Cash Equivalents		23.3	%
		100.0	%

Please refer to the Portfolio of Investments in this semi-annual report for a detailed listing of the Fund’s holdings.

E V E N T I D E		7

S E M I - A N N U A L R E P O R T

December 31, 2020

Eventide Healthcare & Life Sciences Fund

Portfolio Review (Unaudited)

December 31, 2020

Average Annual Total Return				Since
Through December 31, 2020,¹ as compared to its benchmarks	Six Month	1 Year	5 Year	Inception²
Class N	30.26%	36.76%	21.37%	25.95%
Class A without load	30.19%	36.69%	21.28%	25.86%
Class A with 5.75% load	22.70%	28.84%	19.85%	24.93%
Class C	29.71%	35.67%	20.38%	24.93%
Class I	30.38%	37.04%	21.61%	26.19%
S&P 500 Total Return Index³	22.16%	18.40%	15.22%	15.24%
S&P Biotechnology Select Industry Index⁴	25.79%	48.10%	15.13%	21.91%

Eventide Healthcare & Life Sciences Fund commenced operations on December 27, 2012.

The S&P Biotechnology Select Industry Index is designed to measure the performance of narrow GICS® sub-industries and is comprised of stock in the S&P Total Market Index that are classified in the GICS biotechnology sub-industry. Investors cannot invest directly in an index.

Holdings by Industry	% of Net Assets
Biotechnology & Pharmaceuticals		78.6	%
Short-Term Investments		8.1	%
Medical Equipment & Devices		8.0	%
Health Care Facilities & Services		1.2	%
Asset Management		1.0	%
Put Options Purchased		0.4	%
Warrants		0.0	% ¹
Other / Cash & Cash Equivalents		2.7	%
		100.0	%

Amount is less than 0.1%

Please refer to the Portfolio of Investments in this semi-annual report for a detailed listing of the Fund’s holdings.

E V E N T I D E		8

S E M I - A N N U A L R E P O R T

December 31, 2020

Eventide Limited-Term Bond Fund

Portfolio Review (Unaudited)

December 31, 2020

Average Annual Total Return Through December 31, 2020, ¹ as compared to its benchmarks	Six Month	1 Year Return	5 Year Return	10 Year Return	Since Inception²	Since Inception³
Class N	1.03%	3.65%	N/A	N/A	N/A	4.92%
Class A without load	1.01%	3.60%	2.60%	2.73%	2.91%	N/A
Class A with 5.75% load	(4.80)%	(2.36)%	1.40%	2.13%	2.32%	N/A
Class C	0.65%	2.89%	N/A	N/A	N/A	4.11%
Class I	1.09%	3.84%	2.56%	2.36%	2.48%	N/A
Bloomberg Barclays 1-5 Year Government/Credit Bond Index⁴	0.70%	4.71%	2.77%	2.19%	2.15%	5.09%
Bloomberg Barclays U.S. Intermediate Aggregate Bond Index⁵	0.89%	5.60%	3.46%	3.10%	3.02%	6.46%

The performance data quoted here represents past performance. Current performance may be lower or higher than the performance data quoted above. Investment return and principal value will fluctuate, so that shares, when redeemed, may be worth more or less than their original cost. The returns shown do not reflect the deduction of taxes that a shareholder would pay on Fund distributions or on the redemptions of Fund shares. Total returns would have been lower absent the advisor fee waiver. Past performance is no guarantee of future results. Performance figures for periods greater than 1 year are annualized. The Fund’s manager has contractually agreed to waive fees and/or reimburse expenses of the Fund to the extent necessary to limit operating expenses (excluding front-end or contingent deferred loads, taxes, leverage interest, brokerage commissions, expenses incurred in connection with any merger or reorganization, dividend expenses on securities sold short, underlying fund fees and expenses or extraordinary expenses such as litigation) at 0.80%, 1.55%, 0.75% and 0.55% for Class A shares, Class C shares, Class N shares and Class I shares, respectively, through October 31, 2021. Per the Fund’s most recent prospectus, total annual Fund expenses before waiver are 1.16%, 1.91%, 1.11% and 0.91% for Class A, Class C, Class N, and Class I, respectively. Class A shares are subject to a maximum sales charge of 5.75% imposed on purchases and have a maximum deferred sales charge of 1.00% on purchases of $1 million or more made without an initial sales charge and applies to shares sold within 18 months. Class C shares are subject to a maximum deferred sales charge of 1.00% on shares sold within 12 months. For performance information current to the most recent month-end, please call toll-free 1-877-771-3836.

Class A and Class I commenced operations on July 28, 2010.

Class N and Class C commenced operations on December 14, 2018.

The Bloomberg Barclays 1-5 Year Government/Credit Bond Index measures the performance of U.S. dollar-denominated U.S. Treasury bonds, government related bonds (i.e., U.S. and non-U.S. agencies, sovereign, quasi-sovereign, supranational and local authority debt) and investment grade U.S. corporate bonds that have a remaining maturity of greater than or equal to one year and less than five years. Investors cannot invest directly in an index.

The Bloomberg Barclays U.S. Intermediate Aggregate Bond Index is a market capitalization-weighted index, meaning the securities in the index are weighted according to the market size of each bond type. Most U.S. traded investment grade bonds are represented. Municipal bonds, and Treasury Inflation-Protected Securities are excluded, due to tax treatment issues. The index includes Treasury securities, Government agency bonds, Mortgage-backed bonds, Corporate bonds, and a small amount of foreign bonds traded in U.S. Investors cannot invest directly in an index.

Holdings by Industry	% of Net Assets
Agency Fixed Rate		19.1	%
Government Owned		11.9	%
Electric Utilities		10.3	%
Real Estate Investment Trusts		8.2	%
Banking		8.1	%
Government Sponsored		7.6	%
Agency Mortgage Backed Securities - Other		5.7	%
Institutional Financial Services		4.2	%
Insurance		3.5	%
Short-Term Investments		3.1	%
Other / Cash & Cash Equivalents		18.3	%
		100.0	%

Please refer to the Portfolio of Investments in this semi-annual report for a detailed listing of the Fund’s holdings.

E V E N T I D E		9

S E M I - A N N U A L R E P O R T

December 31, 2020

Eventide Multi- Asset Income Fund

Portfolio Review (Unaudited)

December 31, 2020

Average Annual Total Return				Since
Through December 31, 2020, ¹ as compared to its benchmarks	Six Month	1 Year	5 Year	Inception²
Class N	17.29%	18.20%	9.57%	8.37%
Class A without load	17.27%	18.25%	9.54%	8.32%
Class A with 5.75% load	10.57%	11.42%	8.24%	7.15%
Class C	16.81%	17.26%	8.71%	7.51%
Class I	17.39%	18.41%	9.78%	8.57%
Russell Midcap Value Index³	28.14%	4.96%	9.73%	7.67%
Bloomberg Barclays U.S. Intermediate Aggregate Bond Index⁴	0.89%	5.60%	3.46%	3.25%
Eventide Multi-Asset Income Blended Index⁵	14.01%	6.84%	7.07%	5.93%

The performance data quoted here represents past performance. Current performance may be lower or higher than the performance data quoted above. Investment return and principal value will fluctuate, so that shares, when redeemed, may be worth more or less than their original cost. The returns shown do not reflect the deduction of taxes that a shareholder would pay on Fund distributions or on the redemptions of Fund shares. Past performance is no guarantee of future results. Performance figures for periods greater than 1 year are annualized. The Fund’s manager has contractually agreed to waive fees and/or reimburse expenses of the Fund to the extent necessary to limit operating expenses (excluding front-end or contingent deferred loads, taxes, leverage interest, brokerage commissions, expenses incurred in connection with any merger or reorganization, dividend expenses on securities sold short, underlying fund fees and expenses or extraordinary expenses such as litigation) at 1.07%, 1.82%, 1.02% and 0.82% for Class A shares, Class C shares, Class N shares and Class I shares, respectively, through October 31, 2021. The expense limits prior to March 2, 2020 were 1.20%, 1.95%, 1.15% and 0.95% for Class, A shares, Class C shares, Class N shares and Class I shares, respectively. Per the Fund’s most recent prospectus, total annual Fund expenses before waiver were 1.11%, 1.86%, 1.06% and 0.86% for Class A, Class C, Class N, and Class I, respectively. Class A shares are subject to a maximum sales charge of 5.75% imposed on purchases and have a maximum deferred sales charge of 1.00% on purchases of $1 million or more made without an initial sales charge and applies to shares sold within 18 months. Class C shares are subject to a maximum deferred sales charge of 1.00% on shares sold within 12 months. For performance information current to the most recent month-end, please call toll-free 1-877-771-3836.

Eventide Multi-Asset Income Fund commenced operations on July 15, 2015.

The Russell Midcap Value Index measures the performance of the mid-capitalization U.S. equities that exhibit value characteristics. It includes those Russell Midcap Index companies with higher price-to-book ratios and higher forecasted growth values. Investors cannot invest directly in an index.

The Eventide Multi-Asset Income Blended Index is comprised of 50% of the Russell Mid Cap Value Index and 50% of the Bloomberg Barclays U.S. Intermediate Aggregate Bond Index. The Eventide Multi-Asset Income Blended Index rebalances its weightings on a monthly frequency. Investors cannot invest directly in an index.

Holdings by Industry	% of Net Assets
Real Estate Investment Trusts (REITS)		11.2	%
Electric Utilities		10.2	%
Agency Fixed Rate		7.7	%
Banking		7.3	%
Software		7.2	%
Semiconductors		5.2	%
Medical Equipment & Devices		5.0	%
Electrical Equipment		3.9	%
Automotive		3.3	%
Diversified Industrials		3.0	%
Other / Cash & Cash Equivalents		36.0	%
		100.0	%

Please refer to the Portfolio of Investments in this semi-annual report for a detailed listing of the Fund’s holdings.

E V E N T I D E		10

S E M I - A N N U A L R E P O R T

December 31, 2020

Eventide Core Bond Fund
Portfolio of Investments (Unaudited)	December 31, 2020

Par Value			Coupon Rate (%)	Maturity	Fair Value
		CORPORATE BONDS - 59.1%
		AUTOMOTIVE - 1.7%
$	820,000	BorgWarner, Inc.	2.6500	7/1/27	$	882,508

		BANKING - 8.9%
	900,000	Bank of America Corp., Quarterly US LIBOR +0.87% ¹	2.4560	10/22/25		959,950
	20,000	First Horizon National Corp.	3.5500	5/26/23		21,261
	750,000	First Horizon National Corp.	4.0000	5/26/25		838,727
	1,000,000	JPMorgan Chase & Co., SOFR +0.60% ¹	0.6530	9/16/24		1,005,565
	900,000	National Bank of Canada	0.5500	11/15/24		903,166
	870,000	Regions Financial Corp.	2.2500	5/18/25		923,561
						4,652,230
		ELECTRIC UTILITIES - 18.6%
	515,000	AES Corp. ²	1.3750	1/15/26		519,916
	765,000	Avangrid, Inc.	3.1500	12/1/24		834,759
	850,000	CMS Energy Corp.	3.8750	3/1/24		926,947
	690,000	DTE Electric Co.	3.9500	3/1/49		897,472
	820,000	Duke Energy Florida LLC	2.5000	12/1/29		896,538
	700,000	Florida Power & Light Co.	3.9500	3/1/48		914,533
	245,000	Georgia Power Co.	3.2500	4/1/26		274,442
	640,000	Interstate Power and Light Co.	3.5000	9/30/49		742,647
	665,000	MidAmerican Energy Co.	4.2500	7/15/49		894,463
	875,000	National Rural Utilities Cooperative Finance Corp.	1.3500	3/15/31		864,693
	800,000	Northern States Power Co.	2.9000	3/1/50		905,687
	500,000	TerraForm Power Operating LLC ²	5.0000	1/31/28		562,762
	470,000	WEC Energy Group, Inc.	0.5500	9/15/23		472,666
						9,707,525
		ELECTRICAL EQUIPMENT - 4.2%
	500,000	Acuity Brands Lighting, Inc.	2.1500	12/15/30		508,373
	770,000	Lennox International, Inc.	1.3500	8/1/25		788,232
	795,000	Roper Technologies, Inc.	3.8000	12/15/26		919,674
						2,216,279
		ENGINEERING & CONSTRUCTION - 0.5%
	250,000	MasTec, Inc. ²	4.5000	8/15/28		262,813

		FOOD - 0.6%
	250,000	Conagra Brands, Inc.	4.8500	11/1/28		310,873

		INDUSTRIAL SUPPORT SERVICES - 0.7%
	350,000	United Rentals North America, Inc.	5.8750	9/15/26		370,935

		INSTITUTIONAL FINANCIAL SERVICES - 3.6%
	1,000,000	Morgan Stanley, SOFR +0.75% ¹	0.8640	10/21/25		1,008,783
	775,000	Nasdaq, Inc.	3.2500	4/28/50		854,033
						1,862,816

See accompanying notes to financial statements.

E V E N T I D E		11

S E M I - A N N U A L R E P O R T

December 31, 2020

Eventide Core Bond Fund
Portfolio of Investments (Unaudited) (Continued)	December 31, 2021

Par Value			Coupon Rate (%)	Maturity	Fair Value
		CORPORATE BONDS - 59.1% (Continued)
		INSURANCE - 4.1%
$	400,000	Aflac, Inc.	3.6000	4/1/30	$	471,362
	375,000	Athene Holding, Ltd.	3.5000	1/15/31		397,126
	820,000	Brown & Brown, Inc.	4.2000	9/15/24		913,614
	325,000	Reinsurance Group of America, Inc.	3.9500	9/15/26		373,617
						2,155,719
		MACHINERY - 1.4%
	700,000	Xylem, Inc.	1.9500	1/30/28		738,576

		REAL ESTATE INVESTMENT TRUSTS (REITs) - 8.6%
	795,000	Alexandria Real Estate Equities, Inc.	3.8000	4/15/26		915,416
	750,000	American Tower Corp.	3.3750	5/15/24		816,033
	500,000	Crown Castle International Corp.	3.6500	9/1/27		565,308
	750,000	Equinix, Inc.	1.5500	3/15/28		763,405
	500,000	HAT Holdings I LLC / HAT Holdings II LLC ²	5.2500	7/15/24		520,990
	915,000	Prologis LP	1.2500	10/15/30		907,309
						4,488,461
		RETAIL - DISCRETIONARY - 1.7%
	750,000	O’Reilly Automotive, Inc.	4.2000	4/1/30		905,207

		SEMICONDUCTORS - 1.2%
	510,000	NVIDIA Corp.	3.5000	4/1/50		621,052

		TECHNOLOGY SERVICES - 3.3%
	15,000	Verisk Analytics, Inc.	4.1250	3/15/29		18,038
	550,000	Verisk Analytics, Inc.	5.5000	6/15/45		781,709
	920,000	Visa, Inc.	0.7500	8/15/27		918,546
						1,718,293
		TOTAL CORPORATE BONDS (Cost $30,631,472)				30,893,287

		MUNICIPAL BONDS - 1.2%
		NEW YORK - 1.2%
	500,000	New York City Housing Development Corp.	0.6500	11/1/25		500,360
	100,000	New York State Housing Finance Agency	0.7000	11/1/25		100,024
		TOTAL MUNICIPAL BONDS (Cost $600,000)				600,384

		U.S. GOVERNMENT & AGENCIES - 37.6%
		AGENCY FIXED RATE - 24.0%
	1,550,870	Fannie Mae Pool	1.5000	9/1/35		1,596,662
	1,419,457	Fannie Mae Pool	2.0000	8/1/35		1,484,317
	1,397,849	Fannie Mae Pool	2.0000	9/1/35		1,461,793
	1,409,174	Fannie Mae Pool	2.5000	9/1/40		1,487,846
	1,433,496	Fannie Mae Pool	2.5000	6/1/50		1,512,881
	43,175	Fannie Mae Pool	2.5000	8/1/50		45,566
	1,316,969	Fannie Mae Pool	2.5000	9/1/50		1,389,901
	500,000	Fannie Mae Pool	4.0000	3/1/34		532,219
	1,464,152	Freddie Mac Pool	2.0000	9/1/50		1,521,541

See accompanying notes to financial statements.

E V E N T I D E		12

S E M I - A N N U A L R E P O R T

December 31, 2020

Eventide Core Bond Fund
Portfolio of Investments (Unaudited) (Continued)	December 31, 2021

Par Value			Coupon Rate (%)	Maturity	Fair Value
		U.S. GOVERNMENT & AGENCIES - 37.6% (Continued)
		AGENCY FIXED RATE - 24.0% (Continued)
$	41,948	Freddie Mac Pool	2.5000	7/1/50	$	44,271
	1,419,678	Freddie Mac Pool	2.5000	9/1/50		1,498,298
						12,575,295
		GOVERNMENT SPONSORED - 1.9%
	1,000,000	Federal Farm Credit Banks Funding Corp.	0.4800	9/3/24		999,488

		GOVERNMENT OWNED - 11.7%
	300,000	Federal Home Loan Mortgage Corp.	0.3200	11/2/23		300,144
	500,000	Federal Home Loan Mortgage Corp.	0.4000	2/26/24		500,014
	1,065,000	Federal Home Loan Mortgage Corp.	1.5000	2/12/25		1,117,661
	1,150,000	Federal National Mortgage Association	0.7500	10/8/27		1,155,232
	1,000,000	Federal National Mortgage Association	0.8750	8/5/30		982,288
	1,745,000	Federal National Mortgage Association	1.8750	9/24/26		1,887,811
	100,000	Federal National Mortgage Association	5.6250	7/15/37		158,839
						6,101,989
		TOTAL U.S. GOVERNMENT & AGENCIES (Cost $19,605,114)				19,676,772
Shares
		SHORT-TERM INVESTMENTS - 1.5%
	803,239	First American Government Obligations Fund - Class U, 0.04% ³				803,239
		TOTAL SHORT-TERM INVESTMENTS (Cost $803,239)				803,239

		TOTAL INVESTMENTS - 99.4% (Cost $51,639,825)			$	51,973,682
		OTHER ASSETS IN EXCESS OF LIABILITIES - 0.6%				337,955
		TOTAL NET ASSETS - 100.0%			$	52,311,637

LLC - Limited Liability Company

LP - Limited Partnership

SOFR - Secured Overnight Financing Rate

Variable rate, rate shown represents the rate at December 31, 2020.

144A Security - Security exempt from registration under Rule 144A of the Securities Act of 1933. The 144A securities represent 3.57% of total net assets. The securities may be resold in transactions exempt from registration typically only to qualified institutional buyers. Unless otherwise indicated, these securities are not considered to be illiquid.

Interest rate reflects seven-day effective yield on December 31, 2020.

See accompanying notes to financial statements.

E V E N T I D E		13

S E M I - A N N U A L R E P O R T

December 31, 2020

Eventide Dividend Opportunities Fund
Portfolio of Investments (Unaudited)	December 31, 2020

Shares			Fair Value
		COMMON STOCK - 72.1%
		APPAREL & TEXTILE PRODUCTS - 1.2%
	23,600	VF Corp.	$	2,015,676

		AUTOMOTIVE - 2.0%
	46,600	Magna International, Inc.		3,299,280

		BANKING - 7.2%
	363,900	First Horizon National Corp.		4,643,364
	34,800	First Republic Bank		5,113,164
	17,200	Signature Bank		2,326,988
				12,083,516
		BIOTECHNOLOGY & PHARMACEUTICALS - 2.1%
	5,500	Ascendis Pharma A/S - ADR ¹		917,290
	16,100	Zoetis, Inc.		2,664,550
				3,581,840
		CHEMICALS - 1.2%
	2,800	Sherwin-Williams Co.		2,057,748

		DIVERSIFIED INDUSTRIALS - 4.9%
	66,800	ITT, Inc.		5,144,936
	59,100	Pentair PLC		3,137,619
				8,282,555
		ELECTRIC UTILITIES - 5.9%
	95,850	Brookfield Renewable Corp.		5,585,180
	136,800	Clearway Energy, Inc.		4,368,024
				9,953,204
		ELECTRICAL EQUIPMENT - 5.6%
	8,100	Roper Technologies, Inc.		3,491,829
	40,400	Trane Technologies PLC		5,864,464
				9,356,293
		FOOD - 0.7%
	12,840	McCormick & Co., Inc.		1,227,504

		GAS & WATER UTILITIES - 1.5%
	16,600	American Water Works Co., Inc.		2,547,602

		HOME CONSTRUCTION - 2.9%
	69,300	DR Horton, Inc.		4,776,156

		INSTITUTIONAL FINANCIAL SERVICES - 1.5%
	18,800	Nasdaq, Inc.		2,495,512

		LEISURE FACILITIES & SERVICES - 0.7%
	3,110	Domino’s Pizza, Inc.		1,192,560

		MACHINERY - 1.6%
	13,124	IDEX Corp.		2,614,301

See accompanying notes to financial statements.

E V E N T I D E		14

S E M I - A N N U A L R E P O R T

December 31, 2020

Eventide Dividend Opportunities Fund
Portfolio of Investments (Unaudited) (Continued)	December 31, 2020

Shares				Fair Value
			COMMON STOCK - 72.1% (Continued)
			MEDICAL EQUIPMENT & DEVICES - 8.0%
	56,800		Agilent Technologies, Inc.	$	6,730,232
	19,150		STERIS PLC		3,629,691
	20,220		Zimmer Biomet Holdings, Inc.		3,115,700
					13,475,623
			RETAIL - DISCRETIONARY - 1.8%
	19,100		Lowe’s Cos., Inc.		3,065,741

			SEMICONDUCTORS - 8.2%
	33,600		Entegris, Inc.		3,228,960
	9,900		KLA Corp.		2,563,209
	18,200		NXP Semiconductors NV		2,893,982
	32,900		Skyworks Solutions, Inc.		5,029,752
					13,715,903
			SOFTWARE - 3.8%
	74,700		Dynatrace, Inc. ¹		3,232,269
	12,200		Synopsys, Inc. ¹		3,162,728
					6,394,997
			TECHNOLOGY HARDWARE - 0.9%
	12,300		Garmin Ltd.		1,471,818

			TECHNOLOGY SERVICES - 4.7%
	19,600		Jack Henry & Associates, Inc.		3,175,004
	4,050		MSCI, Inc.		1,808,446
	14,300		Verisk Analytics, Inc.		2,968,537
					7,951,987
			TRANSPORTATION & LOGISTICS - 2.4%
	20,400		Old Dominion Freight Line, Inc.		3,981,672

			WHOLESALE - CONSUMER STAPLES - 1.3%
	28,900		Sysco Corp.		2,146,114

			WHOLESALE - DISCRETIONARY - 2.0%
	9,000		Pool Corp.		3,352,500
			TOTAL COMMON STOCK (Cost $100,623,327)		121,040,102

			LIMITED PARTNERSHIPS - 4.4%
			ELECTRIC UTILITIES - 4.4%
	110,900		NextEra Energy Partners LP		7,435,845
			TOTAL LIMITED PARTNERSHIPS (Cost $6,258,211)		7,435,845

		��	PREFERRED STOCK - 3.0%
			AUTOMOTIVE - 3.0%
	32,700		Aptiv PLC		4,994,870
			TOTAL PREFERRED STOCK (Cost $3,986,991)		4,994,870

See accompanying notes to financial statements.

E V E N T I D E		15

S E M I - A N N U A L R E P O R T

December 31, 2020

Eventide Dividend Opportunities Fund
Portfolio of Investments (Unaudited) (Continued)	December 31, 2020

Shares					Fair Value
		REAL ESTATE INVESTMENT TRUSTS (REITs) - 14.3%
	20,800	Alexandria Real Estate Equities, Inc.			$	3,706,976
	23,600	Crown Castle International Corp.				3,756,884
	2,520	Equinix, Inc.				1,799,734
	101,500	Hannon Armstrong Sustainable Infrastructure Capital, Inc.				6,438,145
	50,700	Prologis, Inc.				5,052,762
	11,300	SBA Communications Corp.				3,188,069
		TOTAL REAL ESTATE INVESTMENT TRUSTS (REITs) (Cost $19,136,929)				23,942,570

Par Value			Coupon Rate (%)	Maturity
		CORPORATE BONDS - 3.5%
		ASSET MANAGEMENT - 0.7%
$	1,100,000	Calvert Impact Financial, Inc. ²	0.5000	11/15/21		1,100,000

		BIOTECHNOLOGY & PHARMACEUTICALS - 0.3%
	419,000	Neurocrine Biosciences, Inc.	2.2500	5/15/24		582,315

		MEDICAL EQUIPMENT & DEVICES - 0.7%
	638,000	Exact Sciences Corp.	1.0000	1/15/25		1,211,441

		SOFTWARE - 1.8%
	770,000	HubSpot, Inc. ³	0.3750	6/1/25		1,192,118
	1,304,000	Palo Alto Networks, Inc.	0.7500	7/1/23		1,842,428
						3,034,546
		TOTAL CORPORATE BONDS (Cost $5,113,503)				5,928,302

Shares
		SHORT-TERM INVESTMENTS - 0.9%
	102,526	Fidelity Government Portfolio - Institutional Class, 0.01% ⁴				102,526
	1,479,421	First American Government Obligations - Class U, 0.04% ⁴				1,479,421
		TOTAL SHORT-TERM INVESTMENTS (Cost $1,581,947)				1,581,947

		TOTAL INVESTMENTS - 98.2% (Cost $136,700,908)			$	164,923,636
		OTHER ASSETS IN EXCESS OF LIABILITIES - 1.8%				3,080,705
		TOTAL NET ASSETS - 100.0%			$	168,004,341

ADR - American Depositary Receipt

LP - Limited Partnership

PLC - Public Limited Company

Non-Income producing security.

Illiquid security. Total value of all such securities as of December 31, 2020 amounted to $1,100,000 and represented 0.65% of Total Net Assets.

144A Security - Security exempt from registration under Rule 144A of the Securities Act of 1933. The 144A securities represent 0.71% of total net assets. The securities may be resold in transactions exempt from registration typically only to qualified institutional buyers. Unless otherwise indicated, these securities are not considered to be illiquid.

Interest rate reflects seven-day effective yield on December 31, 2020.

See accompanying notes to financial statements.

E V E N T I D E		16

S E M I - A N N U A L R E P O R T

December 31, 2020

Eventide Exponential Technologies Fund
Portfolio of Investments (Unaudited)	December 31, 2020

Shares						Fair Value
		COMMON STOCK - 95.2%
		ADVERTISING & MARKETING - 8.7%
	2,718	Trade Desk, Inc. ¹				$	2,177,118
	60,851	ZoomInfo Technologies, Inc. ¹					2,934,844
							5,111,962
		FOOD - 3.0%
	68,232	Vital Farms, Inc. ¹					1,726,952

		INTERNET MEDIA & SERVICES - 10.4%
	18,971	Fiverr International Ltd. ¹					3,701,242
	61,611	MediaAlpha, Inc. ¹					2,407,142
							6,108,384
		SEMICONDUCTORS - 21.7%
	20,524	Advanced Micro Devices, Inc. ¹					1,882,256
	25,629	Entegris, Inc.					2,462,947
	4,398	KLA Corp.					1,138,686
	3,081	Lam Research Corp.					1,455,064
	34,944	Lattice Semiconductor Corp. ¹					1,601,134
	4,359	Monolithic Power Systems, Inc.					1,596,397
	9,198	Silicon Laboratories, Inc. ¹					1,171,273
	9,547	Skyworks Solutions, Inc.					1,459,545
							12,767,302
		SOFTWARE - 45.3%
	15,285	Crowdstrike Holdings, Inc. ¹					3,237,669
	13,403	Datadog, Inc. ¹					1,319,391
	4,819	DocuSign, Inc. ¹					1,071,264
	69,267	Dynatrace, Inc. ¹					2,997,183
	18,268	Five9, Inc. ¹					3,185,939
	3,454	HubSpot, Inc. ¹					1,369,304
	2,980	MongoDB, Inc. ¹					1,069,939
	26,237	Outset Medical, Inc. ¹					1,491,311
	6,686	Palo Alto Networks, Inc. ¹					2,376,137
	7,898	RingCentral, Inc. ¹					2,993,105
	53,977	Sprout Social, Inc. ¹					2,451,096
	5,109	Synopsys, Inc. ¹					1,324,457
	5,090	Twilio, Inc. ¹					1,722,965
							26,609,760
		TECHNOLOGY SERVICES - 6.1%
	7,332	Jack Henry & Associates, Inc.					1,187,711
	31,860	Shift4 Payments, Inc. ¹					2,402,244
							3,589,955
		TOTAL COMMON STOCK (Cost $46,485,292)					55,914,315
				��
Par Value			Coupon Rate (%)		Maturity
		CORPORATE BOND - 0.5%
		ASSET MANAGEMENT - 0.5%
$	318,000	Calvert Impact Financial, Inc. ²	0.5000		11/15/21		318,000
		TOTAL CORPORATE BOND (Cost $318,000)					318,000

See accompanying notes to financial statements.

E V E N T I D E		17

S E M I - A N N U A L R E P O R T

December 31, 2020

Eventide Exponential Technologies Fund
Portfolio of Investments (Unaudited) (Continued)	December 31, 2020

Expiration Date -

Contracts ³

Counterparty

Exercise Price

Notional Value

Fair Value

PUT OPTIONS PURCHASED - 0.2% ^1,4

210

American Well Corp.

Interactive Broker

03/19/2021 - $25

525,000

70,980

Appian Corp.

Interactive Broker

03/19/2021 - $125

375,000

23,700

170

Lemonade, Inc.

Interactive Broker

03/19/2021 - $55

935,000

17,000

120

New Relic, Inc.

Interactive Broker

03/19/2021 - $55

660,000

27,000

TOTAL PUT OPTIONS PURCHASED (Cost $167,478)

138,680

Shares

SHORT-TERM INVESTMENTS - 7.1%

50,000

Fidelity Government Portfolio - Institutional Class, 0.01% ⁵

50,000

4,116,922

First American Government Obligations - Class U, 0.04% ⁵

4,116,922

TOTAL SHORT-TERM INVESTMENTS (Cost $4,166,922)

4,166,922

TOTAL INVESTMENTS - 103.0% (Cost $51,137,692)

60,537,917

LIABILITIES IN EXCESS OF OTHER ASSETS - (3.0)%

(1,789,652

)

TOTAL NET ASSETS - 100.0%

58,748,265

Non-Income producing security.

Illiquid security. Total value of all such securities as of December 31, 2020 amounted to $318,000 and represented 0.54% of Total Net Assets.

Each contract is equivalent to 100 shares of the underlying common stock.

Cash collateral held at broker.

Interest rate reflects seven-day effective yield on December 31, 2020.

See accompanying notes to financial statements.

E V E N T I D E		18

S E M I - A N N U A L R E P O R T

December 31, 2020

Eventide Gilead Fund
Portfolio of Investments (Unaudited)	December 31, 2020

Shares			Fair Value
		COMMON STOCK - 87.9%
		ADVERTISING & MARKETING - 6.9%
	269,000	Trade Desk, Inc. ¹	$	215,469,000
	1,838,000	ZoomInfo Technologies, Inc. ¹		88,646,740
				304,115,740
		ASSET MANAGEMENT - 0.0% ²
	590,602	Entasis Therapeutics Holdings, Inc. ^1,3,4		1,385,848

		AUTOMOTIVE - 2.7%
	537,000	Aptiv PLC		69,965,730
	718,000	Magna International, Inc.		50,834,400
				120,800,130
		BIOTECHNOLOGY & PHARMACEUTICALS - 9.5%
	1,123,000	Ascendis Pharma A/S - ADR ¹		187,293,940
	602,000	Biohaven Pharmaceutical Holding Co. Ltd. ¹		51,597,420
	1,344,376	Collegium Pharmaceutical, Inc. ¹		26,927,851
	618,646	Essa Pharma, Inc. ¹		7,011,427
	206,000	GW Pharmaceuticals PLC - ADR ¹		23,774,460
	600,000	Phathom Pharmaceuticals, Inc. ¹		19,932,000
	1,550,892	Pliant Therapeutics, Inc. ¹		35,236,266
	416,512	Sarepta Therapeutics, Inc. ¹		71,011,131
				422,784,495
		CHEMICALS - 1.1%
	230,000	Ecolab, Inc.		49,762,800

		COMMERCIAL SUPPORT SERVICES - 3.9%
	179,000	Cintas Corp.		63,269,340
	727,500	Rollins, Inc.		28,423,425
	804,000	Waste Connections, Inc.		82,466,280
				174,159,045
		E-COMMERCE DISCRETIONARY - 2.0%
	402,000	Wayfair, Inc. ¹		90,775,620

		ELECTRIC UTILITIES - 1.1%
	309,000	Brookfield Renewable Corp.		18,005,430
	1,000,000	Clearway Energy, Inc.		31,930,000
				49,935,430
		ELECTRICAL EQUIPMENT - 7.3%
	359,000	Cognex Corp.		28,822,315
	143,000	Generac Holdings, Inc. ¹		32,519,630
	95,000	Lennox International, Inc.		26,027,150
	280,000	Novanta, Inc. ¹		33,101,600
	293,000	Roper Technologies, Inc.		126,309,370
	538,000	Trane Technologies PLC		78,096,080
				324,876,145

See accompanying notes to financial statements.

E V E N T I D E		19

S E M I - A N N U A L R E P O R T

December 31, 2020

Eventide Gilead Fund
Portfolio of Investments (Unaudited) (Continued)	December 31, 2020

Shares			Fair Value
		COMMON STOCK - 87.9% (Continued)
		FOOD - 1.7%
	203,000	Lamb Weston Holdings, Inc.	$	15,984,220
	116,000	McCormick & Co., Inc.		11,089,600
	1,985,000	Vital Farms, Inc. ^1,5		50,240,350
				77,314,170
		FORESTRY, PAPER & WOOD PRODUCTS - 1.7%
	882,000	Trex Co., Inc. ¹		73,841,040

		HOME CONSTRUCTION - 1.0%
	634,000	DR Horton, Inc.		43,695,280

		INTERNET MEDIA & SERVICES - 2.2%
	508,000	Fiverr International Ltd. ¹		99,110,800

		LEISURE PRODUCTS - 1.1%
	690,000	YETI Holdings, Inc. ¹		47,244,300

		MEDICAL EQUIPMENT & DEVICES - 8.9%
	1,037,000	Exact Sciences Corp. ¹		137,392,130
	240,000	IDEXX Laboratories, Inc. ¹		119,968,800
	25,000	Intuitive Surgical, Inc. ¹		20,452,500
	103,000	Mettler-Toledo International, Inc. ¹		117,387,040
				395,200,470
		RETAIL - DISCRETIONARY - 1.8%
	489,000	Lowe’s Cos, Inc.		78,489,390

		SEMICONDUCTORS - 5.0%
	172,000	ASML Holding NV - ADR		83,887,840
	201,000	Lam Research Corp.		94,926,270
	68,500	Monolithic Power Systems, Inc.		25,086,755
	117,400	Skyworks Solutions, Inc.		17,948,112
				221,848,977
		SOFTWARE - 23.7%
	987,000	Crowdstrike Holdings, Inc. ¹		209,066,340
	454,000	Datadog, Inc. ¹		44,691,760
	2,544,941	Dynatrace, Inc. ¹		110,119,597
	1,151,000	Five9, Inc. ¹		200,734,400
	233,533	HubSpot, Inc. ¹		92,581,822
	86,000	MongoDB, Inc. ¹		30,877,440
	108,000	Okta, Inc. ¹		27,460,080
	141,837	Palo Alto Networks, Inc. ¹		50,407,451
	208,000	RingCentral, Inc. ¹		78,825,760
	437,000	Smartsheet, Inc. ¹		30,279,730
	960,943	Sprout Social, Inc. ¹		43,636,422
	386,000	Twilio, Inc. ¹		130,661,000
				1,049,341,802
		TECHNOLOGY HARDWARE - 0.3%
	267,000	Ciena Corp. ¹		14,110,950

See accompanying notes to financial statements.

E V E N T I D E		20

S E M I - A N N U A L R E P O R T

December 31, 2020

Eventide Gilead Fund
Portfolio of Investments (Unaudited) (Continued)	December 31, 2020

Shares					Fair Value
		COMMON STOCK - 87.9% (Continued)
		TECHNOLOGY SERVICES - 1.9%
	405,000	Verisk Analytics, Inc.			$	84,073,950

		TRANSPORTATION & LOGISTICS - 2.1%
	333,000	Old Dominion Freight Line, Inc.				64,994,940
	220,000	XPO Logistics, Inc. ¹				26,224,000
						91,218,940
		WHOLESALE - DISCRETIONARY - 2.0%
	237,000	Pool Corp.				88,282,500

		TOTAL COMMON STOCK (Cost $1,883,524,416)				3,902,367,822

		LIMITED PARTNERSHIPS - 2.9%
		ELECTRIC UTILITIES - 2.9%
	1,236,000	Brookfield Renewable Partners LP				53,333,400
	1,135,000	NextEra Energy Partners LP				76,101,750
		TOTAL LIMITED PARTNERSHIPS (Cost $66,717,342)				129,435,150

		CONTINGENT VALUE RIGHTS - 0.1%
		BIOTECHNOLOGY & PHARMACEUTICALS - 0.1%
	3,982,940	Peloton Therapeutics, Inc. - CVR ^1,3,4,6,7				3,424,532
		TOTAL CONTINGENT VALUE RIGHTS (Cost $0)				3,424,532

		PREFERRED STOCK - 2.5%
		BIOTECHNOLOGY & PHARMACEUTICALS - 2.5%
	179,406	Beta Bionic Series B/B2 ^1,3,4,6,7				27,269,712
	907,378	Praxis Precision Medicines, Inc. Series C ^1,3,4				47,428,648
	659,330	Praxis Precision Medicines, Inc. Series C1 ^1,3,4				34,463,179
		TOTAL PREFERRED STOCK (Cost $45,400,025)				109,161,539

		REAL ESTATE INVESTMENT TRUSTS (REITs) - 1.8%
	235,000	Crown Castle International Corp.				37,409,650
	635,000	Hannon Armstrong Sustainable Infrastructure Capital, Inc.				40,278,050
		TOTAL REAL ESTATE INVESTMENT TRUSTS (REITs) (Cost $30,087,774)				77,687,700

Par Value			Coupon Rate (%)	Maturity
		CORPORATE BONDS - 1.3%
		ASSET MANAGEMENT - 1.3%
$	27,570,000	Calvert Impact Capital, Inc. ³	0.5000	11/15/21		27,570,000
	15,000,000	Calvert Impact Capital, Inc. ³	1.0000	11/15/22		15,000,000
	15,000,000	Calvert Impact Capital, Inc. ³	1.7500	11/15/21		15,000,000
		TOTAL CORPORATE BONDS (Cost $57,570,000)				57,570,000

Shares
		SHORT-TERM INVESTMENTS - 0.2%
	10,798,471	Fidelity Government Portfolio - Institutional Class, 0.01% ⁸				10,798,471
		TOTAL SHORT-TERM INVESTMENTS (Cost $10,798,471)				10,798,471

See accompanying notes to financial statements.

E V E N T I D E		21

S E M I - A N N U A L R E P O R T

December 31, 2020

Eventide Gilead Fund
Portfolio of Investments (Unaudited) (Continued)	December 31, 2020

	Fair Value
TOTAL INVESTMENTS - 96.7% (Cost $2,094,098,028)	$	4,290,445,214
OTHER ASSETS IN EXCESS OF LIABILITIES - 3.3%		146,543,758
TOTAL NET ASSETS - 100.0%	$	4,436,988,972

ADR - American Depositary Receipt

CVR - Contingent Value Rights

LP - Limited Partnership

PLC - Public Limited Company

Non-Income producing security.

Amount is less than 0.1%.

Illiquid security. Total value of all such securities as of December 31, 2020 amounted to $171,541,919 and represented 3.87% of Total Net Assets.

Restricted security.

Affiliated company - the Fund holds in excess of 5% of the outstanding voting securities of this company.

Security fair valued as of December 31, 2020 in accordance with the procedures approved by the Board of Trustees. Total value of all such securities as of December 31, 2020 amounted to $30,694,244, which represents approximately 0.69% of net assets of the Fund.

Private investment.

Interest rate reflects seven-day effective yield on December 31, 2020.

See accompanying notes to financial statements.

E V E N T I D E		22

S E M I - A N N U A L R E P O R T

December 31, 2020

Eventide Healthcare & Life Sciences Fund
Portfolio of Investments (Unaudited)	December 31, 2020

Shares			Fair Value
		COMMON STOCK - 79.3%
		ASSET MANAGEMENT - 1.0%
	288,939	Entasis Therapeutics Holdings, Inc. ^1,2,3	$	677,995
	1,118,000	Longview Acquisition Corp. ¹		22,125,220
				22,803,215
		BIOTECHNOLOGY & PHARMACEUTICALS - 69.1%
	869,000	89bio, Inc. ¹		21,177,530
	300,000	AbCellera Biologics, Inc. ¹		12,072,000
	142,900	Acceleron Pharma, Inc. ¹		18,282,626
	1,075,000	ADC Therapeutics SA ¹		34,410,750
	317,000	Allakos, Inc. ¹		44,380,000
	1,206,505	Annexon, Inc. ¹		30,198,820
	2,299,000	Aptose Biosciences, Inc. ¹		10,069,620
	160,000	Argenx SE - ADR ¹		47,054,400
	575,648	Ascendis Pharma A/S - ADR ¹		96,006,574
	1,305,307	AvroBio, Inc. ¹		18,195,980
	1,181,761	BioHaven Pharmaceutical Holding Co. Ltd. ¹		101,288,735
	462,000	Blueprint Medicines Corp. ¹		51,813,300
	1,837,108	Celldex Therapeutics, Inc. ¹		32,186,132
	387,000	ChemoCentryx, Inc. ¹		23,963,040
	3,000,326	Chiasma, Inc. ^1,4		13,051,418
	1,083,600	Collegium Pharmaceutical, Inc. ¹		21,704,508
	400,000	Crinetics Pharmaceuticals, Inc. ¹		5,644,000
	243,000	Deciphera Pharmaceuticals, Inc. ¹		13,868,010
	317,417	Eidos Therapeutics, Inc. ¹		41,765,729
	1,716,522	Essa Pharma, Inc. ^1,4		19,454,206
	1,120,000	Fennec Pharmaceuticals, Inc. ¹		8,344,000
	1,257,352	Freeline Therapeutics Holdings plc - ADR ¹		22,959,248
	112,000	Galapagos NV - ADR ¹		11,085,760
	800,000	Immatics NV ¹		8,632,000
	932,000	Immunovant, Inc. ¹		43,049,080
	3,450,000	Kala Pharmaceuticals, Inc. ^1,4		23,391,000
	1,680,000	KalVista Pharmaceuticals, Inc. ^1,4		31,903,200
	901,077	Karuna Therapeutics, Inc. ¹		91,540,412
	346,000	Keros Therapeutics, Inc. ¹		24,406,840
	175,000	Kinnate Biopharma, Inc. ¹		6,961,500
	1,060,000	Kura Oncology, Inc. ¹		34,619,600
	1,000,000	Magenta Therapeutics, Inc. ¹		7,840,000
	129,471	Mirati Therapeutics, Inc. ¹		28,437,010
	353,000	Neurocrine Biosciences, Inc. ¹		33,835,050
	1,050,000	Nurix Therapeutics, Inc. ¹		34,524,000
	430,000	ORIC Pharmaceuticals, Inc.		14,555,500
	1,287,233	Pliant Therapeutics, Inc. ¹		29,245,934
	50,000	Praxis Precision Medicines, Inc. ¹		2,751,000
	30,900	Regeneron Pharmaceuticals, Inc. ¹		14,928,099
	515,000	Sarepta Therapeutics, Inc. ¹		87,802,350
	102,500	Seagen, Inc. ¹		17,951,850
	341,473	Silverback Therapeutics, Inc. ¹		15,823,859

See accompanying notes to financial statements.

E V E N T I D E		23

S E M I - A N N U A L R E P O R T

December 31, 2020

Eventide Healthcare & Life Sciences Fund
Portfolio of Investments (Unaudited) (Continued)	December 31, 2020

Shares			Fair Value
		COMMON STOCK - 79.3% (Continued)
		BIOTECHNOLOGY & PHARMACEUTICALS - 69.1% (Continued)
	2,370,975	Sutro Biopharma, Inc. ^1,4	$	51,473,867
	1,946,000	Syndax Pharmaceuticals, Inc. ¹		43,279,040
	4,781,448	Trillium Therapeutics, Inc. ¹		70,335,100
	583,000	Turning Point Therapeutics, Inc. ¹		71,038,550
	506,000	Xencor, Inc. ¹		22,076,780
	1,030,140	Xenon Pharmaceuticals, Inc. ¹		15,843,553
	832,000	Zentalis Pharmaceuticals, Inc. ¹		43,214,080
				1,568,435,640
		HEALTH CARE FACILITIES & SERVICES - 1.2%
	110,091	American Well Corp. ¹		2,788,605
	870,000	Sotera Health Co. ¹		23,872,800
				26,661,405
		MEDICAL EQUIPMENT & DEVICES - 8.0%
	333,283	908 Devices, Inc. ¹		18,980,467
	703,000	Exact Sciences Corp. ¹		93,140,470
	119,000	Repligen Corp. ¹		22,803,970
	930,000	Veracyte, Inc. ¹		45,514,200
				180,439,107

		TOTAL COMMON STOCK (Cost $1,027,218,063)		1,798,339,367

		CONTINGENT VALUE RIGHTS - 0.1%
		BIOTECHNOLOGY & PHARMACEUTICALS - 0.1%
	1,528,871	Peloton Therapeutics, Inc. - CVR ^1,2,3,5,6		1,314,523
		TOTAL CONTINGENT VALUE RIGHTS (Cost $0)		1,314,523

		PREFERRED STOCK - 9.4%
		BIOTECHNOLOGY & PHARMACEUTICALS - 9.4%
	798,111	Annexon, Inc. ^1,2,3		18,977,883
	122,828	Beta Bionic Series B/B2 ^1,2,3,5,6		18,669,856
	5,000,000	Casma Therapeutics, Inc. ^1,2,3,4,5,6		3,562,500
	5,076,142	Cullinan Oncology, LLC ^1,2,3,5,6		9,500,000
	2,570,925	DiCE Molecules Series C ^1,2,3,5,6		6,333,332
	1,228,304	Freeline Therapeutics Ltd. ^1,2,3,4		21,307,390
	5,000,000	Goldfinch Biopharma, Inc. Series A ^1,2,3,4,5,6		5,600,000
	8,474,576	Goldfinch Biopharma, Inc. Series B ^1,2,3,4,5,6		9,491,525
	907,379	Praxis Precision Medicines, Inc. Series C ^1,2,3,4		47,428,700
	988,994	Praxis Precision Medicines, Inc. Series C1 ^1,2,3,4		51,694,716
	10,177,703	Prometheus Biosciences, Inc. ^1,2,3,4,5,6		6,640,951
	1,017,770	Prometheus Laboratories, Inc. ^1,2,3,4,5,6		667,148
	3,804,347	Talaris Therapeutics, Inc. ^1,2,3,5,6		6,649,999
	6,082,133	VectivBio AG Series A2 ^1,2,3,5,6		6,650,204
		TOTAL PREFERRED STOCK (Cost $123,858,979)		213,174,204

		WARRANTS - 0.0% ⁷
	400,000	Immatics NV ¹		1,152,000
		TOTAL WARRANTS (Cost $1,073,048)		1,152,000

See accompanying notes to financial statements.

E V E N T I D E		24

S E M I - A N N U A L R E P O R T

December 31, 2020

Eventide Healthcare & Life Sciences Fund
Portfolio of Investments (Unaudited) (Continued)	December 31, 2020

Expiration Date –

Contracts ⁸

Counterparty

Exercise Price

Notional Value

Fair Value

PUT OPTIONS PURCHASED - 0.4% ^1,9

5,839

Editas Medicine, Inc.

Interactive Broker

2/19/2021 - $65

37,953,500

6,510,485

189

Fate Therapeutics, Inc.

Interactive Broker

2/19/2021 - $95

1,795,500

292,005

5,514

Intellia Therapeutics, Inc.

Interactive Broker

1/15/2021 - $55

30,327,000

3,528,960

TOTAL PUT OPTIONS PURCHASED (Cost $9,485,892)

10,331,450

Shares

SHORT-TERM INVESTMENTS - 8.1%

3,116,847

Fidelity Government Portfolio - Institutional Class, 0.01% ¹⁰

3,116,847

179,984,183

First American Government Obligations - Class U, 0.04% ¹⁰

179,984,183

TOTAL SHORT-TERM INVESTMENTS (Cost $183,101,030)

183,101,030

TOTAL INVESTMENTS - 97.3% (Cost $1,344,737,012)

2,207,412,574

OTHER ASSETS IN EXCESS OF LIABILITIES - 2.7%

61,070,161

TOTAL NET ASSETS - 100.0%

2,268,482,735

ADR - American Depositary Receipt

CVR - Contingent Value Rights

LLC - Limited Liability Company

PLC - Public Limited Company

Non-Income producing security.

Illiquid security. Total value of all such securities as of December 31, 2020 amounted to $215,166,722 and represented 9.46% of Total Net Assets.

Restricted security.

Affiliated company - the Fund holds in excess of 5% of the outstanding voting securities of this company.

Security fair valued as of December 31, 2020 in accordance with the procedures approved by the Board of Trustees. Total value of all such securities as of December 31, 2020 amounted to $75,080,038, which represents approximately 3.31% of net assets of the Fund.

Private investment.

Amount is less than 0.1%.

Each contract is equivalent to 100 shares of the underlying common stock.

Cash collateral held at broker.

10.

Interest rate reflects seven-day effective yield on December 31, 2020.

See accompanying notes to financial statements.

E V E N T I D E		25

S E M I - A N N U A L R E P O R T

December 31, 2020

Eventide Limited-Term Bond Fund
Portfolio of Investments (Unaudited)	December 31, 2020

Par Value			Coupon Rate (%)	Maturity	Fair Value
		CORPORATE BONDS - 47.1%
		ASSET MANAGEMENT - 0.4%
$	350,000	Eaton Vance Corp.	3.6250	6/15/23	$	377,187

		BANKING - 8.1%
	1,720,000	Bank of America Corp., Quarterly US LIBOR +0.63% ¹	3.4990	5/17/22		1,740,445
	1,430,000	First Horizon National Corp.	3.5500	5/26/23		1,520,191
	1,800,000	JPMorgan Chase & Co., SOFR +0.60% ¹	0.6530	9/16/24		1,810,016
	1,500,000	National Bank of Canada	0.5500	11/15/24		1,505,277
	1,200,000	Regions Financial Corp.	2.2500	5/18/25		1,273,878
						7,849,807
		BIOTECHNOLOGY & PHARMACEUTICALS - 1.7%
	565,000	Celgene Corp.	3.2500	2/20/23		597,938
	1,000,000	Zoetis, Inc.	3.2500	2/1/23		1,052,543
						1,650,481
		COMMERCIAL SUPPORT SERVICES - 0.6%
	500,000	Waste Management, Inc.	3.1250	3/1/25		548,017

		ELECTRIC UTILITIES - 10.3%
	1,050,000	AES Corp. ²	1.3750	1/15/26		1,060,022
	1,100,000	Avangrid, Inc.	3.1500	12/1/24		1,200,307
	1,100,000	CMS Energy Corp.	3.8750	3/1/24		1,199,579
	500,000	Florida Power & Light Co.	3.1250	12/1/25		555,324
	1,025,000	Georgia Power Co.	3.2500	4/1/26		1,148,174
	700,000	MidAmerican Energy Co.	3.1000	5/1/27		785,800
	1,150,000	National Rural Utilities Cooperative Finance Corp.	3.4000	11/15/23		1,241,479
	600,000	NextEra Energy Capital Holdings, Inc.	3.1500	4/1/24		648,891
	850,000	TerraForm Power Operating LLC ²	4.2500	1/31/23		880,281
	1,200,000	WEC Energy Group, Inc.	0.5500	9/15/23		1,206,807
						9,926,664
		ELECTRICAL EQUIPMENT - 2.6%
	1,100,000	Lennox International, Inc.	1.3500	8/1/25		1,126,046
	1,275,000	Roper Technologies, Inc.	3.6500	9/15/23		1,383,952
						2,509,998
		FOOD - 1.0%
	775,000	Conagra Brands, Inc.	4.6000	11/1/25		913,677

		HOME CONSTRUCTION - 0.9%
	775,000	Lennar Corp.	4.5000	4/30/24		857,828

		INSTITUTIONAL FINANCIAL SERVICES - 4.2%
	1,000,000	Lazard Group LLC	3.7500	2/13/25		1,111,789
	1,800,000	Morgan Stanley, SORF +0.75% ¹	0.8640	10/21/25		1,815,809
	1,000,000	Nasdaq, Inc.	4.2500	6/1/24		1,110,249
						4,037,847

See accompanying notes to financial statements.

E V E N T I D E		26

S E M I - A N N U A L R E P O R T

December 31, 2020

Eventide Limited-Term Bond Fund
Portfolio of Investments (Unaudited) (Continued)	December 31, 2020

Par Value			Coupon Rate (%)	Maturity	Fair Value
		CORPORATE BONDS - 47.1% (Continued)
		INSURANCE - 3.5%
$	500,000	Aflac, Inc.	2.8750	10/15/26	$	553,881
	1,000,000	Brown & Brown, Inc.	4.2000	9/15/24		1,114,163
	750,000	Primerica, Inc.	4.7500	7/15/22		799,065
	750,000	Reinsurance Group of America, Inc.	3.9500	9/15/26		862,193
						3,329,302
		MACHINERY - 0.5%
	500,000	Xylem, Inc.	4.8750	10/1/21		516,210

		REAL ESTATE INVESTMENT TRUSTS (REITs) - 8.2%
	775,000	Alexandria Real Estate Equities, Inc.	3.8000	4/15/26		892,386
	400,000	Alexandria Real Estate Equities, Inc.	4.0000	1/15/24		440,653
	1,100,000	American Tower Corp.	3.3750	5/15/24		1,196,849
	875,000	Crown Castle International Corp.	5.2500	1/15/23		957,752
	1,300,000	Equinix, Inc.	1.0000	9/15/25		1,305,068
	925,000	HAT Holdings I LLC / HAT Holdings II LLC ²	5.2500	7/15/24		963,832
	1,000,000	Highwoods Realty LP	3.6250	1/15/23		1,042,000
	1,000,000	Prologis LP	3.7500	11/1/25		1,136,507
						7,935,047
		RETAIL - 1.4%
	450,000	AutoZone, Inc.	2.8750	1/15/23		469,024
	500,000	AutoZone, Inc.	3.2500	4/15/25		548,361
	350,000	O’Reilly Automotive, Inc.	3.8500	6/15/23		375,201
						1,392,586
		SEMICONDUCTORS - 1.2%
	574,000	Lam Research Corp.	3.8000	3/15/25		645,833
	500,000	NVIDIA Corp.	2.2000	9/16/21		506,146
						1,151,979
		TECHNOLOGY SERVICES - 2.1%
	1,150,000	Verisk Analytics, Inc.	4.0000	6/15/25		1,303,996
	715,000	Visa, Inc.	0.7500	8/15/27		713,870
						2,017,866
		TRANSPORTATION & LOGISTICS - 0.4%
	400,000	JB Hunt Transport Services, Inc.	3.3000	8/15/22		416,576

		TOTAL CORPORATE BONDS (Cost $44,616,810)				45,431,072

		MUNICIPAL BONDS - 2.8%
		CALIFORNIA - 0.6%
	575,000	California Municipal Finance Authority	1.4860	11/1/22		582,165

		DELAWARE - 0.0% ³
	35,000	Delaware State Housing Authority	2.7500	12/1/41		36,233

		MARYLAND - 0.1%
	125,000	Maryland Community Development Administration	3.2420	9/1/48		129,001

		MASSACHUSETTS - 0.1%
	125,000	Massachusetts Housing Finance Agency	4.0000	6/1/39		133,075

See accompanying notes to financial statements.

E V E N T I D E		27

S E M I - A N N U A L R E P O R T

December 31, 2020

Eventide Limited-Term Bond Fund
Portfolio of Investments (Unaudited) (Continued)	December 31, 2020

Par Value			Coupon Rate (%)	Maturity	Fair Value
		MUNICIPAL BONDS - 2.8% (Continued)
		NEW YORK - 0.9%
$	500,000	New York City Housing Development Corp.	1.9300	2/1/25	$	517,415
	250,000	New York State Housing Finance Agency	2.2000	11/1/24		252,948
	100,000	New York State Housing Finance Agency	0.5000	5/1/24		99,923
						870,286
		OREGON - 1.1%
	200,000	State of Oregon	0.5020	5/1/22		200,692
	200,000	State of Oregon	0.6550	5/1/23		201,656
	300,000	State of Oregon	0.7950	5/1/24		303,618
	300,000	State of Oregon	0.8950	5/1/25		304,293
						1,010,259

		TOTAL MUNICIPAL BONDS (Cost $2,714,658)				2,761,019

		NON U.S. GOVERNMENT & AGENCIES - 1.0%
	850,000	European Investment Bank	2.5000	10/15/24		921,383
		TOTAL NON U.S. GOVERNMENT & AGENCIES (Cost $920,983)				921,383

		U.S. GOVERNMENT & AGENCIES - 44.5%
		ADJUSTABLE RATE MORTGAGES - 0.2%
	52,698	Fannie Mae Pool, H15T1Y +2.18% ⁴	2.5150	6/1/36		52,824
	2,102	Fannie Mae Pool, H15T1Y +2.17% ⁴	2.5450	8/1/34		2,108
	1,182	Freddie Mac Non Gold Pool, H15T1Y +2.16% ⁴	2.2820	1/1/24		1,186
	7,194	Freddie Mac Non Gold Pool, H15T1Y +2.10% ⁴	2.4700	9/1/22		7,192
	2,340	Freddie Mac Non Gold Pool, H15T1Y +2.42% ⁴	3.4440	1/1/24		2,348
	1,612	Ginnie Mae II Pool, H15T1Y +1.50% ⁴	2.2500	7/20/23		1,641
	1,566	Ginnie Mae II Pool, H15T1Y +1.50% ⁴	2.2500	8/20/23		1,594
	3,660	Ginnie Mae II Pool, H15T1Y +1.50% ⁴	2.2500	9/20/24		3,735
	1,729	Ginnie Mae II Pool, H15T1Y +1.50% ⁴	2.2500	7/20/25		1,787
	18,408	Ginnie Mae II Pool, H15T1Y +1.50% ⁴	2.2500	7/20/31		19,205
	729	Ginnie Mae II Pool, H15T1Y +1.50% ⁴	2.8750	4/20/24		741
	1,683	Ginnie Mae II Pool, H15T1Y +1.50% ⁴	2.8750	5/20/24		1,724
	1,300	Ginnie Mae II Pool, H15T1Y +1.50% ⁴	3.0000	2/20/24		1,332
	1,303	Ginnie Mae II Pool, H15T1Y +1.50% ⁴	3.0000	3/20/24		1,331
	7,930	Ginnie Mae II Pool, H15T1Y +1.50% ⁴	3.0000	2/20/25		8,162
	19,974	Ginnie Mae II Pool, H15T1Y +1.50% ⁴	3.0000	1/20/32		20,862
	1,866	Ginnie Mae II Pool, H15T1Y +1.50% ⁴	3.1250	10/20/22		1,873
	5,497	Ginnie Mae II Pool, H15T1Y +1.50% ⁴	3.1250	12/20/24		5,576
	2,451	Ginnie Mae II Pool, H15T1Y +1.50% ⁴	3.1250	12/20/32		2,559
						137,780
		AGENCY FIXED RATE - 19.1%
	961,061	Fannie Mae Pool	1.5000	8/1/35		989,421
	924,045	Fannie Mae Pool	2.0000	5/1/35		966,129
	1,393,228	Fannie Mae Pool	2.0000	7/1/35		1,456,875
	1,419,457	Fannie Mae Pool	2.0000	8/1/35		1,484,317
	1,086,105	Fannie Mae Pool	2.0000	8/1/40		1,131,010
	1,472,448	Fannie Mae Pool	3.0000	10/1/26		1,545,396
	1,415,433	Fannie Mae Pool	3.0000	2/1/27		1,485,297

See accompanying notes to financial statements.

E V E N T I D E		28

S E M I - A N N U A L R E P O R T

December 31, 2020

Eventide Limited-Term Bond Fund
Portfolio of Investments (Unaudited) (Continued)	December 31, 2020

Par Value			Coupon Rate (%)	Maturity	Fair Value
		U.S. GOVERNMENT & AGENCIES - 44.5% (Continued)
		AGENCY FIXED RATE - 19.1% (Continued)
$	1,625,000	Fannie Mae Pool	4.0000	3/1/34	$	1,729,714
	657,254	Fannie Mae Pool	5.5000	11/1/25		680,032
	1,210,462	Freddie Mac Gold Pool	2.5000	1/1/31		1,268,907
	1,433,924	Freddie Mac Pool	1.5000	9/1/35		1,476,235
	1,492,529	Freddie Mac Pool	2.0000	7/1/30		1,563,320
	903,393	Freddie Mac Pool	2.0000	6/1/35		944,626
	1,604,621	Freddie Mac Pool	3.0000	9/1/33		1,740,823
	518	Ginnie Mae I Pool	6.5000	1/15/24		575
	29	Ginnie Mae I Pool	6.5000	4/15/26		33
	62	Ginnie Mae I Pool	7.0000	9/15/23		65
	5,535	Ginnie Mae I Pool	7.0000	4/15/28		5,671
	379	Ginnie Mae I Pool	7.5000	12/15/23		384
						18,468,830
		AGENCY HYBRID AJUSTABLE RATE MORTGAGES - 0.0% ³
	11,895	Ginnie Mae II Pool, H15T1Y +1.50% ⁴	2.2500	8/20/41		12,418
	24,188	Ginnie Mae II Pool, H15T1Y +1.50% ⁴	3.1250	10/20/34		25,319
						37,737
		AGENCY MORTGAGE BACKED SECURITIES - OTHER - 5.7%
	1,000,000	Fannie Mae Pool	2.2700	9/1/26		1,063,329
	472,739	Fannie Mae Pool	2.5200	12/1/26		507,356
	250,000	Fannie Mae Pool	2.6000	9/1/24		256,847
	750,000	Fannie Mae Pool	2.6700	1/1/25		791,338
	948,772	Fannie Mae Pool	2.6700	1/1/25		1,014,998
	680,000	Fannie Mae Pool	2.7000	12/1/24		701,229
	975,631	Fannie Mae Pool	2.7100	7/1/26		1,046,527
	150,000	Fannie Mae Pool	3.9400	7/1/21		151,598
						5,533,222
		GOVERNMENT OWNED - 11.9%
	1,000,000	Federal Home Loan Mortgage Corp.	0.2500	8/24/23		1,002,235
	1,250,000	Federal Home Loan Mortgage Corp.	0.3000	9/28/23		1,250,308
	750,000	Federal Home Loan Mortgage Corp.	0.3200	11/2/23		750,360
	1,000,000	Federal Home Loan Mortgage Corp.	0.3750	2/12/24		998,926
	1,650,000	Federal Home Loan Mortgage Corp.	0.3750	3/25/24		1,648,623
	1,500,000	Federal Home Loan Mortgage Corp.	0.4000	2/26/24		1,500,043
	1,000,000	Federal Home Loan Mortgage Corp.	1.5000	2/12/25		1,049,447
	1,000,000	Federal National Mortgage Association	0.3100	2/2/24		1,000,174
	1,250,000	Federal National Mortgage Association	0.3750	8/24/23		1,249,653
	1,000,000	Federal National Mortgage Association	0.4200	7/27/23		1,001,398
						11,451,167

See accompanying notes to financial statements.

E V E N T I D E		29

S E M I - A N N U A L R E P O R T

December 31, 2020

Eventide Limited-Term Bond Fund
Portfolio of Investments (Unaudited) (Continued)	December 31, 2020

Par Value			Coupon Rate (%)	Maturity	Fair Value
		U.S. GOVERNMENT & AGENCIES - 44.5% (Continued)
		GOVERNMENT SPONSORED - 7.6%
$	1,300,000	Federal Farm Credit Banks Funding Corp.	0.3700	4/13/23	$	1,300,002
	1,500,000	Federal Farm Credit Banks Funding Corp.	0.3000	3/28/24		1,496,935
	1,000,000	Federal Farm Credit Banks Funding Corp.	0.5600	12/1/25		1,000,734
	1,750,000	Federal Farm Credit Banks Funding Corp.	0.3200	12/23/24		1,747,890
	1,750,000	Federal Farm Credit Banks Funding Corp.	0.2100	12/28/23		1,748,687
						7,294,248

		TOTAL U.S. GOVERNMENT & AGENCIES (Cost $42,668,491)				42,922,984

		COLLATERALIZED MORTGAGE OBLIGATIONS - 0.9%
	113,838	Fannie Mae Interest Strip	3.0000	11/25/42		122,106
	218,525	Fannie Mae REMICS	3.0000	8/25/36		228,274
	250,000	Fannie Mae REMICS	3.0000	12/25/40		264,121
	136,347	Fannie Mae REMICS	3.0000	10/25/42		146,078
	85,106	Freddie Mac Multifamily Structured Pass Through Certificates	1.5830	4/25/22		85,757
		TOTAL COLLATERALIZED MORTGAGE OBLIGATIONS (Cost $800,047)				846,336

Shares
		SHORT-TERM INVESTMENTS - 3.1%
	3,044,263	First American Government Obligations - Class U, 0.04% ⁵				3,044,263
		TOTAL SHORT-TERM INVESTMENTS (Cost $3,044,263)				3,044,263

		TOTAL INVESTMENTS - 99.4% (Cost $94,765,252)			$	95,927,057
		OTHER ASSETS IN EXCESS OF LIABILITIES - 0.6%				563,377
		TOTAL NET ASSETS - 100.0%			$	96,490,434

H15T1Y - U.S. Treasury Yield Curve Rate T-Note Constant Maturity 1 Year

LLC - Limited Liability Company

LP - Limited Partnership

REMICS - Real Estate Mortgage Investment Conduits

SOFR - Secured Overnight Financing Rate

Variable rate, rate shown represents the rate at December 31, 2020.

144A Security - Security exempt from registration under Rule 144A of the Securities Act of 1933. The 144A securities represent 3.01% of total net assets. The securities may be resold in transactions exempt from registration typically only to a qualified institutional buyers. Unless otherwise indicated, these securities are not considered to be illiquid.

Amount is less than 0.1%.

Floating rate, rate shown represents the rate at December 31, 2020.

Interest rate reflects seven-day effective yield on December 31, 2020.

See accompanying notes to financial statements.

E V E N T I D E		30

S E M I - A N N U A L R E P O R T

December 31, 2020

Eventide Multi-Asset Income Fund
Portfolio of Investments (Unaudited)	December 31, 2020

Shares			Fair Value
		COMMON STOCK - 35.3%
		AUTOMOTIVE - 1.3%
	38,700	Magna International, Inc.	$	2,739,960

		BANKING - 4.7%
	329,800	First Horizon National Corp.		4,208,248
	29,500	First Republic Bank		4,334,435
	8,700	Signature Bank		1,177,023
				9,719,706
		BIOTECHNOLOGY & PHARMACEUTICALS - 0.5%
	6,100	Zoetis, Inc.		1,009,550

		CHEMICALS - 0.5%
	1,400	Sherwin-Williams Co.		1,028,874

		DIVERSIFIED INDUSTRIALS - 3.0%
	51,000	ITT, Inc.		3,928,020
	41,000	Pentair PLC		2,176,690
				6,104,710
		ELECTRIC UTILITIES - 3.5%
	62,550	Brookfield Renewable Corp.		3,644,789
	110,500	Clearway Energy, Inc.		3,528,265
				7,173,054
		ELECTRICAL EQUIPMENT - 3.1%
	5,100	Roper Technologies, Inc.		2,198,559
	28,700	Trane Technologies PLC		4,166,092
				6,364,651
		GAS & WATER UTILITIES - 0.9%
	12,300	American Water Works Co., Inc.		1,887,681

		HOME CONSTRUCTION - 1.9%
	56,500	DR Horton, Inc.		3,893,980

		MACHINERY - 0.4%
	4,400	IDEX Corp.		876,480

		MEDICAL EQUIPMENT & DEVICES - 3.2%
	35,700	Agilent Technologies, Inc.		4,230,093
	12,500	STERIS PLC		2,369,250
				6,599,343
		RETAIL - DISCRETIONARY - 1.4%
	18,200	Lowe’s Cos, Inc.		2,921,282

		SEMICONDUCTORS - 5.2%
	18,400	Entegris, Inc.		1,768,240
	11,200	KLA Corp.		2,899,792
	20,700	Skyworks Solutions, Inc.		3,164,616
	25,800	Taiwan Semiconductor Manufacturing Co. Ltd.		2,813,232
				10,645,880
		SOFTWARE - 0.5%
	25,100	Dynatrace, Inc. ¹		1,086,077

See accompanying notes to financial statements.

E V E N T I D E		31

S E M I - A N N U A L R E P O R T

December 31, 2020

Eventide Multi-Asset Income Fund
Portfolio of Investments (Unaudited) (Continued)	December 31, 2020

Shares					Fair Value
		COMMON STOCK - 35.3% (Continued)
		TECHNOLOGY HARDWARE - 0.5%
	8,600	Garmin Ltd.			$	1,029,076

		TECHNOLOGY SERVICES - 1.7%
	13,200	Jack Henry & Associates, Inc.				2,138,268
	3,100	MSCI, Inc.				1,384,243
						3,522,511
		TRANSPORTATION & LOGISTICS - 1.0%
	10,600	Old Dominion Freight Line, Inc.				2,068,908

		WHOLESALE - CONSUMER STAPLES - 0.9%
	26,100	Sysco Corp.				1,938,186

		WHOLESALE - DISCRETIONARY - 1.1%
	5,800	Pool Corp.				2,160,500
		TOTAL COMMON STOCK (Cost $53,805,428)				72,770,409

		LIMITED PARTNERSHIPS - 2.9%
		ELECTRIC UTILITIES - 2.9%
	89,300	NextEra Energy Partners LP				5,987,565
		TOTAL LIMITED PARTNERSHIPS (Cost $4,007,685)				5,987,565

		PREFERRED STOCK - 2.0%
		AUTOMOTIVE - 2.0%
	26,900	Aptiv PLC				4,108,930
		TOTAL PREFERRED STOCK (Cost $3,181,015)				4,108,930

		REAL ESTATE INVESTMENT TRUSTS (REITs) - 8.2%
	11,500	Alexandria Real Estate Equities, Inc.				2,049,530
	18,800	Crowne Castle International Corp.				2,992,772
	95,700	Hannon Armstrong Sustainable Infrastructure Capital, Inc.				6,070,251
	40,400	Prologis, Inc.				4,026,264
	6,166	SBA Communications Corp.				1,739,614
		TOTAL REAL ESTATE INVESTMENT TRUSTS (REITs) (Cost $11,314,853)				16,878,431

Par Value			Coupon Rate (%)	Maturity
		CORPORATE BONDS - 32.0%
		ASSET MANAGEMENT - 1.5%
$	1,800,000	Calvert Impact Capital, Inc. ²	0.5000	11/15/21		1,800,000
	340,000	Eaton Vance Corp.	3.6250	6/15/23		366,410
	1,000,000	Hercules Capital, Inc.	4.6250	10/23/22		1,017,163
						3,183,573
		AUTO PARTS & EQUIPMENT - 0.4%
	670,000	BorgWarner, Inc.	2.6500	7/1/27		721,074

See accompanying notes to financial statements.

E V E N T I D E		32

S E M I - A N N U A L R E P O R T

December 31, 2020

Eventide Multi-Asset Income Fund
Portfolio of Investments (Unaudited) (Continued)	December 31, 2020

Par Value			Coupon Rate (%)	Maturity	Fair Value
		CORPORATE BONDS - 32.0% (Continued)
		BANKING - 2.6%
$	1,200,000	Bank of America Corp., Quarterly US LIBOR +0.63% ³	3.4990	5/17/22	$	1,214,264
	750,000	First Horizon National Corp.	3.5500	5/26/23		797,303
	1,275,000	JPMorgan Chase & Co., SOFR +0.60% ³	0.6530	9/16/24		1,282,095
	1,125,000	National Bank of Canada	0.5500	11/15/24		1,128,958
	925,000	Regions Financial Corp.	2.2500	5/18/25		981,948
						5,404,568
		BIOTECHNOLOGY & PHARMACEUTICALS - 1.5%
	2,150,000	Neurocrine Biosciences, Inc.	2.2500	5/15/24		2,988,012

		CONSTRUCTION MATERIALS - 0.1%
	265,000	Vulcan Materials Co., Quarterly US LIBOR +0.65% ⁴	0.8754	3/1/21		265,117

		CONTAINERS & PACKAGING - 0.2%
	400,000	TriMas Corp. ⁵	4.8750	10/15/25		410,938

		E-COMMERCE DISCRETIONARY - 1.2%
	2,495,000	Wayfair, Inc. ⁵	0.6250	10/1/25		2,366,839

		ELECTRIC UTILITIES - 3.8%
	635,000	AES Corp. ⁵	1.3750	1/15/26		641,061
	790,000	Avangrid, Inc.	3.1500	12/1/24		862,039
	850,000	CMS Energy Corp.	3.8750	3/1/24		926,947
	350,000	Duke Energy Carolinas LLC	3.3500	5/15/22		364,646
	600,000	Duke Energy Florida LLC	2.5000	12/1/29		656,004
	1,100,000	MidAmerican Energy Co.	3.1000	5/1/27		1,234,828
	925,000	National Rural Utilities Cooperative Finance Corp.	1.3500	3/15/31		914,104
	875,000	NextEra Energy Capital Holdings, Inc.	3.1500	4/1/24		946,299
	600,000	TerraForm Power Operating LLC ⁵	5.0000	1/31/28		675,315
	635,000	WEC Energy Group, Inc.	0.5500	9/15/23		638,602
						7,859,845
		ELECTRICAL EQUIPMENT - 0.8%
	725,000	Lennox International, Inc.	1.3500	8/1/25		742,166
	825,000	Roper Technologies, Inc.	3.8000	12/15/26		954,378
						1,696,544
		ENGINEERING & CONSTRUCTION - 0.3%
	600,000	MasTec, Inc. ⁵	4.5000	8/15/28		630,750

		FOOD - 0.2%
	400,000	Conagra Brands, Inc.	4.8500	11/1/28		497,398

		FORESTRY, PAPER & WOOD PRODUCTS - 0.3%
	575,000	Louisiana-Pacific Corp.	4.8750	9/15/24		590,453

		HOME & OFFICE PRODUCTS - 0.3%
	650,000	Tempur Sealy International, Inc.	5.5000	6/15/26		677,268

		HOME CONSTRUCTION - 0.5%
	400,000	BMC East LLC ⁵	5.5000	10/1/24		411,000
	625,000	Lennar Corp.	4.5000	4/30/24		691,797
						1,102,797

See accompanying notes to financial statements.

E V E N T I D E		33

S E M I - A N N U A L R E P O R T

December 31, 2020

Eventide Multi-Asset Income Fund
Portfolio of Investments (Unaudited) (Continued)	December 31, 2020

Par Value			Coupon Rate (%)	Maturity	Fair Value
		CORPORATE BONDS - 32.0% (Continued)
		INDUSTRIAL SUPPORT SERVICES - 0.6%
$	500,000	Ashtead Capital, Inc. ⁵	4.1250	8/15/25	$	514,750
	675,000	United Rentals North America, Inc.	5.8750	9/15/26		715,375
						1,230,125
		INSTITUTIONAL FINANCIAL SERVICES - 1.0%
	750,000	Lazard Group LLC	3.7500	2/13/25		833,842
	1,250,000	Morgan Stanley, SOFR +0.75% ²	0.8640	10/21/25		1,260,979
						2,094,821
		INSURANCE - 1.2%
	500,000	Aflac, Inc.	3.2500	3/17/25		552,988
	850,000	Brown & Brown, Inc.	4.2000	9/15/24		947,039
	750,000	Reinsurance Group of America, Inc.	3.9500	9/15/26		862,193
						2,362,220
		INTERNET MEDIA & SERVICES - 2.2%
	3,175,000	Fiverr International Ltd. ⁵	0.0000	11/1/25		3,847,782
	625,000	VeriSign, Inc.	5.2500	4/1/25		711,328
						4,559,110
		MACHINERY - 0.8%
	700,000	Mueller Water Products, Inc. ⁵	5.5000	6/15/26		727,867
	875,000	Xylem, Inc.	1.9500	1/30/28		923,219
						1,651,086
		MEDICAL EQUIPMENT & DEVICES - 1.8%
	1,773,000	Exact Sciences Corp.	1.0000	1/15/25		3,366,593
	400,000	Hill-Rom Holdings, Inc. ⁵	4.3750	9/15/27		423,578
						3,790,171
		REAL ESTATE INVESTMENT TRUSTS (REITs) - 3.0%
	875,000	Alexandria Real Estate Equities, Inc.	3.8000	4/15/26		1,007,533
	625,000	American Tower Corp.	0.6000	1/15/24		625,844
	425,000	AvalonBay Communities, Inc.	2.9500	5/11/26		470,739
	500,000	Crown Castle International Corp.	3.6500	9/1/27		565,308
	1,000,000	Equinix, Inc.	1.0000	9/15/25		1,003,899
	700,000	HAT Holdings I LLC / HAT Holdings II LLC ⁵	5.2500	7/15/24		729,386
	144,000	Highwoods Realty LP	3.2000	6/15/21		145,011
	985,000	Prologis LP	1.2500	10/15/30		976,720
	500,000	Welltower, Inc.	2.7000	2/15/27		550,247
						6,074,687
		SEMICONDUCTORS - DISCRETIONARY - 0.3%
	500,000	Amkor Technology, Inc. ⁵	6.6250	9/15/2027		543,125

		SOFTWARE - 6.7%
	2,140,000	Five9, Inc. ⁵	0.5000	6/1/25		3,119,377
	1,335,000	HubSpot, Inc. ⁵	0.3750	6/1/25		2,066,853
	600,000	Open Text Corp. ⁵	5.8750	6/1/26		624,000
	3,030,000	Palo Alto Networks, Inc.	0.7500	7/1/23		4,281,102
	2,880,000	RingCentral, Inc. ⁵	0.0000	3/1/25		3,688,091
						13,779,423

See accompanying notes to financial statements.

E V E N T I D E		34

S E M I - A N N U A L R E P O R T

December 31, 2020

Eventide Multi-Asset Income Fund
Portfolio of Investments (Unaudited) (Continued)	December 31, 2020

Par Value			Coupon Rate (%)	Maturity	Fair Value
		CORPORATE BONDS - 32.0% (Continued)
		TECHNOLOGY SERVICES - 0.7%
$	500,000	Verisk Analytics, Inc.	4.1250	3/15/29	$	601,276
	900,000	Visa, Inc.	0.7500	8/15/27		898,577
						1,499,853
		TOTAL CORPORATE BONDS (Cost $61,608,075)				65,979,797

		MUNICIPAL BONDS - 1.7%
		CALIFORNIA - 0.8%
	1,000,000	California Health Facilities Financing Authority	1.8960	6/1/21		1,006,320
	425,000	California Municipal Finance Authority	1.4860	11/1/22		430,295
	200,000	City of Los Angeles, CA Wastewater System Revenue	3.6940	6/1/32		226,082
	100,000	City of Napa, CA Solid Waste Revenue	2.3300	8/1/25		107,051
						1,769,748
		HAWAII - 0.1%
	150,000	City & County of Honolulu, HI	2.5180	10/1/26		164,276

		NEW YORK - 0.3%
	500,000	New York City Housing Development Corp.	1.3500	11/1/26		518,775
	100,000	New York State Housing Finance Agency	0.6500	5/1/25		100,273
						619,048
		OREGON - 0.5%
	200,000	State of Oregon	0.8950	5/1/25		202,862
	250,000	State of Oregon	1.1850	5/1/26		255,845
	500,000	State of Oregon	1.3150	5/1/27		512,950
						971,657
		TOTAL MUNICIPAL BONDS (Cost $3,426,447)				3,524,729

		NON U.S. GOVERNMENT & AGENCIES - 0.2%
		SUPRANATIONAL - 0.2%
	475,000	European Investment Bank	2.5000	10/15/24		514,890
		TOTAL NON U.S. GOVERNMENT & AGENCIES (Cost $488,832)				514,890

		U.S. GOVERNMENT & AGENCIES - 11.5%
		AGENCY FIXED RATE - 7.7%
	1,218,370	Fannie Mae Pool	1.5000	10/1/35		1,254,017
	1,159,756	Fannie Mae Pool	2.0000	6/1/35		1,212,640
	946,305	Fannie Mae Pool	2.0000	8/1/35		989,545
	903,937	Fannie Mae Pool	2.5000	10/1/43		964,674
	1,229,799	Fannie Mae Pool	2.5000	5/1/50		1,297,903
	1,336,310	Fannie Mae Pool	2.5000	6/1/50		1,410,313
	1,079,369	Fannie Mae Pool	2.5000	8/1/50		1,139,143
	796,181	Fannie Mae Pool	3.0000	2/1/27		835,480
	766,126	Fannie Mae Pool	3.0000	12/1/45		830,898
	785,181	Fannie Mae Pool	3.0000	11/1/46		829,442
	696,842	Fannie Mae Pool	3.0000	2/1/47		742,300
	133,305	Fannie Mae Pool	4.5000	6/1/44		148,958
	494,379	Fannie Mae Pool	5.5000	11/1/25		511,512
	182,078	Freddie Mac Gold Pool	4.0000	5/1/32		193,606

See accompanying notes to financial statements.

E V E N T I D E		35

S E M I - A N N U A L R E P O R T

December 31, 2020

Eventide Multi-Asset Income Fund
Portfolio of Investments (Unaudited) (Continued)	December 31, 2020

Par Value			Coupon Rate (%)	Maturity	Fair Value
		U.S. GOVERNMENT & AGENCIES - 11.5% (Continued)
		AGENCY FIXED RATE - 7.7% (Continued)
$	1,165,226	Freddie Mac Pool	2.5000	7/1/50	$	1,229,755
	1,307,469	Freddie Mac Pool	3.0000	9/1/33		1,418,449
	806,205	Ginnie Mae II Pool	3.0000	1/20/46		859,298
						15,867,933
		GOVERNMENT OWNED - 3.3%
	1,000,000	Federal Home Loan Mortgage Corp.	0.3000	12/29/23		1,000,325
	625,000	Federal Home Loan Mortgage Corp.	0.3200	11/2/23		625,300
	1,350,000	Federal Home Loan Mortgage Corp.	1.5000	2/12/25		1,416,753
	1,000,000	Federal National Mortgage Association	0.3100	2/2/24		1,000,174
	1,000,000	Federal National Mortgage Association	0.3400	8/25/23		1,000,086
	1,000,000	Federal National Mortgage Association	0.5000	6/17/25		1,005,747
	600,000	Federal National Mortgage Association	1.8750	9/24/26		649,104
						6,697,489
		GOVERNMENT SPONSORED - 0.5%
	1,000,000	Federal Farm Credit Banks Funding Corp.	2.5800	6/15/27		1,117,952

		TOTAL U.S. GOVERNMENT & AGENCIES (Cost $23,189,197)				23,683,374

		COLLATERALIZED MORTGAGE OBLIGATIONS - 1.1%
	1,000,000	Freddie Mac Multifamily Structured Pass Through Certificates	2.4120	8/25/29		1,084,461
	1,000,000	Freddie Mac Multifamily Structured Pass Through Certificates	2.9390	4/25/29		1,135,736
		TOTAL COLLATERALIZED MORTGAGE OBLIGATIONS (Cost $2,052,447)				2,220,197

Shares
		SHORT-TERM INVESTMENTS - 1.1%
	102,077	Fidelity Government Portfolio - Institutional Class, 0.01% ⁶				102,077
	2,198,078	First American Government Obligations - Class U, 0.04% ⁶				2,198,078
		TOTAL SHORT-TERM INVESTMENTS (Cost $2,300,155)				2,300,155

		TOTAL INVESTMENTS - 96.0% (Cost $165,374,134)			$	197,968,477
		OTHER ASSETS IN EXCESS OF LIABILITIES - 4.0%				8,213,053
		TOTAL NET ASSETS - 100.0%			$	206,181,530

LLC - Limited Liability Company

LP - Limited Partnership

PLC - Public Limited Company

SOFR - Secured Overnight Financing Rate

Non-Income producing security.

Illiquid security. Total value of all such securities as of December 31, 2020 amounted to $1,800,000 and represented 0.87% of Total Net Assets.

Variable rate, rate shown represents the rate at December 31, 2020.

Floating rate, rate shown represents the rate at December 31, 2020.

144A Security - Security exempt from registration under Rule 144A of the Securities Act of 1933. The 144A securities represent 10.39% of total net assets. The securities may be resold in transactions exempt from registration typically only to a qualified institutional buyers. Unless otherwise indicated, these securities are not considered to be illiquid.

Interest rate reflects seven-day effective yield on December 31, 2020.

See accompanying notes to financial statements.

E V E N T I D E		36

S E M I - A N N U A L R E P O R T

December 31, 2020

Eventide Funds
Statement of Assets and Liabilities (Unaudited)	December 31, 2020

	Eventide		Eventide		Eventide				Eventide
	Core Bond		Dividend		Exponential		Eventide		Healthcare &
	Fund		Opportunities Fund		Technologies Fund		Gilead Fund		Life Sciences Fund
ASSETS
Investment securities:
Unaffiliated investments at cost	$	51,639,825	$	136,700,908	$	51,137,692	$	2,036,361,279	$	1,178,378,384
Affiliated investments at cost		—		—		—		57,736,749		166,358,628
Investments at cost		51,639,825		136,700,908		51,137,692		2,094,098,028		1,344,737,012
Unaffiliated investments at value	$	51,973,682	$	164,923,636	$	60,537,917	$	4,240,204,864	$	1,921,745,953
Affiliated investments at value		—		—		—		50,240,350		285,666,621
Total investments at value		51,973,682		164,923,636		60,537,917		4,290,445,214		2,207,412,574
Cash held at custodian		49,000		4,941,260		100,000		137,079,512		35,000,000
Cash held at broker		—		100,410		—		11,711,841		—
Deposits with broker for options		—		—		32,522		—		39,624,194
Receivable for securities sold		—		—		874,498		—		3,192,913
Receivable for Fund shares sold		64,657		386,391		328,456		5,139,866		2,320,848
Dividends and interest receivable		252,232		131,976		4,744		859,222		9,892
Prepaid expenses and other assets		—		39,414		42,015		116,046		80,332
TOTAL ASSETS		52,339,571		170,523,087		61,920,152		4,445,351,701		2,287,640,753

LIABILITIES
Payable for investments purchased		—		2,370,040		3,084,035		—		15,714,537
Payable for Fund shares repurchased		108		48,076		5,228		3,291,556		1,081,293
Management fees payable		5,126		70,788		45,125		3,596,087		2,102,528
Distribution (12b-1) fees payable		3,321		3,063		568		1,024,243		36,007
Payable to related parties		8,941		19,544		17,289		400,579		200,753
Accrued expenses and other liabilities		10,438		7,235		19,642		50,264		22,900
TOTAL LIABILITIES		27,934		2,518,746		3,171,887		8,362,729		19,158,018
NET ASSETS	$	52,311,637	$	168,004,341	$	58,748,265	$	4,436,988,972	$	2,268,482,735

Composition of Net Assets:
Paid in capital	$	52,080,854	$	140,819,909	$	49,608,029	$	2,159,639,078	$	1,307,760,489
Accumulated earnings		230,783		27,184,432		9,140,236		2,277,349,894		960,722,246
NET ASSETS	$	52,311,637	$	168,004,341	$	58,748,265	$	4,436,988,972	$	2,268,482,735

See accompanying notes to financial statements.

E V E N T I D E		37

S E M I - A N N U A L R E P O R T

December 31, 2020

Eventide Funds
Statement of Assets and Liabilities (Unaudited) (Continued)	December 31, 2020

	Eventide		Eventide		Eventide				Eventide
	Core Bond		Dividend		Exponential		Eventide		Healthcare &
	Fund		Opportunities Fund		Technologies Fund		Gilead Fund		Life Sciences Fund
Net Asset Value Per Share:
Class N Shares:
Net Assets	$	50,058,185	$	43,399,563	$	5,519,764	$	748,681,658	$	281,822,753
Shares of beneficial interest outstanding ¹		5,040,513		3,146,540		349,754		11,856,041		5,168,379
Net asset value (Net Assets ÷ Shares Outstanding), offering price, and redemption price per share ²	$	9.93	$	13.79	$	15.78	$	63.15	$	54.53

Class A Shares:
Net Assets	$	330,372	$	6,975,421	$	2,684,352	$	405,430,121	$	222,320,217
Shares of beneficial interest outstanding ¹	$	33,254	$	506,183	$	170,128		6,454,533		4,101,710
Net asset value (Net Assets ÷ Shares Outstanding) and redemption price per share ²	$	9.93	$	13.78	$	15.78	$	62.81	$	54.20

Maximum offering price per share (net asset value plus maximum sales charge of 5.75%)	$	10.54	$	14.62	$	16.74	$	66.65	$	57.51

Class C Shares:
Net Assets	$	47,654	$	1,638,448	$	353,326	$	370,488,002	$	140,553,300
Shares of beneficial interest outstanding ¹		4,809		119,317		22,449		6,487,492		2,772,277
Net asset value (Net Assets ÷ Shares Outstanding), offering price, and redemption price per share ²	$	9.91	$	13.73	$	15.74	$	57.11	$	50.70

Class I Shares:
Net Assets	$	1,875,426	$	115,990,909	$	50,190,823	$	2,912,389,191	$	1,623,786,465
Shares of beneficial interest outstanding ¹		188,894		8,404,905		3,176,131		45,047,135		29,270,153
Net asset value (Net Assets ÷ Shares Outstanding), offering price, and redemption price per share ²	$	9.93	$	13.80	$	15.80	$	64.65	$	55.48

Unlimited number of shares of beneficial interest authorized, no par value.

Redemptions made in the Eventide Exponential Technologies Fund within 180 days of purchased may be assessed a redemption fee of 1.00%.

See accompanying notes to financial statements.

E V E N T I D E		38

S E M I - A N N U A L R E P O R T

December 31, 2020

Eventide Funds
Statement of Assets and Liabilities (Unaudited) (Continued)	December 31, 2020

	Eventide		Eventide
	Limited-Term		Multi-Asset
	Bond Fund		Income Fund
ASSETS
Investment securities:
Unaffiliated investments at cost	$	94,765,252	$	165,374,134
Unaffiliated investments at value	$	95,927,057	$	197,968,477
Cash held at custodian		2,504,000		7,912,965
Cash held at broker		—		104,006
Receivable for securities sold		466		—
Receivable for Fund shares sold		1,216,531		945,912
Dividends and interest receivable		403,008		487,136
Prepaid expenses and other assets		28,409		62,444
TOTAL ASSETS	$	100,079,471	$	207,480,940

LIABILITIES
Payable for investments purchased		3,497,157		984,092
Payable for Fund shares repurchased		58,860		158,956
Management fees payable		1,492		93,180
Distribution (12b-1) fees payable		1,722		22,879
Payable to related parties		26,020		28,830
Accrued expenses and other liabilities		3,786		11,473
TOTAL LIABILITIES		3,589,037		1,299,410
NET ASSETS	$	96,490,434	$	206,181,530

Composition of Net Assets:
Paid in capital	$	95,315,183	$	168,886,694
Accumulated earnings		1,175,251		37,294,836
NET ASSETS	$	96,490,434	$	206,181,530

See accompanying notes to financial statements.

E V E N T I D E		39

S E M I - A N N U A L R E P O R T

December 31, 2020

Eventide Funds
Statement of Assets and Liabilities (Unaudited) (Continued)	December 31, 2020

	Eventide		Eventide
	Limited-Term		Multi-Asset
	Bond Fund		Income Fund
Net Asset Value Per Share:
Class N Shares:
Net Assets	$	9,040,897	$	27,488,784
Shares of beneficial interest outstanding ¹		852,996		2,077,600
Net asset value (Net Assets ÷ Shares Outstanding), offering price, and redemption price per share	$	10.60	$	13.23

Class A Shares:
Net Assets	$	20,267,861	$	14,226,891
Shares of beneficial interest outstanding ¹		1,908,299		1,075,606
Net asset value (Net Assets ÷ Shares Outstanding) and redemption price per share	$	10.62	$	13.23

Maximum offering price per share (net asset value plus maximum sales charge of 5.75%)	$	11.27	$	14.04

Class C Shares:
Net Assets	$	1,243,603	$	12,697,350
Shares of beneficial interest outstanding ¹		117,807		963,772
Net asset value (Net Assets ÷ Shares Outstanding), offering price, and redemption price per share	$	10.56	$	13.17

Class I Shares:
Net Assets	$	65,938,073	$	151,768,505
Shares of beneficial interest outstanding ¹		6,071,597		11,467,801
Net asset value (Net Assets ÷ Shares Outstanding), offering price, and redemption price per share	$	10.86	$	13.23

Unlimited number of shares of beneficial interest authorized, no par value.

See accompanying notes to financial statements.

E V E N T I D E		40

S E M I - A N N U A L R E P O R T

December 31, 2020

Eventide Funds
Statements of Operations (Unaudited)	December 31, 2020

	Eventide			Eventide			Eventide						Eventide
	Core Bond			Dividend			Exponential			Eventide			Healthcare &
	Fund ¹			Opportunities Fund			Technologies Fund ²			Gilead Fund			Life Sciences Fund
INVESTMENT INCOME
Dividend income	$	—		$	938,355		$	14,119		$	10,110,149		$	—
Interest		258,556			12,567			503			273,548			15,057
Less: Foreign dividend withholding taxes		—			(8,447	)		—			(363,668	)		—
TOTAL INVESTMENT INCOME		258,556			942,475			14,622			10,020,029			15,057

EXPENSES
Management fees		64,581			383,921			116,152			18,066,102			10,176,765
Distribution (12b-1) fees:
Class N		34,587			28,099			1,517			643,605			242,751
Class A		122			6,202			1,321			437,399			237,565
Class C		31			5,625			848			1,642,928			586,115
Shareholder servicing fees		17,939			35,909			10,559			1,123,748			527,869
Registration fees		15,000			27,600			18,300			110,400			110,400
Administrative fees		12,205			23,066			11,890			522,409			263,135
Transfer agent fees		7,500			23,666			9,150			172,469			94,263
Legal fees		6,987			7,540			8,524			10,054			10,054
Management services fees		6,246			14,858			4,954			442,343			219,484
Printing and postage expenses		6,165			7,540			7,521			138,252			76,415
Audit fees		5,856			6,159			7,144			13,574			9,552
Compliance officer fees		5,343			4,537			6,519			41,234			23,594
Trustees fees and expenses		4,932			6,033			6,017			6,033			6,033
Custodian fees		3,288			5,248			4,011			60,328			31,370
Insurance expense		150			644			183			39,560			20,240
Other expenses		2,049			2,099			2,500			20,109			3,921
TOTAL EXPENSES		192,981			588,746			217,110			23,490,547			12,639,526

Less: Fees waived/reimbursed by the Manager		(53,087	)		(46,397	)		(60,056	)		—			—
NET EXPENSES		139,894			542,349			157,054			23,490,547			12,639,526

NET INVESTMENT INCOME (LOSS)		118,662			400,126			(142,432	)		(13,470,518	)		(12,624,469	)

REALIZED AND UNREALIZED GAIN (LOSS) FROM INVESTMENTS
Net realized gain (loss) from:
Unaffiliated investments		(49,067	)		1,153,685			(63,814	)		158,577,240			219,031,652
Securities sold short		—			—			—			(23,531,540	)		—
Foreign currency transactions		—			3			—			—			—
Net realized gain (loss)		(49,067	)		1,153,688			(63,814	)		135,045,700			219,031,652
Net change in unrealized appreciation (depreciation) on:
Unaffiliated investments		333,857			22,910,631			9,400,225			1,035,756,209			207,504,544
Affiliated investments (See Note 5)		—			—			—			(38,321,257	)		100,263,164
Foreign currency translations		—			10			—			—			—
Net change in unrealized appreciation		333,857			22,910,641			9,400,225			997,434,952			307,767,708

NET REALIZED AND UNREALIZED GAIN FROM INVESTMENTS		284,790			24,064,329			9,336,411			1,132,480,652			526,799,360

NET INCREASE IN NET ASSETS RESULTING FROM OPERATIONS	$	403,452		$	24,464,455		$	9,193,979		$	1,119,010,134		$	514,174,891

Eventide Core Bond Fund commenced on July 31, 2020.

Eventide Exponential Technologies Fund commenced on June 30, 2020.

See accompanying notes to financial statements.

E V E N T I D E		41

S E M I - A N N U A L R E P O R T

December 31, 2020

Eventide Funds
Statements of Operations (Unaudited) (Continued)	December 31, 2020

	Eventide			Eventide
	Limited-Term			Multi-Asset
	Bond Fund			Income Fund
INVESTMENT INCOME
Dividend income	$	732		$	939,972
Interest		617,151			724,881
Less: Foreign dividend withholding taxes		—			(18,987	)
TOTAL INVESTMENT INCOME		617,883			1,645,866

EXPENSES
Management fees		136,261			521,380
Distribution (12b-1) fees:
Class N		15,942			22,567
Class A		20,178			15,508
Class C		3,876			50,614
Shareholder servicing fees		46,380			48,775
Registration fees		32,200			55,200
Administrative fees		31,198			39,572
Management services fees		12,244			22,965
Transfer agent fees		15,105			13,176
Compliance officer fees		9,653			8,052
Legal fees		8,076			8,045
Printing and postage expenses		7,540			20,109
Audit fees		7,163			7,163
Trustees fees and expenses		6,033			6,033
Custodian fees		3,268			7,239
Insurance expense		736			2,024
Other expenses		2,550			2,513
TOTAL EXPENSES		358,403			850,935

Less: Fees waived/reimbursed by the Manager		(91,163	)		(48,226	)
NET EXPENSES		267,240			802,709

NET INVESTMENT INCOME		350,643			843,157

REALIZED AND UNREALIZED GAIN (LOSS) FROM INVESTMENTS
Net realized gain (loss) from:
Investments		1,013,231			6,007,799
Foreign currency transactions		—			(86	)
Net realized gain		1,013,231			6,007,713
Net change in unrealized appreciation (depreciation) on:
Investments		(481,046	)		20,675,754
Foreign currency translations		—			432
Net change in unrealized appreciation (depreciation)		(481,046	)		20,676,186

NET REALIZED AND UNREALIZED GAIN FROM INVESTMENTS		532,185			26,683,899

NET INCREASE IN NET ASSETS RESULTING FROM OPERATIONS	$	882,828		$	27,527,056

See accompanying notes to financial statements.

E V E N T I D E		42

S E M I - A N N U A L R E P O R T

December 31, 2020

Eventide Core Bond Fund

Statement of Changes in Net Assets

	For the
	Period Ended
	December 31, 2020 ¹
	(Unaudited)
FROM OPERATIONS
Net investment income	$	118,662
Net realized loss from investments		(49,067	)
Net change in unrealized appreciation on investments		333,857
Net increase in net assets resulting from operations		403,452
		��
DISTRIBUTIONS TO SHAREHOLDERS
Total Distributions Paid
Class N		(165,379	)
Class A		(712	)
Class C		(91	)
Class I		(6,487	)
Total distributions to shareholders		(172,669	)

FROM SHARES OF BENEFICIAL INTEREST
Proceeds from shares sold:
Class N		51,877,606
Class A		326,998
Class C		47,455
Class I		2,073,399
Net asset value of shares issued in reinvestment of distributions:
Class N		164,108
Class A		712
Class C		91
Class I		5,390
Payments for shares repurchased:
Class N		(2,211,701	)
Class I		(203,204	)
Net increase in net assets from shares of beneficial interest		52,080,854

TOTAL INCREASE IN NET ASSETS		52,311,637

NET ASSETS
Beginning of Period		—
End of Period	$	52,311,637

Eventide Core Bond Fund commenced on July 31, 2020.

See accompanying notes to financial statements.

E V E N T I D E		43

S E M I - A N N U A L R E P O R T

December 31, 2020

Eventide Core Bond Fund

Statement of Changes in Net Assets (Continued)

	For the
	Period Ended
	December 31, 2020 ¹
	(Unaudited)
SHARE ACTIVITY
Class N:
Shares Sold		5,247,893
Shares Reinvested		16,627
Shares Repurchased		(224,007	)
Net increase in shares of beneficial interest outstanding		5,040,513

Class A:
Shares Sold		33,182
Shares Reinvested		72
Net increase in shares of beneficial interest outstanding		33,254

Class C:
Shares Sold		4,800
Shares Reinvested		9
Net increase in shares of beneficial interest outstanding		4,809

Class I:
Shares Sold		208,883
Shares Reinvested		546
Shares Repurchased		(20,535	)
Net increase in shares of beneficial interest outstanding		188,894

Eventide Core Bond Fund commenced on July 31, 2020.

See accompanying notes to financial statements.

E V E N T I D E		44

S E M I - A N N U A L R E P O R T

December 31, 2020

Eventide Dividend Opportunities Fund

Statement of Changes in Net Assets

	For the
	Six Months Ended			For the
	December 31, 2020			Year Ended
	(Unaudited)			June 30, 2020
FROM OPERATIONS
Net investment income	$	400,126		$	337,657
Net realized gain (loss) from investments and foreign currency transactions		1,153,688			(2,115,764	)
Net change in unrealized appreciation on investments and foreign currency translations		22,910,641			4,508,376
Net increase in net assets resulting from operations		24,464,455			2,730,269

DISTRIBUTIONS TO SHAREHOLDERS
Total Distributions Paid
Class N		(112,247	)		(85,975	)
Class A		(18,501	)		(12,551	)
Class C		(2,361	)		(3,003	)
Class I		(258,286	)		(111,972	)
Return of Capital
Class N		—			(106,946	)
Class A		—			(17,705	)
Class C		—			(2,253	)
Class I		—			(272,411	)
Total distributions to shareholders		(391,395	)		(612,816	)

FROM SHARES OF BENEFICIAL INTEREST
Proceeds from shares sold:
Class N		21,622,666			16,652,395
Class A		3,016,606			2,390,226
Class C		676,280			320,594
Class I		73,027,992			47,673,793
Net asset value of shares issued in reinvestment of distributions:
Class N		100,257			179,791
Class A		16,598			27,549
Class C		1,985			4,509
Class I		192,158			263,108
Payments for shares repurchased:
Class N		(3,585,087	)		(6,532,626	)
Class A		(390,908	)		(361,342	)
Class C		(124,358	)		(85,563	)
Class I		(18,240,670	)		(11,676,517	)
Net increase in net assets from shares of beneficial interest		76,313,519			48,855,917

TOTAL INCREASE IN NET ASSETS		100,386,579			50,973,370

NET ASSETS
Beginning of Period		67,617,762			16,644,392
End of Period	$	168,004,341		$	67,617,762

See accompanying notes to financial statements.

E V E N T I D E		45

S E M I - A N N U A L R E P O R T

December 31, 2020

Eventide Dividend Opportunities Fund

Statement of Changes in Net Assets (Continued)

	For the
	Six Months Ended			For the
	December 31, 2020			Year Ended
	(Unaudited)			June 30, 2020
SHARE ACTIVITY
Class N:
Shares Sold		1,716,356			1,604,918
Shares Reinvested		8,369			17,301
Shares Repurchased		(284,986	)		(615,120	)
Net increase in shares of beneficial interest outstanding		1,439,739			1,007,099

Class A:
Shares Sold		242,764			232,645
Shares Reinvested		1,387			2,660
Shares Repurchased		(30,779	)		(34,874	)
Net increase in shares of beneficial interest outstanding		213,372			200,431

Class C:
Shares Sold		52,986			30,918
Shares Reinvested		166			435
Shares Repurchased		(9,714	)		(7,730	)
Net increase in shares of beneficial interest outstanding		43,438			23,623

Class I:
Shares Sold		5,770,984			4,488,755
Shares Reinvested		16,040			25,485
Shares Repurchased		(1,520,175	)		(1,137,521	)
Net increase in shares of beneficial interest outstanding		4,266,849			3,376,719

See accompanying notes to financial statements.

E V E N T I D E		46

S E M I - A N N U A L R E P O R T

December 31, 2020

Eventide Exponential Technologies Fund

Statement of Changes in Net Assets

	For the
	Six Months Ended
	December 31, 2020 ¹
	(Unaudited)
FROM OPERATIONS
Net investment loss	$	(142,432	)
Net realized loss from investments		(63,814	)
Net change in unrealized appreciation on investments		9,400,225
Net increase in net assets resulting from operations		9,193,979

DISTRIBUTIONS TO SHAREHOLDERS
Total Distributions Paid
Class N		(3,796	)
Class A		(2,461	)
Class C		(370	)
Class I		(47,116	)
Total distributions to shareholders		(53,743	)

FROM SHARES OF BENEFICIAL INTEREST
Proceeds from shares sold:
Class N		5,011,337
Class A		2,268,731
Class C		269,857
Class I		48,978,873
Net asset value of shares issued in reinvestment of distributions:
Class N		3,785
Class A		2,328
Class C		194
Class I		46,277
Redemption fee proceeds:
Class N		389
Class A		215
Class C		34
Class I		3,982
Payments for shares repurchased:
Class N		(127,318	)
Class A		(27,699	)
Class C		(12	)
Class I		(6,822,944	)
Net increase in net assets from shares of beneficial interest		49,608,029

TOTAL INCREASE IN NET ASSETS		58,748,265

NET ASSETS
Beginning of Period		—
End of Period	$	58,748,265

Eventide Exponential Technologies Fund commenced on June 30, 2020.

See accompanying notes to financial statements.

E V E N T I D E		47

S E M I - A N N U A L R E P O R T

December 31, 2020

Eventide Exponential Technologies Fund

Statement of Changes in Net Assets (Continued)

	For the
	Six Months Ended
	December 31, 2020 ¹
	(Unaudited)
SHARE ACTIVITY
Class N:
Shares Sold		357,942
Shares Reinvested		240
Shares Repurchased		(8,428	)
Net increase in shares of beneficial interest outstanding		349,754

Class A:
Shares Sold		171,951
Shares Reinvested		148
Shares Repurchased		(1,971	)
Net increase in shares of beneficial interest outstanding		170,128

Class C:
Shares Sold		22,438
Shares Reinvested		12
Shares Repurchased		(1	)
Net increase in shares of beneficial interest outstanding		22,449

Class I:
Shares Sold		3,642,373
Shares Reinvested		2,931
Shares Repurchased		(469,173	)
Net increase in shares of beneficial interest outstanding		3,176,131

Eventide Exponential Technologies Fund commenced on June 30, 2020.

See accompanying notes to financial statements.

E V E N T I D E		48

S E M I - A N N U A L R E P O R T

December 31, 2020

Eventide Gilead Fund

Statements of Changes in Net Assets

	For the
	Six Months Ended			For the
	December 31, 2020			Year Ended
	(Unaudited)			June 30, 2020
FROM OPERATIONS
Net investment loss	$	(13,470,518	)	$	(15,181,574	)
Net realized gain (loss) from investments and securities sold short		135,045,700			(7,976,967	)
Net change in unrealized appreciation on investments		997,434,952			468,884,941
Net increase in net assets resulting from operations		1,119,010,134			445,726,400

DISTRIBUTIONS TO SHAREHOLDERS
Total Distributions Paid
Class N		(5,970,623	)		(15,790,226	)
Class A		(3,250,044	)		(8,342,448	)
Class C		(3,300,537	)		(8,983,382	)
Class I		(22,743,540	)		(47,276,336	)
Total distributions to shareholders		(35,264,744	)		(80,392,392	)

FROM SHARES OF BENEFICIAL INTEREST
Proceeds from shares sold:
Class N		97,130,300			134,334,676
Class A		35,659,260			52,413,566
Class C		19,604,822			28,867,225
Class I		514,100,601			673,393,422
Net asset value of shares issued in reinvestment of distributions:
Class N		5,589,536			14,446,702
Class A		2,926,932			7,291,642
Class C		3,181,349			8,577,560
Class I		19,752,008			40,684,962
Payments for shares repurchased:
Class N		(89,962,246	)		(296,708,818	)
Class A		(35,108,590	)		(66,120,145	)
Class C		(35,084,665	)		(43,766,605	)
Class I		(321,908,331	)		(436,306,119	)
Net increase in net assets from shares of beneficial interest		215,880,976			117,108,068

TOTAL INCREASE IN NET ASSETS		1,299,626,366			482,442,076

NET ASSETS
Beginning of Period		3,137,362,606			2,654,920,530
End of Period	$	4,436,988,972		$	3,137,362,606

See accompanying notes to financial statements.

E V E N T I D E		49

S E M I - A N N U A L R E P O R T

December 31, 2020

Eventide Gilead Fund

Statements of Changes in Net Assets (Continued)

	For the
	Six Months Ended			For the
	December 31, 2020			Year Ended
	(Unaudited)			June 30, 2020
SHARE ACTIVITY
Class N:
Shares Sold		1,752,418			3,398,037
Shares Reinvested		87,886			358,924
Shares Repurchased		(1,646,082	)		(7,407,929	)
Net increase (decrease) in shares of beneficial interest outstanding		194,222			(3,650,968	)

Class A:
Shares Sold		637,793			1,298,125
Shares Reinvested		46,261			182,018
Shares Repurchased		(644,632	)		(1,657,391	)
Net increase (decrease) in shares of beneficial interest outstanding		39,422			(177,248	)

Class C:
Shares Sold		386,854			788,726
Shares Reinvested		55,289			233,466
Shares Repurchased		(703,701	)		(1,206,250	)
Net decrease in shares of beneficial interest outstanding		(261,558	)		(184,058	)

Class I:
Shares Sold		9,104,801			16,572,379
Shares Reinvested		303,363			989,420
Shares Repurchased		(5,774,898	)		(10,795,668	)
Net increase in shares of beneficial interest outstanding		3,633,266			6,766,131

See accompanying notes to financial statements.

E V E N T I D E		50

S E M I - A N N U A L R E P O R T

December 31, 2020

Eventide Healthcare & Life Sciences Fund

Statements of Changes in Net Assets

	For the
	Six Months Ended			For the
	December 31, 2020			Year Ended
	(Unaudited)			June 30, 2020
FROM OPERATIONS
Net investment loss	$	(12,624,469	)	$	(16,185,121	)
Net realized gain from investments		219,031,652			11,796,449
Net change in unrealized appreciation on investments		307,767,708			312,680,177
Net increase in net assets resulting from operations		514,174,891			308,291,505

DISTRIBUTIONS TO SHAREHOLDERS
Class N		(9,647,055	)		(3,559,934	)
Class A		(7,687,684	)		(3,322,892	)
Class C		(5,173,596	)		(2,284,943	)
Class I		(54,725,127	)		(17,082,445	)
Total distributions to shareholders		(77,233,462	)		(26,250,214	)

FROM SHARES OF BENEFICIAL INTEREST
Proceeds from shares sold:
Class N		36,956,428			137,084,236
Class A		19,045,603			38,286,542
Class C		16,306,367			16,960,832
Class I		297,873,053			482,305,852
Net asset value of shares issued in reinvestment of distributions:
Class N		9,043,907			3,230,263
Class A		6,612,901			2,890,392
Class C		4,970,800			2,125,066
Class I		38,688,881			12,912,269
Redemption fee proceeds:
Class N		5,253			95,683
Class A		4,051			80,223
Class C		1,995			50,592
Class I		16,487			431,237
Payments for shares repurchased:
Class N		(51,431,150	)		(90,766,352	)
Class A		(22,612,627	)		(39,110,040	)
Class C		(11,692,456	)		(21,406,649	)
Class I		(143,923,251	)		(279,342,660	)
Net increase in net assets from shares of beneficial interest		199,866,242			265,827,486

TOTAL INCREASE IN NET ASSETS		636,807,671			547,868,777

NET ASSETS
Beginning of Period		1,631,675,064			1,083,806,287
End of Period	$	2,268,482,735		$	1,631,675,064

See accompanying notes to financial statements.

E V E N T I D E		51

S E M I - A N N U A L R E P O R T

December 31, 2020

Eventide Healthcare & Life Sciences Fund

Statements of Changes in Net Assets (Continued)

	For the
	Six Months Ended			For the
	December 31, 2020			Year Ended
	(Unaudited)			June 30, 2020
SHARE ACTIVITY
Class N:
Shares Sold		767,538			3,685,599
Shares Reinvested		163,720			80,939
Shares Repurchased		(1,104,251	)		(2,578,490	)
Net increase (decrease) in shares of beneficial interest outstanding		(172,993	)		1,188,048

Class A:
Shares Sold		394,948			1,047,185
Shares Reinvested		120,432			72,806
Shares Repurchased		(477,917	)		(1,114,696	)
Net increase in shares of beneficial interest outstanding		37,463			5,295

Class C:
Shares Sold		365,505			498,801
Shares Reinvested		96,746			56,653
Shares Repurchased		(259,189	)		(603,070	)
Net increase (decrease) in shares of beneficial interest outstanding		203,062			(47,616	)

Class I:
Shares Sold		6,084,108			13,331,631
Shares Reinvested		688,414			318,900
Shares Repurchased		(2,965,816	)		(7,785,089	)
Net increase in shares of beneficial interest outstanding		3,806,706			5,865,442

See accompanying notes to financial statements.

E V E N T I D E		52

S E M I - A N N U A L R E P O R T

December 31, 2020

Eventide Limited-Term Bond Fund

Statements of Changes in Net Assets

	For the
	Six Months Ended			For the
	December 31, 2020			Year Ended
	(Unaudited)			June 30, 2020
FROM OPERATIONS
Net investment income	$	350,643		$	667,949
Net realized gain from investments		1,013,231			28,058
Net change in unrealized appreciation (depreciation) on investments		(481,046	)		1,334,256
Net increase in net assets resulting from operations		882,828			2,030,263

DISTRIBUTIONS TO SHAREHOLDERS
Total Distributions Paid
Class N		(142,372	)		(290,729	)
Class A		(219,238	)		(250,954	)
Class C		(11,092	)		(1,851	)
Class I		(729,970	)		(189,176	)
Return of Capital
Class N		—			(70,271	)
Class A		—			(22,179	)
Class C		—			(648	)
Class I		—			(53,761	)
Total distributions to shareholders		(1,102,672	)		(879,569	)

FROM SHARES OF BENEFICIAL INTEREST
Proceeds from shares sold:
Class N		10,271,204			41,350,706
Class A		11,071,020			8,999,487
Class C		1,240,024			423,480
Class I		55,297,692			37,139,054
Net asset value of shares issued in reinvestment of distributions:
Class N		132,972			327,319
Class A		214,397			267,570
Class C		10,870			2,168
Class I		653,846			220,429
Payments for shares repurchased:
Class N		(39,438,284	)		(5,856,973	)
Class A		(3,819,806	)		(10,689,609	)
Class C		(401,125	)		(99,440	)
Class I		(18,616,030	)		(12,099,715	)
Net increase in net assets from shares of beneficial interest		16,616,780			59,984,476

TOTAL INCREASE IN NET ASSETS		16,396,936			61,135,170

NET ASSETS
Beginning of Period		80,093,498			18,958,328
End of Period	$	96,490,434		$	80,093,498

See accompanying notes to financial statements.

E V E N T I D E		53

S E M I - A N N U A L R E P O R T

December 31, 2020

Eventide Limited-Term Bond Fund

Statements of Changes in Net Assets (Continued)

	For the
	Six Months Ended			For the
	December 31, 2020			Year Ended
	(Unaudited)			June 30, 2020
SHARE ACTIVITY
Class N:
Shares Sold		964,474			3,944,452
Shares Reinvested		12,508			31,111
Shares Repurchased		(3,698,394	)		(562,912	)
Net increase (decrease) in shares of beneficial interest outstanding		(2,721,412	)		3,412,651

Class A:
Shares Sold		1,038,103			855,930
Shares Reinvested		20,152			25,445
Shares Repurchased		(358,153	)		(1,015,182	)
Net increase (decrease) in shares of beneficial interest outstanding		700,102			(133,807	)

Class C:
Shares Sold		116,817			40,239
Shares Reinvested		1,029			207
Shares Repurchased		(37,864	)		(9,524	)
Net increase in shares of beneficial interest outstanding		79,982			30,922

Class I:
Shares Sold		5,069,494			3,453,073
Shares Reinvested		60,112			20,477
Shares Repurchased		(1,707,521	)		(1,127,711	)
Net increase in shares of beneficial interest outstanding		3,422,085			2,345,839

See accompanying notes to financial statements.

E V E N T I D E		54

S E M I - A N N U A L R E P O R T

December 31, 2020

Eventide Multi-Asset Income Fund

Statements of Changes in Net Assets

	For the
	Six Months Ended			For the
	December 31, 2020			Year Ended
	(Unaudited)			June 30, 2020
FROM OPERATIONS
Net investment income	$	843,157		$	1,893,437
Net realized gain (loss) from investments and foreign securities transactions		6,007,713			(1,201,911	)
Net change in unrealized appreciation on investments, and foreign currency translations		20,676,186			8,201,833
Net increase in net assets resulting from operations		27,527,056			8,893,359

DISTRIBUTIONS TO SHAREHOLDERS
Total Distributions Paid
Class N		(201,066	)		(227,546	)
Class A		(107,901	)		(113,782	)
Class C		(59,686	)		(55,884	)
Class I		(1,248,991	)		(1,115,115	)
Return of Capital
Class N		—			(250,303	)
Class A		—			(132,332	)
Class C		—			(66,682	)
Class I		—			(1,222,038	)
Total distributions to shareholders		(1,617,644	)		(3,183,682	)

FROM SHARES OF BENEFICIAL INTEREST
Proceeds from shares sold:
Class N		8,333,614			12,780,530
Class A		3,292,280			4,564,245
Class C		4,173,279			3,552,934
Class I		37,574,652			71,655,886
Net asset value of shares issued in reinvestment of distributions:
Class N		160,222			386,479
Class A		96,764			206,918
Class C		50,515			99,981
Class I		1,016,792			1,673,076
Payments for shares repurchased:
Class N		(3,815,392	)		(11,564,960	)
Class A		(1,673,691	)		(3,361,542	)
Class C		(1,120,053	)		(2,003,821	)
Class I		(16,315,303	)		(46,827,596	)
Net increase in net assets from shares of beneficial interest		31,773,679			31,162,130

TOTAL INCREASE IN NET ASSETS		57,683,091			36,871,807

NET ASSETS
Beginning of Period		148,498,439			111,626,632
End of Period	$	206,181,530		$	148,498,439

See accompanying notes to financial statements.

E V E N T I D E		55

S E M I - A N N U A L R E P O R T

December 31, 2020

Eventide Multi-Asset Income Fund

Statements of Changes in Net Assets (Continued)

	For the
	Six Months Ended			For the
	December 31, 2020			Year Ended
	(Unaudited)			June 30, 2020
SHARE ACTIVITY
Class N:
Shares Sold		666,856			1,145,087
Shares Reinvested		12,950			34,811
Shares Repurchased		(311,873	)		(1,039,930	)
Net increase in shares of beneficial interest outstanding		367,933			139,968

Class A:
Shares Sold		265,075			411,856
Shares Reinvested		7,829			18,634
Shares Repurchased		(134,233	)		(302,900	)
Net increase in shares of beneficial interest outstanding		138,671			127,590

Class C:
Shares Sold		336,081			315,979
Shares Reinvested		4,072			9,040
Shares Repurchased		(89,864	)		(181,651	)
Net increase in shares of beneficial interest outstanding		250,289			143,368

Class I:
Shares Sold		3,032,027			6,429,635
Shares Reinvested		82,262			150,588
Shares Repurchased		(1,338,823	)		(4,184,893	)
Net increase in shares of beneficial interest outstanding		1,775,466			2,395,330

See accompanying notes to financial statements.

E V E N T I D E		56

S E M I - A N N U A L R E P O R T

December 31, 2020

Eventide Core Bond Fund

Financial Highlights, Class N

Per Share Data and Ratios for a Share of Beneficial Interest Outstanding Throughout the Period Presented

	Class N
	Period Ended
	December 31, 2020 ¹
	(Unaudited)
Net asset value, beginning of period	$	10.00
Activity from investment operations:
Net investment income ²		0.02
Net realized and unrealized loss on investments		(0.06	)
Total from investment operations		(0.04	)
Less distributions from:
Net investment income		(0.03	)
Total distributions		(0.03	)

Net asset value, end of period	$	9.93
Total return ³		(0.36	)% ⁶
Net assets, at end of period (000s)	$	50,058
Ratio of gross expenses to average net assets before expense reimbursement ^{4, 5}		2.16	% ⁷
Ratio of net expenses to average net assets after expense reimbursement ⁵		0.77	% ⁷
Ratio of net investment income to average net assets ⁵		0.64	% ⁷
Portfolio Turnover Rate		12	% ⁶

Eventide Core Bond Fund commenced on July 31, 2020.

Per share amounts calculated using the average shares method.

Total return in the above table is historical in nature and represents the rate that the investor would have earned or lost on an investment in the Fund assuming reinvestment of dividends and capital gain distributions, if any. Had the manager not waived a portion of the Fund’s expenses in certain periods, total returns would have been lower.

Represents the ratio of expenses to average net assets absent fee waivers and/or expense reimbursements by the manager.

The ratios of expenses to average net assets and net investment income to average net assets do not reflect the expenses of the underlying investment companies in which the Fund invests.

Not annualized.

Annualized.

See accompanying notes to financial statements.

E V E N T I D E		57

S E M I - A N N U A L R E P O R T

December 31, 2020

Eventide Core Bond Fund

Financial Highlights, Class A

Per Share Data and Ratios for a Share of Beneficial Interest Outstanding Throughout the Period Presented

	Class A
	Period Ended
	December 31, 2020 ¹
	(Unaudited)
Net asset value, beginning of period	$	10.00
Activity from investment operations:
Net investment income ²		0.02
Net realized and unrealized loss on investments		(0.06	)
Total from investment operations		(0.04	)
Less distributions from:
Net investment income		(0.03	)
Total distributions		(0.03	)

Net asset value, end of period	$	9.93
Total return ³		(0.35	)% ⁶
Net assets, at end of period (000s)	$	330
Ratio of gross expenses to average net assets before expense reimbursement ^{4, 5}		2.21	% ⁷
Ratio of net expenses to average net assets after expense reimbursement ⁵		0.82	% ⁷
Ratio of net investment income to average net assets ⁵		0.62	% ⁷
Portfolio Turnover Rate		12	% ⁶

Eventide Core Bond Fund commenced on July 31, 2020.

Per share amounts calculated using the average shares method.

Represents the ratio of expenses to average net assets absent fee waivers and/or expense reimbursements by the manager.

The ratios of expenses to average net assets and net investment income to average net assets do not reflect the expenses of the underlying investment companies in which the Fund invests.

Not annualized.

Annualized.

See accompanying notes to financial statements.

E V E N T I D E		58

S E M I - A N N U A L R E P O R T

December 31, 2020

Eventide Core Bond Fund

Financial Highlights, Class C

Per Share Data and Ratios for a Share of Beneficial Interest Outstanding Throughout the Period Presented

	Class C
	Period Ended
	December 31, 2020 ¹
	(Unaudited)
Net asset value, beginning of period	$	10.00
Activity from investment operations:
Net investment income ²		(0.01	)
Net realized and unrealized loss on investments		(0.05	)
Total from investment operations		(0.06	)
Less distributions from:
Net investment income		(0.03	)
Total distributions		(0.03	)

Net asset value, end of period	$	9.91
Total return ³		(0.58	)% ⁶
Net assets, at end of period (000s)	$	48
Ratio of gross expenses to average net assets before expense reimbursement ^{4, 5}		2.96	% ⁷
Ratio of net expenses to average net assets after expense reimbursement ⁵		1.57	% ⁷
Ratio of net investment income to average net assets ⁵		(0.15	)% ⁷
Portfolio Turnover Rate		12	% ⁶

Eventide Core Bond Fund commenced on July 31, 2020.

Per share amounts calculated using the average shares method.

Represents the ratio of expenses to average net assets absent fee waivers and/or expense reimbursements by the manager.

The ratios of expenses to average net assets and net investment income to average net assets do not reflect the expenses of the underlying investment companies in which the Fund invests.

Not annualized.

Annualized.

See accompanying notes to financial statements.

E V E N T I D E		59

S E M I - A N N U A L R E P O R T

December 31, 2020

Eventide Core Bond Fund

Financial Highlights, Class I

Per Share Data and Ratios for a Share of Beneficial Interest Outstanding Throughout the Period Presented

	Class I
	Period Ended
	December 31, 2020 ¹
	(Unaudited)
Net asset value, beginning of period	$	10.00
Activity from investment operations:
Net investment income ²		0.04
Net realized and unrealized loss on investments		(0.07	)
Total from investment operations		(0.03	)
Less distributions from:
Net investment income		(0.04	)
Total distributions		(0.04	)

Net asset value, end of period	$	9.93
Total return ³		(0.29	)% ⁶
Net assets, at end of period (000s)	$	1,875
Ratio of gross expenses to average net assets before expense reimbursement ^{4, 5}		1.96	% ⁷
Ratio of net expenses to average net assets after expense reimbursement ⁵		0.57	% ⁷
Ratio of net investment income to average net assets ⁵		0.81	% ⁷
Portfolio Turnover Rate		12	% ⁶

Eventide Core Bond Fund commenced on July 31, 2020.

Per share amounts calculated using the average shares method.

Represents the ratio of expenses to average net assets absent fee waivers and/or expense reimbursements by the manager.

The ratios of expenses to average net assets and net investment income to average net assets do not reflect the expenses of the underlying investment companies in which the Fund invests.

Not annualized.

Annualized.

See accompanying notes to financial statements.

E V E N T I D E		60

S E M I - A N N U A L R E P O R T

December 31, 2020

Eventide Dividend Opportunities Fund

Financial Highlights, Class N

Per Share Data and Ratios for a Share of Beneficial Interest Outstanding Throughout the Periods Presented

	Class N
	Six Months Ended
	December 31, 2020			Year Ended			Year Ended			Period Ended
	(Unaudited)			June 30, 2020			June 30, 2019			June 30, 2018 ¹
Net asset value, beginning of period	$	10.88		$	10.37		$	9.66		$	10.00
Activity from investment operations:
Net investment income ²		0.04			0.11			0.22			0.33
Net realized and unrealized gain (loss) on investments		2.92			0.57			0.66			(0.52	)
Total from investment operations		2.96			0.68			0.88			(0.19	)
Less distributions from:
Net investment income		(0.05	)		(0.04	)		(0.16	)		(0.14	)
Net realized gains		—			—			—			(0.01	)
Return of capital		—			(0.13	)		(0.01	)		—
Total distributions		(0.05	)		(0.17	)		(0.17	)		(0.15	)

Net asset value, end of period	$	13.79		$	10.88		$	10.37		$	9.66
Total return ³		27.28	% ⁶		6.60	%		9.20	%		(1.87	)% ⁶
Net assets, at end of period (000s)	$	43,400		$	18,576		$	7,254		$	4,929
Ratio of gross expenses to average net assets before expense reimbursement ^{4, 5}		1.24	% ⁷		1.50	%		2.00	%		3.30	% ⁷
Ratio of net expenses to average net assets after expense reimbursement ⁵		1.15	% ⁷		1.15	%		1.15	%		1.15	% ⁷
Ratio of net investment income to average net assets ⁵		0.61	% ⁷		1.01	%		2.25	%		4.43	% ⁷
Portfolio Turnover Rate		20	% ⁶		90	%		50	%		13	% ⁶

Eventide Dividend Opportunities Fund commenced on September 29, 2017.

Per share amounts calculated using the average shares method.

Represents the ratio of expenses to average net assets absent fee waivers and/or expense reimbursements by the manager.

The ratios of expenses to average net assets and net investment income to average net assets do not reflect the expenses of the underlying investment companies in which the Fund invests.

Not annualized.

Annualized.

See accompanying notes to financial statements.

E V E N T I D E		61

S E M I - A N N U A L R E P O R T

December 31, 2020

Eventide Dividend Opportunities Fund

Financial Highlights, Class A

Per Share Data and Ratios for a Share of Beneficial Interest Outstanding Throughout the Periods Presented

	Class A
	Six Months Ended
	December 31, 2020			Year Ended			Year Ended			Period Ended
	(Unaudited)			June 30, 2020			June 30, 2019			June 30, 2018 ¹
Net asset value, beginning of period	$	10.87		$	10.36		$	9.65		$	10.00
Activity from investment operations:
Net investment income ²		0.04			0.09			0.22			0.27
Net realized and unrealized gain (loss) on investments		2.92			0.58			0.65			(0.47	)
Total from investment operations		2.96			0.67			0.87			(0.20	)
Less distributions from:
Net investment income		(0.05	)		(0.04	)		(0.15	)		(0.14	)
Net realized gains		—			—			—			(0.01	)
Return of capital		—			(0.12	)		(0.01	)		—
Total distributions		(0.05	)		(0.16	)		(0.16	)		(0.15	)

Net asset value, end of period	$	13.78		$	10.87		$	10.36		$	9.65
Total return ³		27.29	% ⁶		6.55	%		9.15	%		(2.01	)% ⁶
Net assets, at end of period (000s)	$	6,975		$	3,184		$	957		$	511
Ratio of gross expenses to average net assets before expense reimbursement ^{4, 5}		1.29	% ⁷		1.55	%		2.05	%		3.35	% ⁷
Ratio of net expenses to average net assets after expense reimbursement ⁵		1.20	% ⁷		1.20	%		1.20	%		1.20	% ⁷
Ratio of net investment income to average net assets ⁵		0.55	% ⁷		0.89	%		2.28	%		3.58	% ⁷
Portfolio Turnover Rate		20	% ⁶		90	%		50	%		13	% ⁶

Eventide Dividend Opportunities Fund commenced on September 29, 2017.

Per share amounts calculated using the average shares method.

Represents the ratio of expenses to average net assets absent fee waivers and/or expense reimbursements by the manager.

The ratios of expenses to average net assets and net investment income to average net assets do not reflect the expenses of the underlying investment companies in which the Fund invests.

Not annualized.

Annualized.

See accompanying notes to financial statements.

E V E N T I D E		62

S E M I - A N N U A L R E P O R T

December 31, 2020

Eventide Dividend Opportunities Fund

Financial Highlights, Class C

Per Share Data and Ratios for a Share of Beneficial Interest Outstanding Throughout the Periods Presented

	Class C
	Six Months Ended
	December 31, 2020			Year Ended			Year Ended			Period Ended
	(Unaudited)			June 30, 2020			June 30, 2019			June 30, 2018 ¹
Net asset value, beginning of period	$	10.86		$	10.35		$	9.66		$	10.00
Activity from investment operations:
Net investment income ²		(0.01	)		0.03			0.15			0.25
Net realized and unrealized gain (loss) on investments		2.91			0.56			0.65			(0.49	)
Total from investment operations		2.90			0.59			0.80			(0.24	)
Less distributions from:
Net investment income		(0.03	)		(0.00	) ⁸		(0.10	)		(0.09	)
Net realized gains		—			—			—			(0.01	)
Return of capital		—			(0.08	)		(0.01	)		—
Total distributions		(0.03	)		(0.08	)		(0.11	)		(0.10	)

Net asset value, end of period	$	13.73		$	10.86		$	10.35		$	9.66
Total return ³		26.71	% ⁶		5.78	%		8.34	%		(2.37	)% ⁶
Net assets, at end of period (000s)	$	1,638		$	824		$	541		$	299
Ratio of gross expenses to average net assets before expense reimbursement ^{4, 5}		2.04	% ⁷		2.30	%		2.80	%		4.10	% ⁷
Ratio of net expenses to average net assets after expense reimbursement ⁵		1.95	% ⁷		1.95	%		1.95	%		1.95	% ⁷
Ratio of net investment income to average net assets ⁵		(0.20	)% ⁷		0.25	%		1.53	%		3.39	% ⁷
Portfolio Turnover Rate		20	% ⁶		90	%		50	%		13	% ⁶

Eventide Dividend Opportunities Fund commenced on September 29, 2017.

Per share amounts calculated using the average shares method.

Represents the ratio of expenses to average net assets absent fee waivers and/or expense reimbursements by the manager.

The ratios of expenses to average net assets and net investment income to average net assets do not reflect the expenses of the underlying investment companies in which the Fund invests.

Not annualized.

Annualized.

Amount represents less than $0.01 per share.

See accompanying notes to financial statements.

E V E N T I D E		63

S E M I - A N N U A L R E P O R T

December 31, 2020

Eventide Dividend Opportunities Fund

Financial Highlights, Class I

Per Share Data and Ratios for a Share of Beneficial Interest Outstanding Throughout the Periods Presented

	Class I
	Six Months Ended
	December 31, 2020			Year Ended			Year Ended			Period Ended
	(Unaudited)			June 30, 2020			June 30, 2019			June 30, 2018 ¹
Net asset value, beginning of period	$	10.88		$	10.37		$	9.67		$	10.00
Activity from investment operations:
Net investment income ²		0.06			0.12			0.24			0.26
Net realized and unrealized gain (loss) on investments		2.92			0.57			0.66			(0.43	)
Total from investment operations		2.98			0.69			0.90			(0.17	)
Less distributions from:
Net investment income		(0.06	)		(0.05	)		(0.19	)		(0.15	)
Net realized gains		—			—			—			(0.01	)
Return of capital		—			(0.13	)		(0.01	)		—
Total distributions		(0.06	)		(0.18	)		(0.20	)		(0.16	)

Net asset value, end of period	$	13.80		$	10.88		$	10.37		$	9.67
Total return ³		27.43	% ⁶		6.79	%		9.40	%		(1.68	)% ⁶
Net assets, at end of period (000s)	$	115,991		$	45,034		$	7,892		$	5,438
Ratio of gross expenses to average net assets before expense reimbursement ^{4, 5}		1.04	% ⁷		1.30	%		1.80	%		3.10	% ⁷
Ratio of net expenses to average net assets after expense reimbursement ⁵		0.95	% ⁷		0.95	%		0.95	%		0.95	% ⁷
Ratio of net investment income to average net assets ⁵		0.84	% ⁷		1.16	%		2.47	%		3.35	% ⁷
Portfolio Turnover Rate		20	% ⁶		90	%		50	%		13	% ⁶

Eventide Dividend Opportunities Fund commenced on September 29, 2017.

Per share amounts calculated using the average shares method.

Represents the ratio of expenses to average net assets absent fee waivers and/or expense reimbursements by the manager.

The ratios of expenses to average net assets and net investment income to average net assets do not reflect the expenses of the underlying investment companies in which the Fund invests.

Not annualized.

Annualized.

See accompanying notes to financial statements.

E V E N T I D E		64

S E M I - A N N U A L R E P O R T

December 31, 2020

Eventide Exponential Technologies Fund

Financial Highlights, Class N

Per Share Data and Ratios for a Share of Beneficial Interest Outstanding Throughout the Period Presented

	Class N
	Six Months Ended
	December 31, 2020 ¹
	(Unaudited)
Net asset value, beginning of period	$	10.00
Activity from investment operations:
Net investment loss ²		(0.10	)
Net realized and unrealized gain on investments		5.90
Total from investment operations		5.80
Less distributions from:
Net realized gains		(0.02	)
Total distributions		(0.02	)

Paid-in-capital from redemption fees ²		0.00	⁶
Net asset value, end of period	$	15.78
Total return ³		57.97	% ⁷
Net assets, at end of period (000s)	$	5,520
Ratio of gross expenses to average net assets before expense reimbursement ^{4, 5}		2.19	% ⁸
Ratio of net expenses to average net assets after expense reimbursement ⁵		1.63	% ⁸
Ratio of net investment income to average net assets ⁵		(1.48	)% ⁸
Portfolio Turnover Rate		34	% ⁷

Eventide Exponential Technologies Fund commenced on June 30, 2020.

Per share amounts calculated using the average shares method.

Represents the ratio of expenses to average net assets absent fee waivers and/or expense reimbursements by the manager.

The ratios of expenses to average net assets and net investment income to average net assets do not reflect the expenses of the underlying investment companies in which the Fund invests.

Amount represents less than $0.01 per share.

Not annualized.

Annualized.

See accompanying notes to financial statements.

E V E N T I D E		65

S E M I - A N N U A L R E P O R T

December 31, 2020

Eventide Exponential Technologies Fund

Financial Highlights, Class A

Per Share Data and Ratios for a Share of Beneficial Interest Outstanding Throughout the Period Presented

	Class A
	Six Months Ended
	December 31, 2020 ¹
	(Unaudited)
Net asset value, beginning of period	$	10.00
Activity from investment operations:
Net investment loss ²		(0.11	)
Net realized and unrealized gain on investments		5.91
Total from investment operations		5.80
Less distributions from:
Net realized gains		(0.02	)
Total distributions		(0.02	)

Paid-in-capital from redemption fees ²		0.00	⁶
Net asset value, end of period	$	15.78
Total return ³		57.97	% ⁷
Net assets, at end of period (000s)	$	2,684
Ratio of gross expenses to average net assets before expense reimbursement ^{4, 5}		2.24	% ⁸
Ratio of net expenses to average net assets after expense reimbursement ⁵		1.68	% ⁸
Ratio of net investment income to average net assets ⁵		(1.54	)% ⁸
Portfolio Turnover Rate		34	% ⁷

Eventide Exponential Technologies Fund commenced on June 30, 2020.

Per share amounts calculated using the average shares method.

Represents the ratio of expenses to average net assets absent fee waivers and/or expense reimbursements by the manager.

The ratios of expenses to average net assets and net investment income to average net assets do not reflect the expenses of the underlying investment companies in which the Fund invests.

Amount represents less than $0.01 per share.

Not annualized.

Annualized.

See accompanying notes to financial statements.

E V E N T I D E		66

S E M I - A N N U A L R E P O R T

December 31, 2020

Eventide Exponential Technologies Fund

Financial Highlights, Class C

Per Share Data and Ratios for a Share of Beneficial Interest Outstanding Throughout the Period Presented

	Class C
	Six Months Ended
	December 31, 2020 ¹
	(Unaudited)
Net asset value, beginning of period	$	10.00
Activity from investment operations:
Net investment loss ²		(0.16	)
Net realized and unrealized gain on investments		5.92
Total from investment operations		5.76
Less distributions from:
Net realized gains		(0.02	)
Total distributions		(0.02	)

Paid-in-capital from redemption fees ²		0.00	⁶
Net asset value, end of period	$	15.74
Total return ³		57.57	% ⁷
Net assets, at end of period (000s)	$	353
Ratio of gross expenses to average net assets before expense reimbursement ^{4, 5}		2.99	% ⁸
Ratio of net expenses to average net assets after expense reimbursement ⁵		2.43	% ⁸
Ratio of net investment income to average net assets ⁵		(2.28	)% ⁸
Portfolio Turnover Rate		34	% ⁷

Eventide Exponential Technologies Fund commenced on June 30, 2020.

Per share amounts calculated using the average shares method.

Represents the ratio of expenses to average net assets absent fee waivers and/or expense reimbursements by the manager.

The ratios of expenses to average net assets and net investment income to average net assets do not reflect the expenses of the underlying investment companies in which the Fund invests.

Amount represents less than $0.01 per share.

Not annualized.

Annualized.

See accompanying notes to financial statements.

E V E N T I D E		67

S E M I - A N N U A L R E P O R T

December 31, 2020

Eventide Exponential Technologies Fund

Financial Highlights, Class I

Per Share Data and Ratios for a Share of Beneficial Interest Outstanding Throughout the Period Presented

	Class I
	Six Months Ended
	December 31, 2020 ¹
	(Unaudited)
Net asset value, beginning of period	$	10.00
Activity from investment operations:
Net investment loss ²		(0.09	)
Net realized and unrealized gain on investments		5.91
Total from investment operations		5.82
Less distributions from:
Net realized gains		(0.02	)
Total distributions		(0.02	)

Paid-in-capital from redemption fees ²		0.00	⁶
Net asset value, end of period	$	15.80
Total return ³		58.17	% ⁷
Net assets, at end of period (000s)	$	50,191
Ratio of gross expenses to average net assets before expense reimbursement ^{4, 5}		1.99	% ⁸
Ratio of net expenses to average net assets after expense reimbursement ⁵		1.43	% ⁸
Ratio of net investment income to average net assets ⁵		(1.29	)% ⁸
Portfolio Turnover Rate		34	% ⁷

Eventide Exponential Technologies Fund commenced on June 30, 2020.

Per share amounts calculated using the average shares method.

Represents the ratio of expenses to average net assets absent fee waivers and/or expense reimbursements by the manager.

The ratios of expenses to average net assets and net investment income to average net assets do not reflect the expenses of the underlying investment companies in which the Fund invests.

Amount represents less than $0.01 per share.

Not annualized.

Annualized.

See accompanying notes to financial statements.

E V E N T I D E		68

S E M I - A N N U A L R E P O R T

December 31, 2020

Eventide Gilead Fund

Financial Highlights, Class N

Per Share Data and Ratios for a Share of Beneficial Interest Outstanding Throughout each of the Periods Presented

	Class N
	Six Months Ended
	December 31, 2020			Year Ended			Year Ended			Year Ended			Year Ended			Year Ended
	(Unaudited)			June 30, 2020			June 30, 2019			June 30, 2018			June 30, 2017			June 30, 2016
Net asset value, beginning of period	$	47.16		$	41.75		$	37.80		$	29.99		$	23.38		$	29.19
Activity from investment operations:
Net investment loss ¹		(0.21	)		(0.25	)		(0.14	)		(0.06	)		(0.02	)		(0.10	)
Net realized and unrealized gain (loss) on investments		16.71			6.98			5.80			7.87			6.63			(5.42	)
Total from investment operations		16.50			6.73			5.66			7.81			6.61			(5.52	)
Less distributions from:
Net realized gains		(0.51	)		(1.32	)		(1.71	)		—			—			(0.29	)
Total distributions		(0.51	)		(1.32	)		(1.71	)		—			—			(0.29	)

Net asset value, end of period	$	63.15		$	47.16		$	41.75		$	37.80		$	29.99		$	23.38
Total return ²		34.98	% ⁵		16.63	%		16.41	%		26.04	%		28.27	%		(18.99	)%
Net assets, at end of period (000s)	$	748,682		$	549,944		$	639,372		$	435,526		$	327,587		$	355,450
Ratio of net expenses to average net assets ³		1.31	% ⁶		1.38	%		1.39	%		1.39	%		1.40	%		1.39	%
Ratio of net investment loss to average net assets ^{3, 4}		(0.77	)% ⁶		(0.62	)%		(0.37	)%		(0.16	)%		(0.06	)%		(0.36	)%
Portfolio Turnover Rate		9	% ⁵		36	%		38	%		24	%		26	%		28	%

Per share amounts calculated using the average shares method.

The ratios of expenses to average net assets and net investment loss to average net assets do not reflect the expenses of the underlying investment companies in which the Fund invests.

Recognition of net investment loss is affected by the timing and declaration of dividends by the underlying investment companies in which the Fund invests.

Not annualized.

Annualized.

See accompanying notes to financial statements.

E V E N T I D E		69

S E M I - A N N U A L R E P O R T

December 31, 2020

Eventide Gilead Fund

Financial Highlights, Class A

Per Share Data and Ratios for a Share of Beneficial Interest Outstanding Throughout each of the Periods Presented

	Class A
	Six Months Ended
	December 31, 2020			Year Ended			Year Ended			Year Ended			Year Ended			Year Ended
	(Unaudited)			June 30, 2020			June 30, 2019			June 30, 2018			June 30, 2017			June 30, 2016
Net asset value, beginning of period	$	46.92		$	41.57		$	37.66		$	29.89		$	23.32		$	29.13
Activity from investment operations:
Net investment loss ¹		(0.23	)		(0.27	)		(0.16	)		(0.07	)		(0.03	)		(0.10	)
Net realized and unrealized gain (loss) on investments		16.63			6.94			5.78			7.84			6.60			(5.42	)
Total from investment operations		16.40			6.67			5.62			7.77			6.57			(5.52	)
Less distributions from:
Net realized gains		(0.51	)		(1.32	)		(1.71	)		—			—			(0.29	)
Total distributions		(0.51	)		(1.32	)		(1.71	)		—			—			(0.29	)

Net asset value, end of period	$	62.81		$	46.92		$	41.57		$	37.66		$	29.89		$	23.32
Total return ²		34.97	% ⁵		16.58	%		16.36	%		26.00	%		28.17	%		(19.03	)%
Net assets, at end of period (000s)	$	405,430		$	301,013		$	274,059		$	274,257		$	452,153		$	558,602
Ratio of net expenses to average net assets ³		1.36	% ⁶		1.43	%		1.44	%		1.44	%		1.45	%		1.44	%
Ratio of net investment loss to average net assets ^{3, 4}		(0.82	)% ⁶		(0.69	)%		(0.44	)%		(0.21	)%		(0.12	)%		(0.41	)%
Portfolio Turnover Rate		9	% ⁵		36	%		38	%		24	%		26	%		28	%

Per share amounts calculated using the average shares method.

The ratios of expenses to average net assets and net investment loss to average net assets do not reflect the expenses of the underlying investment companies in which the Fund invests.

Recognition of net investment loss is affected by the timing and declaration of dividends by the underlying investment companies in which the Fund invests.

Not annualized.

Annualized.

See accompanying notes to financial statements.

E V E N T I D E		70

S E M I - A N N U A L R E P O R T

December 31, 2020

Eventide Gilead Fund

Financial Highlights, Class C

Per Share Data and Ratios for a Share of Beneficial Interest Outstanding Throughout each of the Periods Presented

	Class C
	Six Months Ended
	December 31, 2020			Year Ended			Year Ended			Year Ended			Year Ended			Year Ended
	(Unaudited)			June 30, 2020			June 30, 2019			June 30, 2018			June 30, 2017			June 30, 2016
Net asset value, beginning of period	$	42.86		$	38.37		$	35.16		$	28.12		$	22.10		$	27.83
Activity from investment operations:
Net investment loss ¹		(0.39	)		(0.53	)		(0.41	)		(0.31	)		(0.21	)		(0.27	)
Net realized and unrealized gain (loss) on investments		15.15			6.34			5.33			7.35			6.23			(5.17	)
Total from investment operations		14.76			5.81			4.92			7.04			6.02			(5.44	)
Less distributions from:
Net realized gains		(0.51	)		(1.32	)		(1.71	)		—			—			(0.29	)
Total distributions		(0.51	)		(1.32	)		(1.71	)		—			—			(0.29	)

Net asset value, end of period	$	57.11		$	42.86		$	38.37		$	35.16		$	28.12		$	22.10
Total return ²		34.43	% ⁵		15.71	%		15.51	%		25.04	%		27.24	%		(19.63	)%
Net assets, at end of period (000s)	$	370,488		$	289,242		$	266,001		$	230,290		$	190,858		$	193,872
Ratio of net expenses to average net assets ³		2.11	% ⁶		2.18	%		2.19	%		2.19	%		2.20	%		2.19	%
Ratio of net investment loss to average net assets ^{3, 4}		(1.57	)% ⁶		(1.42	)%		(1.17	)%		(0.96	)%		(0.86	)%		(1.16	)%
Portfolio Turnover Rate		9	% ⁵		36	%		38	%		24	%		26	%		28	%

Per share amounts calculated using the average shares method.

The ratios of expenses to average net assets and net investment loss to average net assets do not reflect the expenses of the underlying investment companies in which the Fund invests.

Recognition of net investment loss is affected by the timing and declaration of dividends by the underlying investment companies in which the Fund invests.

Not annualized.

Annualized.

See accompanying notes to financial statements.

E V E N T I D E		71

S E M I - A N N U A L R E P O R T

December 31, 2020

Eventide Gilead Fund

Financial Highlights, Class I

Per Share Data and Ratios for a Share of Beneficial Interest Outstanding Throughout each of the Periods Presented

	Class I
	Six Months Ended
	December 31, 2020			Year Ended			Year Ended			Year Ended			Year Ended			Year Ended
	(Unaudited)			June 30, 2020			June 30, 2019			June 30, 2018			June 30, 2017			June 30, 2016
Net asset value, beginning of period	$	48.22		$	42.59		$	38.44		$	30.43		$	23.68		$	29.50
Activity from investment operations:
Net investment income (loss) ¹		(0.16	)		(0.18	)		(0.07	)		0.01			0.04			(0.04	)
Net realized and unrealized gain (loss) on investments		17.10			7.13			5.93			8.00			6.71			(5.49	)
Total from investment operations		16.94			6.95			5.86			8.01			6.75			(5.53	)
Less distributions from:
Net realized gains		(0.51	)		(1.32	)		(1.71	)		—			—			(0.29	)
Total distributions		(0.51	)		(1.32	)		(1.71	)		—			—			(0.29	)

Net asset value, end of period	$	64.65		$	48.22		$	42.59		$	38.44		$	30.43		$	23.68
Total return ²		35.15	% ⁵		16.85	%		16.66	%		26.32	%		28.51	%		(18.82	)%
Net assets, at end of period (000s)	$	2,912,389		$	1,997,163		$	1,475,489		$	968,578		$	399,169		$	291,704
Ratio of net expenses to average net assets ³		1.11	% ⁶		1.18	%		1.19	%		1.19	%		1.20	%		1.19	%
Ratio of net investment income (loss) to average net assets ^{3, 4}		(0.57	)% ⁶		(0.43	)%		(0.17	)%		0.03	%		0.14	%		(0.16	)%
Portfolio Turnover Rate		9	% ⁵		36	%		38	%		24	%		26	%		28	%

Per share amounts calculated using the average shares method.

The ratios of expenses to average net assets and net investment loss to average net assets do not reflect the expenses of the underlying investment companies in which the Fund invests.

Recognition of net investment loss is affected by the timing and declaration of dividends by the underlying investment companies in which the Fund invests.

Not annualized.

Annualized.

See accompanying notes to financial statements.

E V E N T I D E		72

S E M I - A N N U A L R E P O R T

December 31, 2020

Eventide Healthcare & Life Sciences Fund

Financial Highlights, Class N

Per Share Data and Ratios for a Share of Beneficial Interest Outstanding Throughout each of the Periods Presented

	Class N
	Six Months Ended
	December 31, 2020			Year Ended			Year Ended			Year Ended			Year Ended			Year Ended
	(Unaudited)			June 30, 2020			June 30, 2019			June 30, 2018			June 30, 2017			June 30, 2016
Net asset value, beginning of period	$	43.33		$	35.51		$	34.52		$	23.41		$	18.70		$	26.15
Activity from investment operations:
Net investment loss ¹		(0.34	)		(0.52	)		(0.46	)		(0.40	)		(0.30	)		(0.30	)
Net realized and unrealized gain (loss) on investments		13.48			9.19			3.39			11.87			5.01			(6.90	)
Total from investment operations		13.14			8.67			2.93			11.47			4.71			(7.20	)
Less distributions from:
Net realized gains		(1.94	)		(0.87	)		(1.98	)		(0.37	)		—			(0.29	)
Total distributions		(1.94	)		(0.87	)		(1.98	)		(0.37	)		—			(0.29	)

Paid-in-capital from redemption fees ¹		0.00	⁶		0.02			0.04			0.01			0.00	⁶		0.04
Net asset value, end of period	$	54.53		$	43.33		$	35.51		$	34.52		$	23.41		$	18.70
Total return ²		30.26	% ⁷		24.68	%		10.38	% ⁵		49.45	% ⁵		25.19	%		(27.64	)%
Net assets, at end of period (000s)	$	281,823		$	231,460		$	147,468		$	93,030		$	37,369		$	39,558
Ratio of net expenses to average net assets ³		1.45	% ⁸		1.50	%		1.49	%		1.50	% ⁴		1.54	%		1.52	%
Ratio of net investment loss to average net assets ³		(1.45	)% ⁸		(1.44	)%		(1.38	)%		(1.35	)% ⁴		(1.42	)%		(1.42	)%
Portfolio Turnover Rate		35	% ⁷		33	%		53	%		43	%		27	%		28	%

Per share amounts calculated using the average shares method.

The ratios of expenses to average net assets and net investment loss to average net assets do not reflect the expenses of the underlying investment companies in which the Fund invests.

The ratios include 0.01% for the year ended June 30, 2018 attributed to interest expense.

Includes adjustments in accordance with accounting principles generally accepted in the United States of America and, consequently, the net asset value for financial reporting purposes and the returns based upon those net asset values may differ from the net asset values and returns for shareholder transactions.

Amount represents less than $0.01 per share.

Not annualized.

Annualized.

See accompanying notes to financial statements.

E V E N T I D E		73

S E M I - A N N U A L R E P O R T

December 31, 2020

Eventide Healthcare & Life Sciences Fund

Financial Highlights, Class A

Per Share Data and Ratios for a Share of Beneficial Interest Outstanding Throughout each of the Periods Presented

	Class A
	Six Months Ended
	December 31, 2020			Year Ended			Year Ended			Year Ended			Year Ended			Year Ended
	(Unaudited)			June 30, 2020			June 30, 2019			June 30, 2018			June 30, 2017			June 30, 2016
Net asset value, beginning of period	$	43.10		$	35.33		$	34.40		$	23.33		$	18.65		$	26.09
Activity from investment operations:
Net investment loss ¹		(0.35	)		(0.53	)		(0.48	)		(0.40	)		(0.31	)		(0.31	)
Net realized and unrealized gain (loss) on investments		13.39			9.15			3.35			11.83			4.99			(6.88	)
Total from investment operations		13.04			8.62			2.87			11.43			4.68			(7.19	)
Less distributions from:
Net realized gains		(1.94	)		(0.87	)		(1.98	)		(0.37	)		—			(0.29	)
Total distributions		(1.94	)		(0.87	)		(1.98	)		(0.37	)		—			(0.29	)

Paid-in-capital from redemption fees ¹		0.00	⁶		0.02			0.04			0.01			0.00	⁶		0.04
Net asset value, end of period	$	54.20		$	43.10		$	35.33		$	34.40		$	23.33		$	18.65
Total return ²		30.19	% ⁷		24.67	%		10.24	% ⁵		49.45	% ⁵		25.09	%		(27.64	)%
Net assets, at end of period (000s)	$	222,320		$	175,151		$	143,407		$	133,329		$	138,722		$	148,927
Ratio of net expenses to average net assets ³		1.50	% ⁸		1.55	%		1.54	%		1.55	% ⁴		1.59	%		1.57	%
Ratio of net investment loss to average net assets ³		(1.50	)% ⁸		(1.49	)%		(1.43	)%		(1.40	)% ⁴		(1.47	)%		(1.47	)%
Portfolio Turnover Rate		35	% ⁷		33	%		53	%		43	%		27	%		28	%

Per share amounts calculated using the average shares method.

The ratios of expenses to average net assets and net investment loss to average net assets do not reflect the expenses of the underlying investment companies in which the Fund invests.

The ratios include 0.01% for the year ended June 30, 2018 attributed to interest expense.

Amount represents less than $0.01 per share.

Not annualized.

Annualized.

See accompanying notes to financial statements.

E V E N T I D E		74

S E M I - A N N U A L R E P O R T

December 31, 2020

Eventide Healthcare & Life Sciences Fund

Financial Highlights, Class C

Per Share Data and Ratios for a Share of Beneficial Interest Outstanding Throughout each of the Periods Presented

	Class C
	Six Months Ended
	December 31, 2020			Year Ended			Year Ended			Year Ended			Year Ended			Year Ended
	(Unaudited)			June 30, 2020			June 30, 2019			June 30, 2018			June 30, 2017			June 30, 2016
Net asset value, beginning of period	$	40.56		$	33.54		$	33.00		$	22.57		$	18.18		$	25.62
Activity from investment operations:
Net investment loss ¹		(0.50	)		(0.76	)		(0.69	)		(0.60	)		(0.45	)		(0.46	)
Net realized and unrealized gain (loss) on investments		12.58			8.63			3.17			11.39			4.84			(6.72	)
Total from investment operations		12.08			7.87			2.48			10.79			4.39			(7.18	)
Less distributions from:
Net realized gains		(1.94	)		(0.87	)		(1.98	)		(0.37	)		—			(0.29	)
Total distributions		(1.94	)		(0.87	)		(1.98	)		(0.37	)		—			(0.29	)

Paid-in-capital from redemption fees ¹		0.00	⁶		0.02			0.04			0.01			0.00	⁶		0.03
Net asset value, end of period	$	50.70		$	40.56		$	33.54		$	33.00		$	22.57		$	18.18
Total return ²		29.71	% ⁷		23.70	%		9.50	% ⁵		48.27	% ⁵		24.15	%		(28.15	)%
Net assets, at end of period (000s)	$	140,553		$	104,202		$	87,773		$	75,025		$	48,916		$	43,851
Ratio of net expenses to average net assets ³		2.25	% ⁸		2.30	%		2.29	%		2.30	% ⁴		2.34	%		2.32	%
Ratio of net investment loss to average net assets ³		(2.25	)% ⁸		(2.23	)%		(2.18	)%		(2.15	)% ⁴		(2.22	)%		(2.22	)%
Portfolio Turnover Rate		35	% ⁷		33	%		53	%		43	%		27	%		28	%

Per share amounts calculated using the average shares method.

The ratios of expenses to average net assets and net investment loss to average net assets do not reflect the expenses of the underlying investment companies in which the Fund invests.

The ratios include 0.01% for the year ended June 30, 2018 attributed to interest expense.

Amount represents less than $0.01 per share.

Not annualized.

Annualized.

See accompanying notes to financial statements.

E V E N T I D E		75

S E M I - A N N U A L R E P O R T

December 31, 2020

Eventide Healthcare & Life Sciences Fund

Financial Highlights, Class I

Per Share Data and Ratios for a Share of Beneficial Interest Outstanding Throughout each of the Periods Presented

	Class I
	Six Months Ended
	December 31, 2020			Year Ended			Year Ended			Year Ended			Year Ended			Year Ended
	(Unaudited)			June 30, 2020			June 30, 2019			June 30, 2018			June 30, 2017			June 30, 2016
Net asset value, beginning of period	$	44.02		$	35.98		$	34.88		$	23.60		$	18.82		$	26.26
Activity from investment operations:
Net investment loss (1)		(0.30	)		(0.46	)		(0.40	)		(0.34	)		(0.26	)		(0.26	)
Net realized and unrealized gain (loss) on investments		13.70			9.35			3.44			11.98			5.04			(6.93	)
Total from investment operations		13.40			8.89			3.04			11.64			4.78			(7.19	)
Less distributions from:
Net realized gains		(1.94	)		(0.87	)		(1.98	)		(0.37	)		—			(0.29	)
Total distributions		(1.94	)		(0.87	)		(1.98	)		(0.37	)		—			(0.29	)

Paid-in-capital from redemption fees ¹		0.00	⁶		0.02			0.04			0.01			0.00	⁶		0.04
Net asset value, end of period	$	55.48		$	44.02		$	35.98		$	34.88		$	23.60		$	18.82
Total return ²		30.38	% ⁷		24.97	%		10.60	% ⁵		49.77	% ⁵		25.40	%		(27.46	)%
Net assets, at end of period (000s)	$	1,623,786		$	1,120,862		$	705,159		$	389,458		$	131,304		$	69,257
Ratio of net expenses to average net assets ³		1.25	% ⁸		1.30	%		1.29	%		1.30	% ⁴		1.34	%		1.32	%
Ratio of net investment loss to average net assets ³		(1.25	)% ⁸		(1.24	)%		(1.19	)%		(1.15	)% ⁴		(1.23	)%		(1.22	)%
Portfolio Turnover Rate		35	% ⁷		33	%		53	%		43	%		27	%		28	%

Per share amounts calculated using the average shares method.

The ratios of expenses to average net assets and net investment loss to average net assets do not reflect the expenses of the underlying investment companies in which the Fund invests.

The ratios include 0.01% for the year ended June 30, 2018 attributed to interest expense.

Amount represents less than $0.01 per share.

Not annualized.

Annualized.

See accompanying notes to financial statements.

E V E N T I D E		76

S E M I - A N N U A L R E P O R T

December 31, 2020

Eventide Limited-Term Bond Fund

Financial Highlights, Class N

Per Share Data and Ratios for a Share of Beneficial Interest Outstanding Throughout the Periods Presented

	Class N
	Six Months Ended
	December 31, 2020			Year Ended			Year Ended
	(Unaudited)			June 30, 2020			June 30, 2019 ¹
Net asset value, beginning of period	$	10.62		$	10.38		$	10.03
Activity from investment operations:
Net investment income ²		0.05			0.15			0.12
Net realized and unrealized gain on investments		0.20			0.30			0.34
Total from investment operations		0.25			0.45			0.46
Less distributions from:
Net investment income		(0.20	)		(0.19	)		(0.11	)
Net realized gains		(0.07	)		—			—
Return of capital		—			(0.02	)		—
Total distributions		(0.27	)		(0.21	)		(0.11	)

Net asset value, end of period	$	10.60		$	10.62		$	10.38
Total return ³		1.03	% ⁵		4.37	%		4.64	% ⁵
Net assets, at end of period (000s)	$	9,041		$	37,973		$	1,680
Ratio of gross expenses to average net assets before expense reimbursement ⁴		0.98	% ⁶		1.11	%		2.41	% ⁶
Ratio of net expenses to average net assets after expense reimbursement		0.75	% ⁶		0.75	%		0.98	% ⁶
Ratio of net investment income to average net assets		0.91	% ⁶		1.44	%		2.20	% ⁶
Portfolio Turnover Rate		55	% ⁵		59	%		60	% ⁵

Eventide Limited-Term Bond Fund Class N commenced on December 14, 2018.

Per share amounts calculated using the average shares method.

Represents the ratio of expenses to average net assets absent fee waivers and/or expense reimbursements/recapture by the manager.

Not annualized.

Annualized.

See accompanying notes to financial statements.

E V E N T I D E		77

S E M I - A N N U A L R E P O R T

December 31, 2020

Eventide Limited-Term Bond Fund

Financial Highlights, Class A

Per Share Data and Ratios for a Share of Beneficial Interest Outstanding Throughout Each of the Periods Presented

	Class A
	Six Months
	Ended			Year			Period			Year			Year			Year			Year
	December 31,			Ended			Ended			Ended			Ended			Ended			Ended
	2020			June 30,			June 30,			October 31,			October 31,			October 31,			October 31,
	(Unaudited)			2020			2019 ¹			2018			2017			2016			2015 ²
Net asset value, beginning of period	$	10.65		$	10.41		$	10.06		$	10.44		$	10.48		$	10.45		$	10.62
Activity from investment operations:
Net investment income ³		0.04			0.17			0.14			0.19			0.19			0.21			0.17
Net realized and unrealized gain (loss) on investments		0.07			0.27			0.37			(0.35	)		(0.04	)		0.02			(0.07	)
Total from investment operations		0.11			0.44			0.51			(0.16	)		0.15			0.23			0.10
Less distributions from:
Net investment income		(0.07	)		(0.18	)		(0.16	)		(0.20	)		(0.19	)		(0.20	)		(0.25	)
Net realized gains		(0.07	)		—			—			(0.02	)		—			—			(0.02	)
Return of capital		—			(0.02	)		—			—			—			—			—
Total distributions		(0.14	)		(0.20	)		(0.16	)		(0.22	)		(0.19	)		(0.20	)		(0.27	)

Paid-in-capital from redemption fees		—			—			—			0.00	⁶		0.00	⁶		0.00	⁶		0.00	⁶
Net asset value, end of period	$	10.62		$	10.65		$	10.41		$	10.06		$	10.44		$	10.48		$	10.45
Total return ⁴		1.01	% ⁷		4.30	%		5.08	% ⁷		(1.52	)%		1.49	%		2.25	%		0.97	%
Net assets, at end of period (000s)	$	20,268		$	12,873		$	13,977		$	17,191		$	25,479		$	23,962		$	21,972
Ratio of gross expenses to average net assets before expense reimbursement ⁵		1.03	% ⁸		1.16	%		2.09	% ⁸		1.62	%		1.58	%		1.51	%		1.63	%
Ratio of net expenses to average net assets after expense reimbursement		0.80	% ⁸		0.80	%		1.08	% ⁸		1.25	%		1.25	%		1.25	%		1.25	%
Ratio of net investment income to average net assets		0.67	% ⁸		1.63	%		2.05	% ⁸		1.89	%		1.84	%		1.99	%		1.59	%
Portfolio Turnover Rate		55	% ⁷		59	%		60	% ⁷		27	%		49	%		52	%		43	%

Represents the period November 1, 2018 through June 30, 2019. See Notes to Financial Statements, Note 1.

On June 1, 2015 Epiphany FFV Strategic Income Fund Class N shares were renamed Class A shares.

Per share amounts calculated using the average shares method.

Represents the ratio of expenses to average net assets absent fee waivers and/or expense reimbursements by the manager.

Amount represents less than $0.01 per share.

Not annualized.

Annualized.

See accompanying notes to financial statements.

E V E N T I D E		78

S E M I - A N N U A L R E P O R T

December 31, 2020

Eventide Limited-Term Bond Fund

Financial Highlights, Class C

Per Share Data and Ratios for a Share of Beneficial Interest Outstanding Throughout the Periods Presented

	Class C
	Six Months Ended
	December 31, 2020			Year Ended			Year Ended
	(Unaudited)			June 30, 2020			June 30, 2019 ¹
Net asset value, beginning of period	$	10.60		$	10.37		$	10.03
Activity from investment operations:
Net investment income ²		(0.01	)		(0.01	)		0.07
Net realized and unrealized gain on investments		0.07			0.37			0.35
Total from investment operations		0.06			0.36			0.42
Less distributions from:
Net investment income		(0.03	)		(0.10	)		(0.08	)
Net realized gains		(0.07	)		—			—
Return of capital		—			(0.03	)		—
Total distributions		(0.10	)		(0.13	)		(0.08	)

Net asset value, end of period	$	10.56		$	10.60		$	10.37
Total return ³		0.65	% ⁵		3.50	%		4.24	% ⁵
Net assets, at end of period (000s)	$	1,244		$	401		$	72
Ratio of gross expenses to average net assets before expense reimbursement ⁴		1.78	% ⁶		1.91	%		3.21	% ⁶
Ratio of net expenses to average net assets after expense reimbursement		1.55	% ⁶		1.55	%		1.78	% ⁶
Ratio of net investment income to average net assets		(0.12	)% ⁶		(0.08	)%		1.45	% ⁶
Portfolio Turnover Rate		55	% ⁵		59	%		60	% ⁵

Eventide Limited-Term Bond Fund Class C commenced on December 14, 2018.

Per share amounts calculated using the average shares method.

Represents the ratio of expenses to average net assets absent fee waivers and/or expense reimbursements/recapture by the manager.

Not annualized.

Annualized.

See accompanying notes to financial statements.

E V E N T I D E		79

S E M I - A N N U A L R E P O R T

December 31, 2020

Eventide Limited-Term Bond Fund

Financial Highlights, Class I

Per Share Data and Ratios for a Share of Beneficial Interest Outstanding Throughout Each of the Periods Presented

	Class I
	Six Months
	Ended			Year			Period			Year			Year			Year			Year
	December 31,			Ended			Ended			Ended			Ended			Ended			Ended
	2020			June 30,			June 30,			October 31,			October 31,			October 31,			October 31,
	(Unaudited)			2020			2019 ¹			2018			2017			2016			2015 ²
Net asset value, beginning of period	$	10.89		$	10.64		$	10.27		$	10.63		$	10.51		$	10.40		$	10.55
Activity from investment operations:
Net investment income ³		0.05			0.17			0.16			0.22			0.15			0.13			0.11
Net realized and unrealized gain (loss) on investments		0.07			0.31			0.38			(0.36	)		(0.02	)		0.02			(0.08	)
Total from investment operations		0.12			0.48			0.54			(0.14	)		0.13			0.15			0.03
Less distributions from:
Net investment income		(0.08	)		(0.21	)		(0.17	)		(0.20	)		(0.01	)		(0.04	)		(0.16	)
Net realized gains		(0.07	)		—			—			(0.02	)		—			—			(0.02	)
Return of capital		—			(0.02	)		—			—			—			—			—
Total distributions		(0.15	)		(0.23	)		(0.17	)		(0.22	)		(0.01	)		(0.04	)		(0.18	)

Paid-in-capital from redemption fees		—			—			—			(0.00	) ⁶		(0.00	) ⁶		(0.00	) ⁶		(0.00	) ⁶
Net asset value, end of period	$	10.86		$	10.89		$	10.64		$	10.27		$	10.63		$	10.51		$	10.40
Total return ⁴		1.09	% ⁷		4.58	%		5.30	% ⁷		(1.31	)%		1.20	%		1.41	%		0.33	%
Net assets, at end of period (000s)	$	65,938		$	28,847		$	3,230		$	1,030		$	889		$	1,141		$	914
Ratio of gross expenses to average net assets before expense reimbursement ⁵		0.78	% ⁸		0.91	%		1.97	% ⁸		1.38	%		1.97	%		2.26	%		2.41	%
Ratio of net expenses to average net assets after expense reimbursement		0.55	% ⁸		0.55	%		0.81	% ⁸		1.00	%		1.64	%		2.00	%		2.00	%
Ratio of net investment income to average net assets		0.90	% ⁸		1.58	%		2.30	% ⁸		2.10	%		1.41	%		1.24	%		1.04	%
Portfolio Turnover Rate		55	% ⁷		59	%		60	% ⁷		27	%		49	%		52	%		43	%

Represents the period November 1, 2018 through June 30, 2019. See Notes to Financial Statements, Note 1.

Effective May 30, 2017, Epiphany FFV Strategic Income Fund Class C shares were reclassified Class I shares.

Per share amounts calculated using the average shares method.

Represents the ratio of expenses to average net assets absent fee waivers and/or expense reimbursements by the manager.

Amount represents less than $0.01 per share.

Not annualized.

Annualized.

See accompanying notes to financial statements.

E V E N T I D E		80

S E M I - A N N U A L R E P O R T

December 31, 2020

Eventide Multi -Asset Income Fund

Financial Highlights, Class N

Per Share Data and Ratios for a Share of Beneficial Interest Outstanding Throughout Each of the Periods Presented

	Class N
	Six Months Ended
	December 31, 2020			Year Ended			Year Ended			Year Ended			Year Ended			Period Ended
	(Unaudited)			June 30, 2020			June 30, 2019			June 30, 2018			June 30, 2017			June 30, 2016 ¹
Net asset value, beginning of period	$	11.38		$	10.90		$	10.58		$	11.05		$	10.32		$	10.00
Activity from investment operations:
Net investment income ²		0.05			0.17			0.28			0.34			0.26			0.27
Net realized and unrealized gain (loss) on investments		1.91			0.59			0.39			(0.30	)		0.79			0.21
Total from investment operations		1.96			0.76			0.67			0.04			1.05			0.48
Less distributions from:
Net investment income		(0.09	)		(0.14	)		(0.22	)		(0.36	)		(0.29	)		(0.15	)
Net realized gains		(0.02	)		—			(0.03	)		(0.15	)		(0.03	)		(0.01	)
Return of capital		—			(0.14	)		(0.10	)		—			—			—
Total distributions		(0.11	)		(0.28	)		(0.35	)		(0.51	)		(0.32	)		(0.16	)

Net asset value, end of period	$	13.23		$	11.38		$	10.90		$	10.58		$	11.05		$	10.32
Total return ³		17.29	% ⁸		7.03	%		6.61	%		0.29	%		10.29	%		4.79	% ⁸
Net assets, at end of period (000s)	$	27,489		$	19,454		$	17,104		$	17,028		$	10,823		$	3,899
Ratio of gross expenses to average net assets before expense reimbursement ^{4, 5}		1.08	% ⁹		1.19	%		1.30	%		1.29	% ⁶		1.37	%		2.06	% ⁹
Ratio of net expenses to average net assets after expense reimbursement ⁵		1.02	% ⁹		1.10	%		1.15	%		1.16	% ⁶		1.15	%		1.15	% ⁹
Ratio of net investment income to average net assets ^{5, 7}		0.87	% ⁹		1.44	%		2.71	%		3.05	% ⁶		2.46	%		2.82	% ⁹
Portfolio Turnover Rate		33	% ⁸		110	%		79	%		29	%		38	%		18	% ⁸

The Eventide Multi-Asset Income Fund commenced operations on July 15, 2015.

Per share amounts calculated using the average shares method.

Represents the ratio of expenses to average net assets absent fee waivers and/or expense reimbursements by the manager.

The ratios of expenses to average net assets and net investment income to average net assets do not reflect the expenses of the underlying investment companies in which the Fund invests.

The ratios include 0.01% for the year ended June 30, 2018 attributed to interest expense.

Recognition of net investment income is affected by the timing and declaration of dividends by the underlying investment companies in which the Fund invests.

Not annualized.

Annualized.

See accompanying notes to financial statements.

E V E N T I D E		81

S E M I - A N N U A L R E P O R T

December 31, 2020

Eventide Multi -Asset Income Fund

Financial Highlights, Class A

Per Share Data and Ratios for a Share of Beneficial Interest Outstanding Throughout Each of the Periods Presented

	Class A
	Six Months Ended
	December 31, 2020			Year Ended			Year Ended			Year Ended			Year Ended			Period Ended
	(Unaudited)			June 30, 2020			June 30, 2019			June 30, 2018			June 30, 2017			June 30, 2016 ¹
Net asset value, beginning of period	$	11.38		$	10.89		$	10.57		$	11.05		$	10.32		$	10.00
Activity from investment operations:
Net investment income ²		0.06			0.16			0.28			0.30			0.25			0.27
Net realized and unrealized gain (loss) on investments		1.90			0.60			0.39			(0.28	)		0.79			0.20
Total from investment operations		1.96			0.76			0.67			0.02			1.04			0.47
Less distributions from:
Net investment income		(0.09	)		(0.14	)		(0.22	)		(0.35	)		(0.28	)		(0.14	)
Net realized gains		(0.02	)		—			(0.03	)		(0.15	)		(0.03	)		(0.01	)
Return of capital		—			(0.13	)		(0.10	)		—			—			—
Total distributions		(0.11	)		(0.27	)		(0.35	)		(0.50	)		(0.31	)		(0.15	)

Net asset value, end of period	$	13.23		$	11.38		$	10.89		$	10.57		$	11.05		$	10.32
Total return ³		17.27	% ⁸		7.07	%		6.56	%		0.15	%		10.23	%		4.74	% ⁸
Net assets, at end of period (000s)	$	14,227		$	10,659		$	8,817		$	11,864		$	20,080		$	8,124
Ratio of gross expenses to average net assets before expense reimbursement ^{4, 5}		1.13	% ⁹		1.24	%		1.35	%		1.34	% ⁶		1.42	%		2.13	% ⁹
Ratio of net expenses to average net assets after expense reimbursement ⁵		1.07	% ⁹		1.15	%		1.20	%		1.21	% ⁶		1.20	%		1.20	% ⁹
Ratio of net investment income to average net assets ^{5, 7}		0.82	% ⁹		1.39	%		2.63	%		2.74	% ⁶		2.33	%		2.82	% ⁹
Portfolio Turnover Rate		33	% ⁸		110	%		79	%		29	%		38	%		18	% ⁸

The Eventide Multi-Asset Income Fund commenced operations on July 15, 2015.

Per share amounts calculated using the average shares method.

Represents the ratio of expenses to average net assets absent fee waivers and/or expense reimbursements by the manager.

The ratios of expenses to average net assets and net investment income to average net assets do not reflect the expenses of the underlying investment companies in which the Fund invests.

The ratios include 0.01% for the year ended June 30, 2018 attributed to interest expense.

Recognition of net investment income is affected by the timing and declaration of dividends by the underlying investment companies in which the Fund invests.

Not annualized.

Annualized.

See accompanying notes to financial statements.

E V E N T I D E		82

S E M I - A N N U A L R E P O R T

December 31, 2020

Eventide Multi -Asset Income Fund

Financial Highlights, Class C

Per Share Data and Ratios for a Share of Beneficial Interest Outstanding Throughout Each of the Periods Presented

	Class C
	Six Months Ended
	December 31, 2020			Year Ended			Year Ended			Year Ended			Year Ended			Period Ended
	(Unaudited)			June 30, 2020			June 30, 2019			June 30, 2018			June 30, 2017			June 30, 2016 ¹
Net asset value, beginning of period	$	11.34		$	10.86		$	10.55		$	11.03		$	10.30		$	10.00
Activity from investment operations:
Net investment income ²		0.00	⁸		0.07			0.20			0.24			0.18			0.19
Net realized and unrealized gain (loss) on investments		1.91			0.60			0.38			(0.29	)		0.77			0.22
Total from investment operations		1.91			0.67			0.58			(0.05	)		0.95			0.41
Less distributions from:
Net investment income		(0.06	)		(0.10	)		(0.16	)		(0.28	)		(0.19	)		(0.10	)
Net realized gains		(0.02	)		—			(0.03	)		(0.15	)		(0.03	)		(0.01	)
Return of capital		—			(0.09	)		(0.08	)		—			—			—
Total distributions		(0.08	)		(0.19	)		(0.27	)		(0.43	)		(0.22	)		(0.11	)

Net asset value, end of period	$	13.17		$	11.34		$	10.86		$	10.55		$	11.03		$	10.30
Total return ³		16.81	% ⁹		6.23	%		5.73	%		(0.49	)%		9.29	%		4.08	% ⁸
Net assets, at end of period (000s)	$	12,697		$	8,091		$	6,194		$	6,654		$	5,881		$	2,424
Ratio of gross expenses to average net assets before expense reimbursement ^{4, 5}		1.88	% ¹⁰		1.99	%		2.10	%		2.09	% ⁶		2.17	%		2.81	% ⁹
Ratio of net expenses to average net assets after expense reimbursement ⁵		1.82	% ¹⁰		1.90	%		1.95	%		1.96	% ⁶		1.95	%		1.95	% ⁹
Ratio of net investment income to average net assets ^{5, 7}		0.07	% ¹⁰		0.64	%		1.90	%		2.19	% ⁶		1.63	%		1.99	% ⁹
Portfolio Turnover Rate		33	% ¹⁰		110	%		79	%		29	%		38	%		18	% ⁸

The Eventide Multi-Asset Income Fund commenced operations on July 15, 2015.

Per share amounts calculated using the average shares method.

Represents the ratio of expenses to average net assets absent fee waivers and/or expense reimbursements by the manager.

The ratios of expenses to average net assets and net investment income to average net assets do not reflect the expenses of the underlying investment companies in which the Fund invests.

The ratios include 0.01% for the year ended June 30, 2018 attributed to interest expense.

Recognition of net investment income is affected by the timing and declaration of dividends by the underlying investment companies in which the Fund invests.

Amount represents less than $0.01 per share.

Not annualized.

10.

Annualized.

See accompanying notes to financial statements.

E V E N T I D E		83

S E M I - A N N U A L R E P O R T

December 31, 2020

Eventide Multi-Asset Income Fund

Financial Highlights, Class I

Per Share Data and Ratios for a Share of Beneficial Interest Outstanding Throughout Each of the Periods Presented

	Class I
	Six Months Ended
	December 31, 2020			Year Ended			Year Ended			Year Ended			Year Ended			Period Ended
	(Unaudited)			June 30, 2020			June 30, 2019			June 30, 2018			June 30, 2017			June 30, 2016 ¹
Net asset value, beginning of period	$	11.38		$	10.90		$	10.58		$	11.05		$	10.33		$	10.00
Activity from investment operations:
Net investment income ²		0.06			0.18			0.31			0.36			0.28			0.28
Net realized and unrealized gain (loss) on investments		1.91			0.60			0.38			(0.31	)		0.78			0.22
Total from investment operations		1.97			0.78			0.69			0.05			1.06			0.50
Less distributions from:
Net investment income		(0.10	)		(0.15	)		(0.23	)		(0.37	)		(0.31	)		(0.16	)
Net realized gains		(0.02	)		—			(0.03	)		(0.15	)		(0.03	)		(0.01	)
Return of capital		—			(0.15	)		(0.11	)		—			—			—
Total distributions		(0.12	)		(0.30	)		(0.37	)		(0.52	)		(0.34	)		(0.17	)

Net asset value, end of period	$	13.23		$	11.38		$	10.90		$	10.58		$	11.05		$	10.33
Total return ³		17.39	% ⁸		7.23	%		6.81	%		0.47	%		10.47	%		5.03	% ⁸
Net assets, at end of period (000s)	$	151,769		$	110,295		$	79,513		$	76,764		$	43,821		$	18,081
Ratio of gross expenses to average net assets before expense reimbursement ^{4, 5}		0.88	% ⁹		0.99	%		1.10	%		1.09	% ⁶		1.17	%		1.81	% ⁹
Ratio of net expenses to average net assets after expense reimbursement ⁵		0.82	% ⁹		0.90	%		0.95	%		0.96	% ⁶		0.95	%		0.95	% ⁹
Ratio of net investment income to average net assets ^{5, 7}		1.07	% ⁹		1.65	%		2.92	%		3.32	% ⁶		2.62	%		2.94	% ⁹
Portfolio Turnover Rate		33	% ⁸		110	%		79	%		29	%		38	%		18	% ⁸

The Eventide Multi-Asset Income Fund commenced operations on July 15, 2015.

Per share amounts calculated using the average shares method.

Represents the ratio of expenses to average net assets absent fee waivers and/or expense reimbursements by the manager.

The ratios of expenses to average net assets and net investment income to average net assets do not reflect the expenses of the underlying investment companies in which the Fund invests.

The ratios include 0.01% for the year ended June 30, 2018 attributed to interest expense.

Recognition of net investment income is affected by the timing and declaration of dividends by the underlying investment companies in which the Fund invests.

Not annualized.

Annualized.

See accompanying notes to financial statements.

E V E N T I D E		84

S E M I - A N N U A L R E P O R T

December 31, 2020

Eventide Funds
Notes to Financial Statements (Unaudited)	December 31, 2020

(1)

ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES

Mutual Fund Series Trust (the “Trust”), was organized as an Ohio business trust on February 27, 2006. The Trust is registered as an open-end management investment company under the Investment Company Act of 1940, as amended (“1940 Act”). The Trust currently consists of thirty-nine series. These financial statements include the following series: Eventide Core Bond Fund, Eventide Dividend Opportunities Fund (formerly Eventide Global Dividend Opportunities Fund), Eventide Exponential Technologies Fund, Eventide Gilead Fund, Eventide Healthcare & Life Sciences Fund, Eventide Limited-Term Bond Fund and the Eventide Multi-Asset Income Fund (each a “Fund” or collectively the “Funds”). Each Fund except Eventide Exponential Technologies Fund is a diversified series of the Trust. Eventide Exponential Technologies Fund is a non-diversified series of the Trust. The Funds’ investment manager is Eventide Asset Management, LLC (the “Manager”).

Eventide Core Bond Fund commenced operations on July 31, 2020. The Fund’s investment objective is total return consistent with income generation.

Eventide Dividend Opportunities Fund commenced operations on September 29, 2017. The Fund’s investment objectives are dividend income and long-term capital appreciation. The Fund’s secondary objective is dividend growth.

Eventide Exponential Technologies Fund commenced operations on June 30, 2020. The Fund’s investment objective is to achieve long-term capital appreciation.

Eventide Gilead Fund commenced operations on July 8, 2008. The Fund’s investment objective is to achieve long-term capital appreciation.

Eventide Healthcare & Life Sciences Fund commenced operations on December 27, 2012. The Fund’s investment objective is to achieve long-term capital appreciation.

Eventide Limited-Term Bond Fund (formerly Epiphany FFV Strategic Income Fund) Class A and Class I shares commenced operations on July 28, 2010. On March 29, 2017, the Board of Trustees of Epiphany Funds voted to reclassify (the “Conversion”) all outstanding Class C Shares of the Epiphany FFV Strategic Income Fund to Class I shares to be effective on May 30, 2017 (the “Conversion Date”). On the Conversion Date, each Class C share was reclassified as a Class I shares equal in value to the Class C shares owned by that shareholder for the respective fund. The Eventide Limited-Term Bond Fund’s Class N and Class C shares commenced operations December 14, 2018. The Fund changed its fiscal year end from October 31 to June 30. The Fund’s investment objective is income.

Eventide Multi-Asset Income Fund commenced operations on July 15, 2015. The Fund’s investment objective is to seek current income while maintaining the potential for capital appreciation.

E V E N T I D E		85

S E M I - A N N U A L R E P O R T

December 31, 2020

Each Fund offers four classes of shares, Class N, Class A, Class C and Class I. Each class differs as to sales and redemption charges and ongoing fees.

The following is a summary of significant accounting policies consistently followed by the Funds and are in accordance with accounting principles generally accepted in the United States of America (“GAAP”). The Funds are an investment companies and accordingly follow the investment company accounting and reporting guidance of the Financial Accounting Standards Board (FASB) Accounting Standard Codification Topic 946 “Financial Services – Investment Companies” including Accounting Standards Update 2013-08.

a) Securities Valuation – Securities listed on an exchange are valued at the last reported sale price at the close of the regular trading session of the exchange on the business day the value is being determined, or in the case of securities listed on NASDAQ, at the NASDAQ Official Closing Price (“NOCP”). In the absence of a sale, such securities shall be valued at the last bid price on the day of valuation. Debt securities (other than short-term obligations) are valued each day by an independent pricing service approved by the Board of Trustees (the “Board”) using methods which include current market quotations from a major market maker in the securities and based on methods which include the consideration of yields or prices of securities of comparable quality, coupon, maturity and type. The Funds may invest in portfolios of open-end or closed-end investment companies (the “underlying funds”). Open-end investment companies are valued at their respective net asset values as reported by such investment companies. The underlying funds value securities in their portfolios for which market quotations are readily available at their market values (generally the last reported sale price) and all other securities and assets at their fair value by the methods established by the boards of trustees of the underlying funds. The shares of many closed-end investment companies, after their initial public offering, frequently trade at a price per share, which is different than the net asset value per share. The difference represents a market premium or market discount of such shares. There can be no assurances that the market discount or market premium on shares of any closed-end investment company purchased by the Funds will not change. The independent pricing service does not distinguish between smaller-sized bond positions known as “odd lots” and larger institutional-sized bond positions known as “round lots”. A Fund may fair value a particular bond if the manager does not believe that the round lot value provided by the independent pricing service reflects fair value of the Fund’s holding. Short term debt obligations having 60 days or less remaining until maturity, at time of purchase, may be valued at amortized cost, provided each such valuations represent fair value. Options are valued at their closing price on the exchange they are traded on. When no closing price is available, options are valued at their mean price.

In unusual circumstances, instead of valuing securities in the usual manner, the Funds may value securities at “fair value” as determined in good faith by the Board, pursuant to the procedures (the “Procedures”) approved by the Board. The Procedures consider, among others, the following factors to determine a security’s fair value: the nature and pricing history (if any) of the security; whether any dealer quotations for the security are available; and possible valuation methodologies that could be used to determine the fair value of the security. Fair value may also be used by the Board if extraordinary events occur after the close of the relevant world market but prior to the New York Stock Exchange close.

The Funds utilize various methods to measure the fair value of most of their investments on a recurring basis. GAAP establishes a hierarchy that prioritizes inputs to valuation methods. The three levels of input are:

■

Level 1 – Unadjusted quoted prices in active markets for identical assets and liabilities that the Funds have the ability to access.

E V E N T I D E		86

S E M I - A N N U A L R E P O R T

December 31, 2020

■

Level 2 – Observable inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly or indirectly. These inputs may include quoted prices for the identical instrument in an inactive market, prices for similar instruments, interest rates, prepayment speeds, credit risk, yield curves, default rates and similar data.

■

Level 3 – Unobservable inputs for the asset or liability, to the extent relevant observable inputs are not available, representing the Funds’ own assumptions about the assumptions a market participant would use in valuing the asset or liability, and would be based on the best information available.

The availability of observable inputs can vary from security to security and is affected by a wide variety of factors, including, for example, the type of security, whether the security is new and not yet established in the marketplace, the liquidity of markets, and other characteristics particular to the security. To the extent that valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised in determining fair value is greatest for instruments categorized in Level 3.

The inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, for disclosure purposes, the level in the fair value hierarchy within which the fair value measurement falls in its entirety, is determined based on the lowest level input that is significant to the fair value measurement in its entirety.

The inputs or methodology used for valuing securities are not necessarily an indication of the risk associated with investing in those securities. The following tables summarize the inputs used as of December 31, 2020 for the Funds’ assets measured at fair value:

Eventide Core Bond Fund Assets

Security Classifications	Level 1		Level 2		Level 3		Totals
Corporate Bonds	$	—	$	30,893,287	$	—		30,893,287
Municipal Bonds		—		600,384		—		600,384
U.S. Government & Agencies		—		19,676,772		—		19,676,772
Short-Term Investments		803,239		—		—		803,239
Total	$	803,239	$	51,170,443	$	—	$	51,973,682

Eventide Dividend Opportunities Fund Assets

Security Classifications	Level 1		Level 2		Level 3		Totals
Common Stock ¹	$	121,040,102	$	—	$	—		121,040,102
Corporate Bonds		—		5,928,302		—		5,928,302
Limited Partnerships		7,435,845		—		—		7,435,845
Preferred Stock		4,994,870		—		—		4,994,870
Real Estate Investment Trusts (REITs)		23,942,570		—		—		23,942,570
Short-Term Investments		1,581,947		—		—		1,581,947
Total	$	158,995,334	$	5,928,302	$	—	$	164,923,636

E V E N T I D E		87

S E M I - A N N U A L R E P O R T

December 31, 2020

Eventide Exponential Technologies Fund Assets

Security Classifications	Level 1		Level 2		Level 3		Totals
Common Stock ¹	$	55,914,315	$	—	$	—		55,914,315
Corporate Bond		—		318,000		—		318,000
Limited Partnerships		—		—		—		—
Put Options Purchased		70,980		67,700		—		138,680
Short-Term Investments		4,166,922		—		—		4,166,922
Total	$	60,152,217	$	385,700	$	—	$	60,537,917

Eventide Gilead Fund Assets

Security Classifications	Level 1		Level 2		Level 3		Totals
Common Stock ¹	$	3,893,970,547	$	8,397,275	$	—	$	3,902,367,822
Contingent Value Rights		—		—		3,424,532		3,424,532
Corporate Bonds		—		57,570,000		—		57,570,000
Limited Partnerships		129,435,150		—		—		129,435,150
Preferred Stock		—		81,891,827		27,269,712		109,161,539
Real Estate Invesment Trusts (REITs)		77,687,700		—		—		77,687,700
Short-Term Investments		10,798,471		—		—		10,798,471
Total	$	4,111,891,868	$	147,859,102	$	30,694,244	$	4,290,445,214

Eventide Healthcare & Life Sciences Fund Assets

Security Classifications	Level 1		Level 2		Level 3		Totals
Common Stock ¹	$	1,778,207,166	$	20,132,201	$	—	$	1,798,339,367
Contingent Value Rights		—		—		1,314,523		1,314,523
Preferred Stock		—		139,408,689		73,765,515		213,174,204
Put Options Purchased		10,039,445		292,005		—		10,331,450
Warrants		—		1,152,000		—		1,152,000
Short-Term Investments		183,101,030		—		—		183,101,030
Total	$	1,971,347,641	$	160,984,895	$	75,080,038	$	2,207,412,574

Eventide Limited-Term Bond Fund Assets

Security Classifications	Level 1		Level 2		Level 3		Totals
Collateralized Mortgage Obligations	$	—	$	846,336	$	—	$	846,336
Corporate Bonds		—		45,431,072		—		45,431,072
Municipal Bonds		—		2,761,019		—		2,761,019
Non U.S. Government & Agencies		—		921,383		—		921,383
U.S. Government & Agencies		—		42,922,984		—		42,922,984
Short-Term Investment		3,044,263		—		—		3,044,263
Total	$	3,044,263	$	92,882,794	$	—	$	95,927,057

Eventide Multi-Asset Income Fund Assets

Security Classifications	Level 1		Level 2		Level 3		Totals
Collateralized Mortgage Obligations	$	—	$	2,220,197	$	—	$	2,220,197
Common Stock ¹		72,770,409		—		—		72,770,409
Corporate Bonds		—		65,979,797		—		65,979,797
Limited Partnerships		5,987,565		—		—		5,987,565
Municipal Bonds		—		3,524,729		—		3,524,729
Non U.S. Government & Agencies		—		514,890		—		514,890
Preferred Stock		4,108,930		—		—		4,108,930
Real Estate Investment Trusts (REITs)		16,878,431		—		—		16,878,431
U.S. Government & Agencies		—		23,683,374		—		23,683,374
Short-Term Investment		2,300,155		—		—		2,300,155
Total	$	102,045,490	$	95,922,987	$	—	$	197,968,477

For a detailed break-out of investments by industry, please refer to the Portfolios of Investments.

E V E N T I D E		88

S E M I - A N N U A L R E P O R T

December 31, 2020

The following is a reconciliation of assets in which level 3 inputs were used in determining value:

Eventide Gilead Fund
	Contingent Value Rights		Preferred Stock
Beginning balance 6/30/2020	$	3,424,532	$	36,769,714
Total realized gain (loss)		—		—
Change in unrealized appreciation (depreciation)		—		500,000
Cost of purchases		—		—
Proceeds from sales		—		—
Dividend reinvest		—		—
Net transfers in/out of level 3		—		(10,000,002	)
Ending balance 12/31/2020	$	3,424,532	$	27,269,712

Eventide Healthcare & Life Sciences Fund
	Contingent Value Rights		Preferred Stock
Beginning balance 6/30/2020	$	1,314,523	$	67,723,882
Total realized gain (loss)		—		—
Change in unrealized appreciation (depreciation)		—		(317,337	)
Cost of purchases		—		42,108,971
Proceeds from sales		—		—
Dividend reinvest		—		—
Net transfers in/out of level 3		—		(35,750,001	)
Ending balance 12/31/2020	$	1,314,523	$	73,765,515

The significant unobservable inputs used in the fair value measurement of the Funds’ Level 3 private investment in Beta Bionic Series B/B2, Casma Therapeutics, Inc., Cullinan Oncology, LLC, DiCE Molecules Series C, Goldfinch Biopharma, Inc. Series A, Goldfinch Biopharma, Inc. Series B, Prometheus Biosciences, Inc., Prometheus Laboratories, Inc., Talaris Therapeutics Series B and VectivBio A.G. Series A-2 preferred stocks are as follows (1) recent investor transactions in the companies (2) updates from the companies including new clinical trials data (3) a five-percent discount based on liquidity of the securities held. A significant increase or decrease in the liquidity discount could result in a significantly lower or higher fair value, respectively.

The significant unobservable inputs used in the fair value measurement of the Funds’ Level 3 private investment in Peloton Therapeutics, Inc. contingent value rights are as follows (1) recent investor transactions in the company (2) updates from the company including new clinical trials data (3) a five-percent discount based on liquidity of the securities held. A significant increase or decrease in the liquidity discount could result in a significantly lower or higher fair value, respectively.

Fair Value at December 31, 2020	Valuation Techniques	Unobservable Input	Impact to Valuation
$0.86	Anticipated sale price less discounts plus discounted cash flow of contingent future payments.	2.5 - 75% range for probability of success of milestones, with a per share discounted weighted average of $0.8168.	Increase (Decrease) in Rate of Success Ratio equals increases (decreases) value

		5% Liquidity Risk 5% Deal Risk	Increase (Decrease) in Credit Risk/ Liquidity Risk equals Decrease (Increase) in value

There was a change in fair valuation measurement inputs from Level 3 to Level 2 for two preferred stocks. Level 2 valuations became available based on the Fund receiving daily valuations via the underlying common stock.

E V E N T I D E		89

S E M I - A N N U A L R E P O R T

December 31, 2020

The total change in unrealized appreciation and depreciation included in the Statement of Operations attributable to Level 3 investments still held at December 31, 2020 was $500,000 and $(317,337) for the Eventide Gilead Fund and Eventide Healthcare & Life Sciences Fund, respectively.

b) Accounting for Options – When the Funds write an option, an amount equal to the premium received by the Funds is recorded as a liability and is subsequently adjusted to the current fair value of the option written. Premiums received from writing options that expire unexercised are treated by the Funds on the expiration date as realized gains from investments. The difference between the premium and the amount paid on effecting a closing purchase transaction, including brokerage commissions, is also treated as a realized gain, or, if the premium is less than the amount paid for the closing purchase transaction, as a realized loss. If a call option is exercised, the premium is added to the proceeds from the sale of the underlying security or currency in determining whether the Funds have realized gains or losses. If a put option is exercised, the premium reduces the cost basis of the securities purchased by the Funds.

The Manager may use options strategies, such as puts and covered calls on individual securities, as well as options on securities indices, to generate income, to reduce portfolio volatility, or to reduce downside risk when the manager believes adverse market, political or other conditions are likely. The Manager may also utilize a combination of puts and/or calls regarding the same security (sometimes referred to as “straddles,” “collars” or “spreads”) or utilize puts and calls on related securities. The Funds may purchase a call option on a stock (including securities of exchange traded funds (“ETFs”)) it may purchase at some point in the future. When the Funds purchase an option, the premium paid is recorded as an asset. Each day the option contract is valued in accordance with the procedures for security valuation discussed above. When an offsetting option is written (a closing transaction) or the option contract expires, the Funds realize a gain or loss and the asset representing such option contract is eliminated. When a put option is exercised, the Funds realize a gain or loss from the sale of the underlying security and the proceeds of the sale are decreased by the premiums originally paid. When a call option is exercised, the Funds purchase the underlying security and the cost basis of such purchase is increased by the premium originally paid.

The notional value of the derivative instruments outstanding as of December 31, 2020 as disclosed in the Portfolios of Investments and the amounts realized and changes in unrealized gains and losses on derivative instruments during the six months as disclosed above and within the Statements of Operations serve as indicators of the volume of derivative activity of the Funds.

E V E N T I D E		90

S E M I - A N N U A L R E P O R T

December 31, 2020

The effect of derivative instruments on the Statement of Assets & Liabilities for the six months ended December 31, 2020 was as follows:

Eventide Exponential Technologies Fund

Derivative	Primary Risk Exposure	Location of Derivative on Statement of Assets and Liabilities	Fair Value of Asset Derivative
Put Options Purchased	Equity Risk	Unaffiliated investments at value	$	138,680
Total			$	138,680

Eventide Healthcare & Life Sciences Fund

Derivative	Primary Risk Exposure	Location of Derivative on Statement of Assets and Liabilities	Fair Value of Asset Derivative
Put Options Purchased	Equity Risk	Unaffiliated investments at value		10,331,450
Total				10,331,450

The effect of derivative instruments on the Statement of Operations for the six months ended December 31, 2020 was as follows:

Eventide Exponential Technologies Fund

Derivatives Not Accounted for as Hedging	Primary Risk	Location of Gain (Loss) on Derivatives	Realized and Unrealized Gain (Loss) on Liability
Instruments under GAAP	Exposure	Recognized in Income	Derivatives Recognized in Income
Options Purchased	Equity Risk	Net change unrealized depreciation from unaffiliated investments	$	(28,798	)
Total			$	(28,798	)

Eventide Gilead Fund

Derivatives Not Accounted for as Hedging	Primary Risk	Location of Gain (Loss) on Derivatives	Realized and Unrealized Gain (Loss) on Liability
Instruments under GAAP	Exposure	Recognized in Income	Derivatives Recognized in Income
Options Purchased	Equity Risk	Net realized loss from unaffiliated investments	$	(6,702,200	)
Options Purchased	Equity Risk	Net change unrealized appreciation from unaffiliated investments		2,517,200
Total			$	(4,185,000	)

Eventide Healthcare & Life Sciences Fund

Derivatives Not Accounted for as Hedging	Primary Risk	Location of Gain (Loss) on Derivatives	Realized and Unrealized Gain (Loss) on Liability
Instruments under GAAP	Exposure	Recognized in Income	Derivatives Recognized in Income
Options Purchased	Equity Risk	Net change unrealized appreciation from unaffiliated investments	$	845,558
Total			$	845,558

c) Short Sales – The Funds may sell securities short. A short sale is a transaction in which the Funds sell securities they do not own in anticipation of a decline in the market price of the securities. To deliver the securities to the buyer, the Funds must arrange through a broker to borrow the securities and, in so doing, the Funds become obligated to replace the securities borrowed at their market price at the time of replacement, whatever that price may be. The Funds will make a profit or incur a loss as a result of a short sale depending on whether the price of the securities decrease or increase between the date of the short sale and the date on which the Funds purchased the securities to replace the borrowed securities that have been sold.

d) Federal Income Tax – The Funds have qualified and intend to continue to qualify as regulated investment companies and to comply with the applicable provisions of the Internal Revenue Code of 1986, as amended, and to distribute substantially all of their taxable income to their shareholders. Therefore, no federal income or excise tax provisions are required.

E V E N T I D E		91

S E M I - A N N U A L R E P O R T

December 31, 2020

As of and during the six months ended December 31, 2020, the Funds did not have a liability for any unrecognized tax expense. The Funds recognize interest and penalties, if any, related to unrecognized tax expense as income tax expense in the Statements of Operations. As of December 31, 2020, the Funds did not incur any interest or penalties. Management has analyzed the Funds’ tax positions and has concluded that no liability for unrecognized tax benefits should be recorded related to uncertain tax positions taken on returns filed for open tax years ended June 30, 2018 to June 30, 2020, or expected to be taken in the Funds’ June 30, 2021 year-end tax returns.

e) Distributions to Shareholders – Distributions to shareholders, which are determined in accordance with income tax regulations and may differ from GAAP, are recorded on the ex-dividend date. Each Fund typically distributes substantially all of its net investment income in the form of dividends, interest and taxable capital gains to its shareholders. These distributions are automatically reinvested in the Fund unless you request cash distributions on your application or through a written request to the Fund. Each Fund expects that its distributions will consist of both capital gains, interest and dividend income. Each Fund may make distributions of its net realized capital gains (after any reductions for capital loss carry forwards) annually except for the Eventide Multi-Asset Income Fund which is monthly. The Funds intend to make quarterly distributions if applicable.

f) Multiple Class Allocations – Income, non-class specific expenses and realized/unrealized gains or losses are allocated to each class based on relative net assets. Distribution fees are charged to each respective share class in accordance with the distribution plan. Expenses of the Trust that are directly identifiable to a specific fund are charged to that fund. Expenses, which are not readily identifiable to a specific fund, are allocated in such a manner as deemed equitable, taking into consideration the nature and type of expense and the relative sizes of the funds in the Trust.

g) Security Transactions and Investment Income – Investment and shareholder transactions are recorded on the trade date. The Funds determine the gain or loss realized from the investment transactions by comparing the original cost of the security lot sold with the net sales proceeds. Dividend income is recognized on the ex-dividend date or as soon as information is available to the Funds and interest income is recognized on an accrual basis. Discounts and premiums on debt securities are amortized over their respective lives using the effective interest method, except certain callable debt securities that are held at premium and will be amortized to the earliest call date. Withholding taxes on foreign dividends have been provided for in accordance with the Funds’ understanding of the applicable country’s tax rules and rates. Distributions received from a Fund’s investments in MLPs generally are comprised of income and return of capital. The Funds record these distributions as investment income and subsequently adjusts these distributions within the components of net assets based upon their tax treatment when the information becomes available.

h) Use of Estimates – The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

i) Indemnification – The Trust indemnifies its offers and Trustees for certain liabilities that may arise from the performance of their duties to the Trust. In the normal course of business, the Trust may enter into contracts that contain a variety of representations and warranties and provide general indemnifications. The Funds’ maximum exposure under these arrangements is dependent on future claims that may be made against the Funds and, therefore, cannot be estimated; however, management considers the risk of loss from such claims to be remote.

E V E N T I D E		92

S E M I - A N N U A L R E P O R T

December 31, 2020

j) Redemption Fees and Sales Charges (loads) – A $15 fee may be charged for redemptions made by wire. A maximum sales charge of 5.75% is imposed on Class A shares of the Funds. Class A shares purchased where the sales charge was waived, are subject to a CDSC of 1.00% on redemptions within 180 days of purchase. The respective shareholders pay such CDSC charges, which are not an expense of the Funds. For the six months ended December 31, 2020, there were redemption fees of $0 paid to the Eventide Core Bond Fund, Eventide Dividend Opportunities Fund, Eventide Limited-Term Bond Fund and Eventide Multi-Asset Income Fund and there were $0 in CDSC fees paid to the Distributor. For the six months ended December 31, 2020, there were redemption fees of $4,620, $0 and $27,786 paid to the Eventide Exponential Technologies Fund, Eventide Gilead and Eventide Healthcare & Life Sciences Fund, respectively. There was $1,941 and $4 in CDSC fees paid to the Distributor for the Eventide Healthcare & Life Sciences Fund and Eventide Multi-Asset Income Fund, respectively.

k) Cash and cash equivalents – Cash and cash equivalents are held with a financial institution. The asset of the Fund may be placed in deposit accounts at U.S. banks and such deposits generally exceed Federal Deposit Insurance Corporation (“FDIC”) insurance limits. The FDIC insures deposit accounts up to $250,000 for each accountholder. The counterparty is generally a single bank rather than a group of financial institutions; thus there may be a greater counterparty credit risk. The Fund places deposits only with those counterparties which are believed to be creditworthy and there has been no history of loss.

(2)

INVESTMENT TRANSACTIONS

For the six months ended December 31, 2020, aggregate purchases and proceeds from sales of investment securities (excluding short-term investments) for the Funds were as follows:

	Purchases		Sales
Eventide Core Bond Fund	$	54,052,279	$	5,363,750
Eventide Dividend Opportunities Fund		93,607,285		20,083,780
Eventide Exponential Technologies Fund		54,656,186		8,107,080
Eventide Gilead Fund		526,202,477		320,702,306
Eventide Healthcare & Life Sciences Fund		578,579,207		625,942,367
Eventide Limited-Term Bond Fund		49,264,440		35,654,816
Eventide Multi-Asset Income Fund		78,598,259		53,133,719

(3)

INVESTMENT ADVISORY AGREEMENT AND TRANSACTIONS WITH RELATED PARTIES

Eventide Asset Management, LLC acts as investment manager to the Funds pursuant to the terms of a management agreement between the Manager of the Trust (the “Management Agreement”). Since December 14, 2018, Eventide Asset Management, LLC serves as investment adviser to the Eventide Limited-Term Bond Fund. Prior to December 14, 2018, Trinity Fiduciary Partners, LLC (“Trinity”) served as the Epiphany FFV Strategic Income Fund (“Epiphany FFV Fund”) investment adviser. Boyd Watterson Asset Management, LLC serves as sub-adviser to the Eventide Limited-Term Bond Fund, the Eventide Core Bond Fund, and a portion of the Eventide Multi-Asset Income Fund’s portfolio. Under the terms of the Management Agreement, the Manager manages the investment operations of the Funds in accordance with the Funds’ investment policies and restrictions. The Manager provides the Funds with investment advice and supervision and furnishes an investment program for the Funds. For its investment management services, the Funds pay to the Manager, as of the last day of each month, an annualized fee equal to 0.36% of average net assets of the Eventide Core Bond Fund, 1.00% of average net assets of the Eventide Gilead Fund and 1.10% of average net assets of the Eventide Exponential Technologies Fund and

E V E N T I D E		93

S E M I - A N N U A L R E P O R T

December 31, 2020

Eventide Healthcare & Life Sciences Fund, 0.73% of average net assets of the Eventide Dividend Opportunities Fund, and 0.60% of the Eventide Multi-Asset Income Fund and 0.33% of the average net assets of the Eventide Limited-Term Bond Fund, such fees to be computed daily based upon daily average net assets of the respective Fund. Prior to March 2, 2020 the management fee was 0.73% of the average net assets of the Eventide Multi-Asset Income Fund. The Eventide Limited-Term Bond Fund paid to the Manager, as of the last day of each month, an annualized fee equal to 0.45% of average net assets prior to December 14, 2018. The Manager pays expenses incurred by it in connection with acting as investment manager to the Funds other than costs (including taxes and brokerage commissions, borrowing costs, costs of investing in underlying funds and extraordinary expenses, if any) of securities purchased for the Funds and certain other expenses paid by the Funds (as detailed in the Management Agreement). The Manager pays for all employees, office space and facilities required by it to provide services under the Management Agreement, with the exception of specific items of expense (as detailed in the Management Agreement). For the six months ended December 31, 2020, management fees of $64,581, $383,921, $116,152, $18,066,102, $10,176,765, $136,261 and $521,380 were incurred by the Eventide Core Bond Fund, Eventide Dividend Opportunities Fund, Eventide Exponential Technologies Fund, Eventide Gilead Fund, Eventide Healthcare & Life Sciences Fund, Eventide Limited-Term Bond Fund and Eventide Multi-Asset Income Fund, respectively, before the waivers and reimbursements described below.

The Manager and the Trust have entered into an Expense Limitation Agreement under which the Manager has contractually agreed to waive fees and/or reimburse expenses but only to the extent necessary to maintain total annual operating expenses (excluding brokerage costs; borrowing costs, such as (a) interest and (b) dividends on securities sold short; taxes; costs of investing in underlying funds and extraordinary expenses) at 0.83%, 1.58%, 0.78% and 0.58% of the average daily net assets of Eventide Core Bond Fund’s Class A, Class C, Class N and Class I, 1.20%, 1.95%, 1.15% and 0.95% of the average daily net assets of Eventide Dividend Opportunities Fund’s Class A, Class C, Class N and Class I, 1.68%, 2.43%, 1.63% and 1.43% of the average daily net assets of Eventide Exponential Technologies Fund’s Class A, Class C, Class N and Class I, 1.67%, 2.42%, 1.62% and 1.42% of the average daily net assets of Eventide Gilead Fund’s Class A, Class C, Class N and Class I, 1.68%, 2.43%, 1.63% and 1.43% of the average daily net assets and of Eventide Healthcare & Life Sciences Fund’s Class A, Class C, Class N and Class I, 0.80%, 1.55%, 0.75% and 0.55% of the average daily net assets of Eventide Limited-Term Bond Fund’s Class A, Class C, Class N and Class I respectively at least until October 31, 2021; and 1.07%, 1.82%, 1.02% and 0.82% of the average daily net assets of Eventide Multi-Asset Income Fund’s Class A, Class C, Class N and Class I, respectively at least until October 31, 2021. The expense limits prior to March 2, 2020 were 1.20%, 1.95%, 1.15% and 0.95% of the average daily net assets of Eventide Multi-Asset Income Fund’s Class, A shares, Class C shares, Class N shares and Class I shares, respectively. Prior to December 14, 2018, Trinity had contractually agreed to waive fees and/or reimburse expenses but only to the extent necessary to maintain total annual operating expenses at 1.25% and 1.00% of the average daily net assets of Epiphany FFV Fund’s Class A and Class I. Each waiver or reimbursement by the Manager is subject to repayment by the Fund within the three years following the year in which that particular expense is incurred, if the Fund is able to make the repayment without exceeding the expense limitation in effect at that time and the repayment is approved by the Board of Trustees.

E V E N T I D E		94

S E M I - A N N U A L R E P O R T

December 31, 2020

For the six months ended December 31, 2020, the Manager waived management fees of $0 for each of the Eventide Gilead Fund and Eventide Healthcare & Life Sciences Fund, waived fees of $53,087 from the Eventide Core Bond Fund, $46,397 from the Eventide Dividend Opportunities Fund, $60,056 from the Eventide Exponential Technologies Fund, $91,163 from the Eventide Limited-Term Bond Fund and $48,226 from the Eventide Multi-Asset Income Fund pursuant to its contractual agreement. As of December 31, 2020, the Manager has waived/reimbursed expenses that may be recovered no later than June 30 of the years indicated below:

	2021		2022		2023
Eventide Dividend Opportunities Fund	$	90,311	$	106,626	$	114,935
Eventide Limited-Term Bond Fund		—		111,782		148,648
Eventide Multi-Asset Income Fund		124,623		164,563		103,007

The Eventide Gilead Fund and Healthcare & Life Sciences Fund do not have any expenses previously waived by the Manager that are subject to recapture and did not waive any further expenses during the six months ended December 31, 2020.

The Trust has entered into a Management Services Agreement with MFund, LLC (“MFund”). Pursuant to the Management Services Agreement, MFund provides sponsorship, management and administration services. For MFund’s services to the Fund, the Fund pays MFund a base fee of $5,000 annually, an annualized asset based fee of 0.10% of average daily net assets up to $50 million, with lower fees at higher asset levels, plus reimbursement of out of pocket expenses. For the six months ended December 31, 2020, the Eventide Core Bond Fund, Eventide Dividend Opportunities Fund, Eventide Exponential Technologies Fund, Eventide Gilead Fund, Eventide Healthcare & Life Sciences Fund, Eventide Limited-Term Bond Fund and Eventide Multi-Asset Income Fund incurred $6,246, $14,858, $4,954, $442,343, $219,484, $12,244 and $22,965 for such fees, respectively.

Effective April 2015, pursuant to the Management Services Agreements, MFund provides chief compliance officer services to the Funds. For these services, the Funds pay MFund an annual base fee plus an annual asset-based fee. In addition, the Funds reimburse MFund for any reasonable out- of- pocket expenses incurred in the performance of its duties under the Management Services Agreement.

The amounts due to MFund at December 31, 2020 for chief compliance officer services are listed in the Statements of Assets and Liabilities under “Compliance officer fees payable” and the amounts accrued for the year are shown in the Statements of Operations under “Compliance officer fees.”

A Trustee and Officer of the Trust is also the controlling member of MFund, Alphacentric Advisors LLC, and Catalyst Capital Advisors LLC (Alphacentric and Catalyst each serve as an investment advisor to other series of the Trust), and is not paid any fees directly by the Trust for serving in such capacities.

Trustees who are not “interested persons” as that term is defined in the 1940 Act, are paid a quarterly retainer and receive compensation for each special in-person meeting attended. The fees paid to the Independent Trustees for their attendance at a meeting will be shared equally by the funds of the Trust in which the meeting relates. The Lead Independent Trustee of the Trust and the Chairman of the Trust’s Audit Committee receives an additional quarterly retainer. The “interested persons” of the Trust receive no compensation from the Funds. The Trust reimburses each Trustee and Officer for his or her travel and other expenses related to attendance at such meetings.

E V E N T I D E		95

S E M I - A N N U A L R E P O R T

December 31, 2020

Gemini Fund Services, LLC (“GFS”), an affiliate of the Distributor, provides administrative, fund accounting, and transfer agency services to the Fund’s pursuant to agreements with the Trust, for which it receives from each Fund: (i) basis points in decreasing amounts as assets reach certain breakpoints; and (ii) any related out-of-pocket expenses.

Blu Giant, LLC (“Blu Giant”), an affiliate of GFS and the Distributor, provides EDGAR conversion and filing services as well as print management services for the Funds on an ad-hoc basis. For the provision of these services, Blu Giant receives customary fees from the Funds.

Certain Officers of the Trust are also employees of GFS, and are not paid any fees directly by the Trust for serving in such capacity.

The Trust has adopted a Distribution Plan pursuant to rule 12b-1 under the 1940 Act for each class of shares except Class I, that allows the Funds to pay distribution and shareholder servicing expenses of up to 0.25% per annum for the Class N shares, up to 0.50% per annum for the Class A shares and up to 1.00% for the Class C shares based on average daily net assets of each class. The Class N shares are currently paying 0.20% per annum of 12b-1 fees, Class A shares are currently paying 0.25% per annum of 12b-1 fees and Class C shares are currently paying 1.00% per annum of 12b-1 fees.

The 12b-1 fees may be used for a variety of purposes, including compensating dealers and other financial service organizations for eligible services provided by those parties to the Funds and their shareholders and to reimburse Northern Lights Distributors, LLC. (the “Distributor”) and the Manager for distribution related expenses.

For the six months ended December 31, 2020, the Distributor received $546, $5,627, $11,293, $143,716, $74,956, $4,556 and $11,978 in underwriter commissions from the sale of shares of the Fund from the Eventide Core Bond Fund, Eventide Dividend Opportunities Fund, Eventide Exponential Technologies, Eventide Gilead Fund, Eventide Healthcare & Life Sciences Fund, Eventide Limited-Term Bond Fund and Eventide Multi-Asset Income Fund, respectively.

(4)

DISTRIBUTIONS TO SHAREHOLDERS AND TAX COMPONENTS OF CAPITAL

Represents aggregate cost for federal tax purposes, including options written, for the Funds as of December 31, 2020 and differs from market value by net unrealized appreciation/depreciation which consisted of:

			Gross Unrealized		Gross Unrealized			Total Unrealized
Fund	Aggregate Cost		Appreciation		Depreciation			Appreciation
Eventide Core Bond Fund	$	51,639,825	$	375,990	$	(42,133	)	$	333,857
Eventide Dividend Opportunities Fund		136,689,347		28,537,522		(303,233	)		28,234,289
Eventide Exponential Technologies Fund		51,137,692		9,616,319		(216,094	)		9,400,225
Eventide Gilead Fund		2,092,063,625		2,225,674,120		(27,292,531	)		2,198,381,589
Eventide Healthcare & Life Sciences Fund		1,367,070,021		878,211,000		(37,868,447	)		840,342,553
Eventide Limited-Term Bond Fund		94,765,252		1,184,446		(22,641	)		1,161,805
Eventide Multi-Asset Income Fund		164,898,416		33,630,305		(560,244	)		33,070,061

E V E N T I D E		96

S E M I - A N N U A L R E P O R T

December 31, 2020

The tax character of Fund distributions paid for the year ended June 30, 2020 and June 30, 2019 was as follows:

	For the year ended June 30, 2020:
	Ordinary		Long-Term		Return of
Fund	Income		Capital Gains		Capital		Total
Eventide Dividend Opportunities Fund	$	213,501	$	—	$	399,315	$	612,816
Eventide Gilead Fund		—		80,392,392		—		80,392,392
Eventide Healthcare & Life Sciences Fund		7,562,297		18,687,917		—		26,250,214
Eventide Limited-Term Bond Fund		732,710		—		146,859		879,569
Eventide Multi-Asset Income Fund		1,463,734		48,593		1,671,355		3,183,682

	For the year ended June 30, 2019:
	Ordinary		Long-Term		Return of
Fund	Income		Capital Gains		Capital		Total
Eventide Dividend Opportunities Fund	$	238,546	$	—	$	21,850	$	260,396
Eventide Gilead Fund		—		91,170,811		—		91,170,811
Eventide Healthcare & Life Sciences Fund		24,202,535		24,353,083		—		48,555,618
Eventide Limited-Term Bond Fund		264,337		19,297		—		283,634
Eventide Multi-Asset Income Fund		2,420,976		299,039		1,065,538		3,785,553

As of June 30, 2020, the components of accumulated earnings/(deficit) on a tax basis were as follows:

	Undistributed		Undistributed		Post October Loss			Capital Loss			Other		Unrealized		Total
	Ordinary		Long-Term		and			Carry			Book/Tax		Appreciation/		Accumulated
Fund	Income		Capital Gains		Late Year Loss			Forwards			Differences		(Depreciation)		Earnings/(Deficits)
Eventide Dividend Opportunities Fund	$	—	$	—	$	(1,832,464	)	$	(379,812	)	$	—	$	5,323,648	$	3,111,372
Eventide Gilead Fund		—		3,115,342		(10,457,475	)		—			—		1,200,946,637		1,193,604,504
Eventide Healthcare & Life Sciences Fund		2,580,849		—		(11,374,877	)		—			—		532,574,845		523,780,817
Eventide Limited-Term Bond Fund		—		—		(77,563	)		(170,193	)		—		1,642,851		1,395,095
Eventide Multi-Asset Income Fund		—		—		(1,016,826	)		—			—		12,402,250		11,385,424

The difference between book basis and tax basis undistributed net investment income/(loss), accumulated net realized gain/(loss), and unrealized appreciation/(depreciation) from investments is primarily attributable to the tax deferral of losses on wash sales, passive foreign investment companies, and adjustments for partnerships, real estate investment trusts, C-Corporation return of capital, trust preferred securities, paydowns and deemed distributions.

Late year losses incurred after December 31 within the fiscal year are deemed to arise on the first business day of the following fiscal year for tax purposes. The Funds incurred and elected to defer such capital losses as follows:

	Late Year
Fund	Losses
Eventide Gilead Fund	$	10,457,475

E V E N T I D E		97

S E M I - A N N U A L R E P O R T

December 31, 2020

Capital losses incurred after October 31 within the fiscal year are deemed to arise on the first business day of the following fiscal year for tax purposes. The Funds incurred and elected to defer such capital losses as follows:

	Post October
Fund	Losses
Eventide Dividend Opportunities Fund	$	1,832,464
Eventide Healthcare & Life Sciences Fund		11,374,877
Eventide Limited-Term Bond Fund		77,563
Eventide Multi-Asset Income Fund		1,016,826

At June 30, 2020, the Funds had capital loss carry forwards for federal income tax purposes available to offset future capital gains, utilized capital loss carryforwards as follows:

	Non-Expiring
Fund	Short-Term		Long-Term		Total
Eventide Dividend Opportunities Fund	$	44,615	$	335,197	$	379,812
Eventide Limited-Term Bond Fund		—		170,193		170,193

Permanent book and tax differences, primarily attributable to the book/tax basis treatment of net operating losses, distribution reclasses, non-deductible expenses and adjustments for partnerships, real estate investment trusts, C-Corporation return of capital and deemed distributions, resulted in reclassifications for the Funds for the fiscal year ended June 30, 2020 as follows:

	Paid In			Accumulated
Fund	Capital			Earnings (Losses)
Eventide Dividend Opportunities Fund	$	(99	)	$	99
Eventide Gilead Fund		(14,153,046	)		14,153,046
Eventide Healthcare & Life Sciences Fund		—			—
Eventide Limited-Term Bond Fund		(1,042	)		1,042
Eventide Multi-Asset Income Fund		16,445			(16,445	)

E V E N T I D E		98

S E M I - A N N U A L R E P O R T

December 31, 2020

(5)

INVESTMENTS IN AFFILIATED COMPANIES

An affiliated company is a company in which the Fund has ownership of at least 5% of the voting securities. Companies which are affiliates of the Eventide Gilead Fund and Eventide Healthcare & Life Sciences Fund at December 31, 2020 are noted in the Fund Portfolio of Investments. Transactions during the period with companies which are affiliates are as follows:

Eventide Gilead Fund

			Share										Net Increase/							Share
			Balance at								Dividends		Decrease in			Realized		Market Value		Balance at
	Market Value at		June 30,				Sales				Credited to		Appreciation			Gains		at December		December
Description	June 30, 2020		2020		Purchases		Proceeds		Corporate Actions		Income		(Depreciation)			(Losses)		31, 2020		31, 2020
Vital Farms, Inc.	$	—		—	$	57,736,749	$	—	$	—	$	—	$	(7,496,399	)	$	—	$	50,240,350		1,985,000
Total	$	—		—	$	57,736,749	$	—	$	—	$	—	$	(7,496,399	)	$	—	$	50,240,350		1,985,000

Eventide Gilead Fund

Investments no longer affiliated as of December 31, 2020

			Share											Net Increase/							Share
			Balance at									Dividends		Decrease in			Realized		Market Value		Balance at
	Market Value at		June 30,				Sales					Credited to		Appreciation			Gains		at December		December
Description	June 30, 2020		2020		Purchases		Proceeds		Corporate Actions			Income		(Depreciation)			(Losses)		31, 2020		31, 2020
Pliant Therapeutics Series B ¹	$	31,327,555		1,015,908	$	—	$	—	$	(9,999,999	)	$	—	$	(21,327,556	)	$	—	$	—		—
Pliant Therapeutics Series C ¹		16,497,301		534,984		—		—		(6,999,999	)		—		(9,497,302	)		—		—		—
Total	$	47,824,856		1,550,892	$	—	$	—	$	(16,999,998	)	$	—	$	(30,824,858	)	$	—	$	—		—

	$	47,824,856		1,550,892	$	57,736,749	$	—	$	(16,999,998	)	$	—	$	(38,321,257	)	$	—

Reorganization of private investment to the publicly traded common stock.

E V E N T I D E		99

S E M I - A N N U A L R E P O R T

December 31, 2020

Eventide Healthcare & Life Sciences Fund

															Net Increase/
			Share Balance										Dividends		Decrease in			Realized		Market Value at		Share Balance at
	Market Value at		at June 30,							Corporate			Credited		Appreciation			Gains		December 31,		December 31,
Description	June 30, 2020		2020		Purchases		Sales Proceeds			Actions			to Income		(Depreciation)			(Losses)		2020		2020
Casma Therapeutics, Inc.	$	—		—	$	3,750,000	$	—		$	—		$	—	$	(187,500	)	$	—	$	3,562,500		5,000,000
Chiasma, Inc.		5,186,320		964,000		9,971,812		—			—			—		(2,106,714	)		—		13,051,418		3,000,326
ESSA Pharma, Inc.		8,196,066		1,391,522		1,950,000		—			—			—		9,308,140			—		19,454,206		1,716,522
Freeline Therapeutics Ltd. ¹		14,962,500		7,720,588		—		—			—			—		6,344,890			—		21,307,390		1,228,304
Goldfinch Biopharma, Inc. Series A		5,600,000		5,000,000		—		—			—			—		—			—		5,600,000		5,000,000
Goldfinch Biopharma, Inc. Series B		9,491,525		8,474,576		—		—			—			—		—			—		9,491,525		8,474,576
Kala Pharmaceuticals, Inc.		36,259,500		3,450,000		—		—			—			—		(12,868,500	)		—		23,391,000		3,450,000
KalVista Pharmaceuticals, Inc.		20,328,000		1,680,000		—		—			—			—		11,575,200			—		31,903,200		1,680,000
Praxis Precision Medicines, Inc. Series C ¹		9,500,002		1,941,748		—		—			—			—		37,928,698			—		47,428,700		907,379
Praxis Precision Medicines, Inc. Series C1 ¹		—		—		11,999,999		(8	)		—			—		39,694,725			—		51,694,716		988,994
Prometheus Biosciences, Inc. ²		—		—		7,692,308		—			(702,262	)		—		(349,095	)		—		6,640,951		10,177,703
Prometheus Laboratories, Inc. ²		—		—		—		—			702,262			—		(35,114	)		—		667,148		1,017,770
Sutro Biopharma, Inc.		15,411,166		1,985,975		8,197,200		—			—			—		27,865,501			—		51,473,867		2,370,975
TOTAL	$	124,935,079	$	32,608,409	$	43,561,319	$	(8	)	$	—		$	—	$	117,170,231		$	—	$	285,666,621		45,012,549

Eventide Healthcare & Life Sciences Fund

Investments no longer affiliated as of December 31, 2020

														Net Increase/
			Share Balance									Dividends		Decrease in			Realized		Market Value at		Share Balance at
	Market Value at		at June 30,							Corporate		Credited		Appreciation			Gains		December 31,		December 31,
Description	June 30, 2020		2020		Purchases		Sales Proceeds			Actions		to Income		(Depreciation)			(Losses)		2020		2020
Satsuma Pharmaceuticals, Inc. ¹	$	28,282,066		983,382	$	—	$	(11,374,999	)	$	—	$	—	$	(16,907,067	)	$	—	$	—		—
Total	$	28,282,066		983,382	$	—	$	(11,374,999	)	$	—	$	—	$	(16,907,067	)	$	—	$	—		—

	$	153,217,145		33,591,791	$	43,561,319	$	(11,375,007	)	$	—	$	—	$	100,263,164		$	—

Reverse stock split.

Spin-Off.

E V E N T I D E		100

S E M I - A N N U A L R E P O R T

December 31, 2020

(6)

INVESTMENT IN RESTRICTED SECURITIES

Restricted securities include securities that have not been registered under the Securities Act of 1933, as amended, and securities that are subject to restrictions on resale. Each Fund may invest in restricted securities that are consistent with the Fund’s investment objectives and investment strategies. The Funds will not invest in a restricted security if, immediately after and as a result of the investment in such security, more than 15% of a Fund’s net assets would be invested in illiquid securities. In some cases, the issuer of restricted securities has agreed to register such securities for resale, at the issuer’s expense either upon demand by the Funds or in connection with another registered offering of the securities. Investments in restricted securities are valued at fair value as determined in good faith in accordance with procedures adopted by the Board. It is possible that the estimated value may differ significantly from the amount that might ultimately be realized in the near term, and the difference could be material.

As of December 31, 2020, the Eventide Gilead Fund and Eventide Healthcare & Life Sciences Fund were invested in the following restricted securities:

Eventide Gilead Fund

Security	Initial Acquisition Date	Shares		Cost		Value		% of Net Assets
Beta Bionic Series B/B2	8/31/18		179,406	$	27,400,031	$	27,269,712	0.6%
Entasis Therapeutics Holdings, Inc.	3/29/16		590,602		8,591,860		1,385,848	0.0%
Peloton Therapeutics, Inc. - CVR	2/14/19		3,982,940		—		3,424,532	0.1%
Praxis Precision Medicines, Inc. Series C	4/15/20		907,378		9,999,993		47,428,648	1.1%
Praxis Precision Medicines, Inc. Series C1	7/24/20		659,330		8,000,001		34,463,179	0.8%


Eventide Healthcare & Life Sciences Fund

Security	Initial Acquisition Date	Shares		Cost		Value		% of Net Assets
Annexon, Inc.	6/30/20		798,111	$	9,999,999	$	18,977,883	0.8%
Beta Bionic Series B	8/31/18		122,828		19,000,015		18,669,856	0.8%
Casma Therapeutics, Inc.	8/26/20		5,000,000		3,750,000		3,562,500	0.2%
Cullinan Oncology, LLC	12/16/20		5,076,142		10,000,000		9,500,000	0.4%
DiCE Molecules Series C	12/18/20		2,570,925		6,666,666		6,333,332	0.3%
Entasis Therapeutics Holdings, Inc.	3/29/16		288,939		3,151,248		677,995	0.0%
Freeline Therapeutics Ltd.	6/29/20		1,228,304		15,750,000		21,307,390	0.9%
Goldfinch Biopharma, Inc. Series A	3/15/19		5,000,000		5,000,000		5,600,000	0.2%
Goldfinch Biopharma, Inc. Series B	6/29/20		8,474,576		10,000,000		9,491,525	0.4%
Peloton Therapeutics, Inc. - CVR	2/14/19		1,528,871		—		1,314,523	0.1%
Praxis Precision Medicines, Inc. Series C	11/15/19		907,379		10,000,002		47,428,700	2.1%
Praxis Precision Medicines, Inc. Series C1	7/24/20		988,994		11,999,991		51,694,716	2.3%
Prometheus Biosciences, Inc.	10/30/20		10,177,703		6,990,046		6,640,951	0.3%
Prometheus Laboratories, Inc.	12/31/20		1,017,770		702,262		667,148	0.0%
Talaris Therapeutics Series B	9/22/20		3,804,347		6,999,998		6,649,999	0.3%
VectivBio A.G. Series A-2	9/25/20		6,082,133		7,000,000		6,650,204	0.3%

(7)

PORTFOLIO CONCENTRATION RISK

The Eventide Healthcare & Life Sciences Fund invests primarily in equity and equity-related securities of companies in the healthcare and life sciences sectors that derive or are expected to derive 50% or more of their revenue from healthcare and life science products and services including, but not limited to, biotechnology, pharmaceuticals, diagnostics, life science tools, medical devices, healthcare information technology, healthcare services, synthetic biology, agricultural and environmental management, and pharmaceutical manufacturing

E V E N T I D E		101

S E M I - A N N U A L R E P O R T

December 31, 2020

products and services. Because of its focus on healthcare and life science companies, the Eventide Healthcare & Life Sciences Fund’s investment performance will be closely tied to many factors which affect those companies. As a result, the Eventide Healthcare & Life Sciences Fund’s net asset value is more likely to have greater fluctuations than that of a fund which invests in other industries.

(8)

OPTIONS RISK

There are risks associated with the sale and purchase of call and put options. The seller (writer) of a call option which is covered (e.g., the writer holds the underlying security) assumes the risk of a decline in the market price of an underlying security below the purchase price of an underlying security less the premium received, and gives up the opportunity for gain on the underlying security above the exercise price of the option. The seller of an uncovered call option assumes the risk of a theoretical unlimited increase in the market price of an underlying security above the exercise price of the option. The securities necessary to satisfy the exercise of the call option may be unavailable for purchase except at much higher prices. Purchasing securities to satisfy the exercise of the call option can itself cause the price of securities to rise further, sometimes by a significant amount, thereby exacerbating the loss. The buyer of a call option assumes the risk of losing its entire premium invested in the call option. The seller (writer) of a put option which is covered (e.g., the writer has a short position in the underlying security) assumes the risk of an increase in the market price of the underlying security above the sales price (in establishing the short position) of the underlying security plus the premium received, and gives up the opportunity for gain on the underlying security below the exercise price of the option. The seller of an uncovered put option assumes the risk of a decline in the market price of the underlying security below the exercise price of the option. The buyer of a put option assumes the risk of losing his entire premium invested in the put option.

(9)

BENEFICIAL OWNERSHIP

The beneficial ownership, either directly or indirectly, of more than 25% of the voting securities of a fund creates a presumption of control of the fund, under Section 2(a)(9) of the 1940 Act. As of December 31, 2020, Charles Schwab & Co, Inc. Special Custody Account for the Exclusive Benefit of Customers held 88.91% and 32.70% of the Eventide Core Bond Fund and Eventide Limited-Term Bond Fund, respectively. As of December 31, 2020, TD Ameritrade, Inc. Special Custody Account for the Exclusive Benefit of Customers held 28.21% and 28.92% of the Eventide Dividend Opportunities Fund and Eventide Exponential Technologies Fund, respectively.

(10)

SUBSEQUENT EVENTS

Subsequent events after the date of the Statements of Assets and Liabilities have been evaluated through the date the financial statements were issued. Management has determined that no events or transactions occurred requiring adjustment or disclosure in the financial statements.

E V E N T I D E		102

S E M I - A N N U A L R E P O R T

December 31, 2020

Eventide Exponential Technologies Fund

Eventide Core Bond Fund

Consideration and Approval of Management Agreements between Mutual Fund Series Trust and Eventide Asset Management, LLC with respect to the Eventide Exponential Technologies Fund and the Eventide Core Bond Fund

At a meeting held on May 6, 2020, the Board of Trustees (the “Board” ) of Mutual Fund Series Trust (the “Trust”), including a majority of the Trustees who are not “interested persons” as that term is defined in the Investment Company Act of 1940, as amended, discussed the approval of an advisory agreement between the Trust and Eventide Asset Management, LLC (“Eventide”) with respect to Eventide Exponential Technologies Fund (“Eventide ET”) and a management agreement between the Trust and Eventide with respect to the Eventide Core Bond Fund ( “Eventide CB”) (each agreement a “Management Agreement” and together, the “Management Agreements”)

The Board was assisted by legal counsel throughout the review process. The Board relied upon the advice of legal counsel and its own business judgment in determining the material factors to be considered in evaluating each Advisory Agreement and the weight to be given to each factor considered. The conclusions reached by the Board were based on a comprehensive evaluation of all of the information provided and were not the result of any one factor. Moreover, each Trustee may have afforded different weight to the various factors in reaching his conclusions with respect to approval of the Management Agreements. In connection with its deliberations regarding the approval of each Management Agreement, the Board reviewed materials prepared by Eventide.

Eventide Exponential Technologies Fund

Nature, Extent and Quality of Services. The Board considered its significant experience with Eventide as the advisor to several other series of the Trust, and its strong working relationship with Eventide and its personnel. The Board remarked that Eventide’s portfolio management team would combine its investment experience in the information technology sector with proprietary research provided by research partners and industry experts to identify investment opportunities. It noted that Eventide would review Eventide ET’s portfolio on a regular basis and would monitor Eventide ET’s investment limitations daily through an automated compliance script. The Board noted that Eventide would review Eventide ET’s holdings for consistency with Eventide ET’s ethical screens through Eventide’s Edify system. The Board observed that Eventide directed trades to broker-dealers with an eye toward obtaining best execution in terms of share price, quality of service and commissions. The Board remarked that Eventide did not report any material litigation or administrative actions involving Eventide or any Eventide affiliate and had no pending regulatory examinations or investigations. The Board recognized that Eventide maintained adequate insurance coverage. After discussion, the Board concluded that Eventide had the potential to provide high quality services to Eventide ET and its shareholders.

Performance. The Board noted that Eventide had demonstrated, as evidenced by the other series of the Trust it managed, that it had the ability to successfully manage Eventide ET and ensure compliance with portfolio restrictions and limitations. The Board reviewed the performance of a mutual fund sleeve managed by Eventide ET’s proposed portfolio manager which had outperformed its benchmark over 1- and 3-year periods. The Board

E V E N T I D E		103

S E M I - A N N U A L R E P O R T

December 31, 2020

determined that Eventide’s track record of managing mutual funds gave the Board confidence that Eventide would provide value to shareholders as advisor to Eventide ET.

Fees and Expenses. The Board noted that the 1.10% advisory fee for Eventide ET was higher than the medians and averages of its peer group and Morningstar category, but lower than the peer group and Morningstar category highs of 1.25%. The Board discussed that the 1.68% net expense ratio for Eventide ET was higher than the medians and averages of its peer group and Morningstar category, but lower than the peer group and Morningstar category high of 2.08%. The Board acknowledged Eventide’s robust discussion of the reasonableness of its fee, including the level of expertise and skill required to manage a fund like Eventide ET and Eventide’s highly differentiated values-base screen process. The Board concluded that the proposed advisory fee for Eventide ET was not unreasonable.

Profitability. The Board reviewed a profitability analysis provided by Eventide and noted that it anticipated a loss in connection with its relationship with Eventide ET during the first two years of the Management Agreement. After discussion, the Board agreed that excessive profitability was not an issue for Eventide ET at this time.

Economies of Scale. The Board considered whether there would be economies of scale with respect to the management of Eventide ET, and noted that Eventide was not inclined to offer fee concessions at this time due in part to the high (and continuously increasing) costs of sponsoring mutual funds as well as the business and financial risks assumed by Eventide when managing a mutual fund. The Board noted material economies were not anticipated to be reached during the initial period of the Management Agreement and agreed that the matter of economies of scale would be revisited as Eventide ET’s size materially increased.

Conclusion. Having requested and received such information from Eventide as the Board believed to be reasonably necessary to evaluate the terms of the Management Agreement, and as assisted by the advice of counsel, the Board concluded that the fee structure for Eventide ET was reasonable and that approval of the Management Agreement was in the best interests of Eventide ET and its future shareholders.

Eventide Core Bond Fund

Nature, Extent and Quality of Services. The Board considered its significant experience with Eventide as the advisor to several other series of the Trust, and its strong working relationship with Eventide and its personnel. The Board remarked that Eventide’s continued to invest in quality personnel to enhance its advisory services by hiring additional research analysts and additional support for its compliance department, including a compliance director. It noted that Eventide would monitor Eventide CB’s sub-advisor and review Eventide CB’s portfolio on a regular basis. The Board remarked that Eventide would review Eventide CB’s investment limitations daily through an automated compliance script. The Board noted that Eventide would monitor Eventide CB’s holdings for consistency with Eventide CB’s ethical screens through Eventide’s Edify system. The Board observed that Eventide would delegate responsibility for broker-dealer selection to the sub-advisor. The Board remarked that Eventide did not report any material litigation or administrative actions involving Eventide or any Eventide affiliate and had no pending regulatory examinations or investigations. The Board recognized that Eventide maintained adequate insurance coverage. After discussion, the Board concluded that Eventide had the potential to provide high quality services to Eventide CB and its shareholders.

Performance. The Board noted that Eventide and the sub-advisor would share primary responsibility for the day-to-day management of Eventide CB’s portfolio. The Board noted that Eventide had demonstrated, as evidenced by the other series of the Trust it managed, that it had the ability to successfully manage and oversee sub-advisors

E V E N T I D E		104

S E M I - A N N U A L R E P O R T

December 31, 2020

ensuring compliance with portfolio restrictions and limitations. The Board further noted that Eventide’s track record of managing mutual funds gave the Board confidence that Eventide would provide value to shareholders as advisor to Eventide CB.

Fees and Expenses. The Board noted that the 0.36% advisory fee for Eventide CB was on par with the average of its peer group and median of the Morningstar category. It discussed that the 0.73% net expense ratio for Eventide CB was lower than the median and average of the peer group and well-below the high of the Morningstar category high. The Board concluded that the proposed advisory fee for Eventide CB was not unreasonable.

Profitability. The Board reviewed a profitability analysis provided by Eventide and noted that it anticipated a loss in connection with its relationship with Eventide CB during year one of the Management Agreement and a modest profit in year two. After discussion, the Board agreed that excessive profitability was not an issue for Eventide CB at this time.

Economies of Scale. The Board considered whether there would be economies of scale with respect to the management of Eventide CB, and noted that Eventide was not inclined to offer fee concessions at this time due in part to the high (and continuously increasing) costs of sponsoring mutual funds as well as the business and financial risks assumed by Eventide when managing a mutual fund. The Board noted material economies were not anticipated to be reached during the initial period of the Management Agreement and agreed that the matter of economies of scale would be revisited as Eventide CB’s size materially increased.

Conclusion. Having requested and received such information from Eventide as the Board believed to be reasonably necessary to evaluate the terms of the Management Agreement, and as assisted by the advice of counsel, the Board concluded that the fee structure for Eventide CB was reasonable and that approval of the Management Agreement was in the best interests of Eventide CB and its future shareholders.

E V E N T I D E		105

S E M I - A N N U A L R E P O R T

December 31, 2020

Eventide Core Bond Fund

Consideration and Approval of a Sub-Advisory Agreement between Eventide Asset Management, LLC and Boyd Watterson Asset Management with respect to the Eventide Core Bond Fund

At a meeting held on May 6, 2020, the Board of Trustees (the “Board”) of Mutual Fund Series Trust, including a majority of the Trustees who are not “interested persons” as that term is defined in the Investment Company Act of 1940, as amended, discussed the approval of a sub-advisory agreement (the “Sub-Advisory Agreement”) between Eventide Asset Management, LLC (“Eventide”) and Boyd Watterson Asset Management (“BWAM”) with respect to the Eventide Core Bond Fund (“Eventide CB”).

The Board was assisted by legal counsel throughout the review process. The Board relied upon the advice of legal counsel and its own business judgment in determining the material factors to be considered in evaluating the Sub-Advisory Agreement and the weight to be given to each factor considered. The conclusions reached by the Board were based on a comprehensive evaluation of all of the information provided and were not the result of any one factor. Moreover, each Trustee may have afforded different weight to the various factors in reaching his conclusions with respect to approval of the Sub-Advisory Agreement. In connection with its deliberations regarding the approval of the Sub-Advisory Agreement, the Board reviewed materials prepared by BWAM.

Nature, Extent and Quality of Services. The Board recognized that BWAM was a reputable investment advisor with significant assets under management. The Board expressed familiarity and experience with BWAM as the sub-advisor to another fund in the Trust. The Board discussed that BWAM would conduct research throughout the investment process. The Board remarked that BWAM would apply quantitative and qualitative measures to identify, measure and manage portfolio risk and use a comprehensive, risk-management system provided by Interactive Data Corporation. The Board observed that BWAM’s proprietary information technology system would monitor compliance with Eventide CB’s investment limitations. The Board noted that BWAM chose broker-dealers on the basis of best execution. The Board acknowledged that BWAM reported no material compliance issues in the past 36 months and had adequate errors and omission insurance coverage in place. The Board agreed that BWAM had the experience and resources necessary to provide quality services to Eventide CB.

Performance. The Board reviewed the performance information presented by BWAM. The Board noted that a fund managed by BWAM with a comparable strategy to Eventide CB outperformed the Bloomberg Barclays Aggregate Index over the 1-year, 3-year, 5-year and 10-year periods. The Board agreed that BWAM had the potential to provide reasonable returns to Eventide CB’s future shareholders.

Fees and Expenses. The Board discussed BWAM’s proposed sub-advisory fee schedule for Eventide CB, including the levels at which breakpoints reduce the fee. The Board reviewed the allocation of fees between the Eventide and BWAM relative to their respective duties and other factors and agreed the allocation for Eventide CB was appropriate. After further discussion, the Board concluded that the sub-advisory fee to be charged with respect to Eventide CB was not unreasonable and the sub-advisory fee, in relation to the total advisory fee, was not unreasonable.

Profitability. The Board reviewed a profitability analysis provided by BWAM and noted that it anticipated realizing a modest profit in connection with its relationship with Eventide CB during the first and second year of the Sub-Advisory Agreement. After further discussion, the Board agreed that the projected profits were not excessive.

E V E N T I D E		106

S E M I - A N N U A L R E P O R T

December 31, 2020

Economies of Scale. The Board considered whether there would be economies of scale with respect to BWAM’s management of Eventide CB. The Board agreed that this was primarily an advisor-level issue and should be considered with respect to the overall management agreement, taking into consideration the impact of the sub-advisory expense, including the breakpoints. The Board acknowledged the benefit of the breakpoints in the sub-adviser fee to Eventide.

Conclusion. Having requested and received such information from BWAM as the Board believed to be reasonably necessary to evaluate the terms of the Sub-Advisory Agreement, and as assisted by the advice of counsel, the Board concluded that the fee structure was reasonable and that approval of the Sub-Advisory Agreement was in the best interests of the future shareholders of Eventide CB.

E V E N T I D E		107

S E M I - A N N U A L R E P O R T

December 31, 2020

Eventide Limited-Term Bond Fund

Consideration and Renewal of Management Agreement between Mutual Fund Series Trust and Eventide Asset Management, LLC with respect to the Eventide Limited Term Bond Fund

At a meeting held on November 30, 2020, the Board of Trustees (the “Board” ) of Mutual Fund Series Trust (the “Trust”), including a majority of the Trustees who are not “interested persons” as that term is defined in the Investment Company Act of 1940, as amended, discussed the renewal of a management agreement between the Trust and Eventide Asset Management, LLC (“Eventide”) with respect to Eventide Limited Term Bond Fund (“Eventide LTB”) the (“Management Agreement”)

The Board was assisted by legal counsel throughout the review process. The Board relied upon the advice of legal counsel and its own business judgment in determining the material factors to be considered in evaluating the Management Agreement and the weight to be given to each factor considered. The conclusions reached by the Board were based on a comprehensive evaluation of all of the information provided and were not the result of any one factor. Moreover, each Trustee may have afforded different weight to the various factors in reaching his conclusions with respect to the renewal of the Management Agreement. In connection with its deliberations regarding the approval of the Management Agreement, the Board reviewed materials prepared by Eventide.

Nature, Extent and Quality of Services. The Board confirmed its familiarity with Eventide’s service team from its experience working with Eventide. The Board reviewed Eventide’s management team, noting that Eventide continued to invest in personnel and acquire additional human resources to support its business. The Board recognized that Eventide was effective in monitoring compliance with Eventide LTB’s investment limitations and providing ethical screening services for Eventide LTB through its proprietary screening system and had demonstrated the ability to effectively oversee a sub-adviser, providing daily review of the portfolio. The Board acknowledged that Eventide used a third-party proxy voting firm to vote proxies on behalf of Eventide LTB. The Board observed that Eventide reported no SEC, FINRA, CFTC or other regulatory examinations since the Management Agreement’s approval, nor any material litigation or administrative action involving Eventide or its affiliates. The Board agreed that Eventide’s team members had demonstrated a strong, collaborative working relationship with the Trust. The Board concluded that the services provided by Eventide to Eventide LTB were in line with the Board’s expectations.

Performance. The Board recalled that Eventide LTB acquired the assets of its predecessor fund in December 2018 and focused its review on Eventide LTB’s performance since that date. The Board noted that Eventide LTB outperformed its peer group, Morningstar category and the Bloomberg Barclays 1-5 Year Government/Credit Index for the 1-year period. The Board noted that Eventide attributed Eventide LTB’s performance to its overweight and security selection in corporate and agency bonds and mortgage-backed security passthroughs. The Board concluded that Eventide LTB’s performance was acceptable.

Fees and Expenses. The Board commented that Eventide LTB’s advisory fee was below the average and median of its peer group and Morningstar category. The considered the cost of the sub-advisory services and the allocation of duties among the adviser and sub-adviser. The Board remarked that Eventide LTB’s net expense ratio was lower than the average of the peer group, and slightly higher than the other metrics. The Board concluded that the advisory fee for Eventide LTB was not unreasonable.

E V E N T I D E		108

S E M I - A N N U A L R E P O R T

December 31, 2020

Profitability. The Board discussed Eventide’s profitability from its relationship with Eventide LTB based on the information that Eventide provided. The Board noted that Eventide was managing Eventide LTB at a loss and therefore concluded that excessive profitability of Eventide with respect to Eventide LTB was not an issue at this time.

Economies of Scale. The Board noted that the Management Agreement with respect to Eventide LTB did not contain breakpoints reducing the fee rate on assets above specified levels, but that shareholders had benefitted from Eventide LTB’s expense cap and economies of scale from being in a family of funds. The Board agreed that breakpoints may be an appropriate way for Eventide to share economies of scale with Eventide LTB if it experienced a significant growth in assets. The Board discussed the breakpoints on the fee schedule of the sub-advisor to Eventide LTB and how such breakpoints could benefit Eventide. The Board agreed to revisit the issue of breakpoints at the Management Agreement’s next renewal.

Conclusion. Having requested and received such information from Eventide as the Board believed to be reasonably necessary to evaluate the terms of the Management Agreement with Eventide, and as assisted by the advice and guidance of counsel, the Board concluded that renewal of the Management Agreement was in the best interests of Eventide LTB and its shareholders.

E V E N T I D E		109

S E M I - A N N U A L R E P O R T

December 31, 2020

Eventide Limited-Term Bond Fund

Consideration and Approval of a Sub-Advisory Agreement between Eventide Asset Management, LLC and Boyd Watterson Asset Management with respect to the Eventide Limited Term Bond Fund

The Board was assisted by legal counsel throughout the review process. The Board relied upon the advice of legal counsel and its own business judgment in determining the material factors to be considered in evaluating the Sub-Advisory Agreement and the weight to be given to each factor considered. The conclusions reached by the Board were based on a comprehensive evaluation of all of the information provided and were not the result of any one factor. Moreover, each Trustee may have afforded different weight to the various factors in reaching his conclusions with respect to approval of the Sub-Advisory Agreement. In connection with its deliberations regarding the approval of the Sub-Advisory Agreement, the Board reviewed materials prepared by BWAM.

Nature, Extent and Quality of Services. The Board recognized that BWAM was a reputable investment advisor with significant assets under management. The Board expressed familiarity and experience with BWAM as the sub-advisor to another fund in the Trust. The Board discussed that BWAM would conduct research throughout the investment process. The Board remarked that BWAM would apply quantitative and qualitative measures to identify, measure and manage portfolio risk and use a comprehensive, risk-management system provided by Interactive Data Corporation. The Board observed that BWAM’s proprietary information technology system would monitor compliance with Eventide LTB’s investment limitations. The Board noted that BWAM chose broker-dealers on the basis of best execution. The Board acknowledged that BWAM reported no material compliance issues in the past 36 months and had adequate errors and omission insurance coverage in place. The Board agreed that BWAM had the experience and resources necessary to provide quality services to Eventide LTB.

Performance. The Board reviewed the performance information presented by BWAM. The Board noted that a fund managed by BWAM with a comparable strategy to Eventide LTB outperformed the Barclays 1-5 Year Government Credit Index over the 1-year, 3-year, 5-year and 10-year periods. The Board agreed that BWAM had the potential to provide reasonable returns to Eventide LTB’s shareholders.

Fees and Expenses. The Board discussed BWAM’s proposed sub-advisory fee schedule for Eventide LTB, including the levels at which breakpoints reduce the fee, and how the proposed fees and breakpoints differed from the current fee schedule. The Board reviewed the allocation of fees between the advisor and BWAM relative to their respective duties and other factors, and agreed the allocation for Eventide LTB was appropriate. After further discussion, the Board concluded that the sub-advisory fee to be charged with respect to Eventide LTB was not unreasonable and the sub-advisory fee, in relation to the total advisory fee, was not unreasonable.

Profitability. The Board reviewed a profitability analysis provided by BWAM and noted that it anticipated realizing a reasonable profit in connection with its relationship with Eventide LTB during the first and second year of the sub-advisory agreement. After further discussion, the Board agreed that the projected profits were not excessive.

E V E N T I D E		110

S E M I - A N N U A L R E P O R T

December 31, 2020

Economies of Scale. The Board considered whether there would be economies of scale with respect to BWAM’s management of Eventide LTB. The Board agreed that this was primarily an advisor-level issue and should be considered with respect to the overall management agreement, taking into consideration the impact of the sub-advisory expense, including the breakpoint at the fund family level.

Conclusion. Having requested and received such information from the sub-advisor as the Board believed to be reasonably necessary to evaluate the terms of the sub-advisory agreement, and as assisted by the advice of counsel, the Board concluded that the fee structure was reasonable and that approval of the sub-advisory agreement was in the best interests of the future shareholders of Eventide LTB.

E V E N T I D E		111

S E M I - A N N U A L R E P O R T

December 31, 2020

Eventide Funds
Expense Examples (Unaudited)	December 31, 2020

As a shareholder of a Fund, you incur two types of costs: (1) transaction costs, including sales charges (loads) on purchases of Class A shares; (2) ongoing costs, including management fees; distribution and/or service (12b-1) fees; and other Fund expenses. This example is intended to help you understand your ongoing costs (in dollars) of investing in a Fund and to compare these costs with the ongoing costs of investing in other mutual funds.

The example for Eventide Core Bond Fund is based on an investment of $1,000 invested at the beginning of the period and held for the entire period from July 31, 2020 through December 31, 2020.

The example for Eventide Exponential Technologies Fund, Eventide Global Dividend Opportunities Fund, Eventide Gilead Fund, Eventide Healthcare & Life Sciences Fund, Eventide Limited-Term Bond Fund and Eventide Multi-Asset Income Fund is based on an investment of $1,000 invested at the beginning of the period and held for the entire period from July 1, 2020 through December 31, 2020.

Actual Expenses

The “Actual” columns in the table below provides information about actual account values and actual expenses. You may use the information below, together with the amount you invested, to estimate the expenses that you paid over the period. Simply divide your account value by $1,000 (for example, an $8,600 account value divided by $1,000 = 8.6), then multiply the result by the number in the table under the heading entitled “Expenses Paid During Period” to estimate the expenses you paid on your account during this period.

Hypothetical Example for Comparison Purposes

The “Hypothetical” columns in the table below provide information about hypothetical account values and hypothetical expenses based on the Eventide Core Bond Fund’s, Eventide Exponential Technologies Fund’s, Eventide Global Dividend Opportunities Fund’s, Eventide Gilead Fund’s, Eventide Healthcare & Life Sciences Fund’s, Eventide Limited-Term Bond Fund’s and Eventide Multi-Asset Income Fund’s actual expense ratio and an assumed rate of return of 5% per year before expenses, which is not the Funds’ actual returns. The hypothetical account values and expenses may not be used to estimate the actual ending account balances or expenses you paid for the period. You may use this information to compare this 5% hypothetical example with the 5% hypothetical examples that appear in the shareholder reports of other funds.

Please note that the expenses shown in the table are meant to highlight your ongoing costs only and do not reflect any transactional costs, such as sales charges (loads), or redemption fees. Therefore, the table is useful in comparing ongoing costs only, and will not help you determine the relative total costs of owning different funds. In addition, if these transactional costs were included, your costs would have been higher.

E V E N T I D E		112

S E M I - A N N U A L R E P O R T

December 31, 2020

Hypothetical Example for Comparison Purposes

								Hypothetical
		Actual						(5% return before expenses)
		Beginning		Ending		Expenses		Beginning		Ending		Expenses
	Funds’ Annualized	Account Value		Account Value		Paid During		Account Value		Account Value		Paid During
	Expense Ratio	7/31/20		12/31/20		Period ¹		7/1/20		12/31/20		Period ²
Eventide Core Bond Fund - Class N	0.77%	$	1,000.00	$	996.40	$	3.22	$	1,000.00	$	1,021.32	$	3.92
Eventide Core Bond Fund – Class A	0.82%		1,000.00		996.50		4.13		1,000.00		1,021.07		4.18
Eventide Core Bond Fund – Class C	1.57%		1,000.00		994.20		6.56		1,000.00		1,017.29		7.98
Eventide Core Bond Fund – Class I	0.57%		1,000.00		997.10		2.38		1,000.00		1,022.34		2.90

Expenses are equal to the average account value over the period, multiplied by the Funds’ annualized expense ratio, multiplied by the number of days in the period (153) divided by the number of days in the fiscal year (365).

Expenses are equal to the average account value over the period, multiplied by the Funds’ annualized expense ratio, multiplied by the number of days in the period (184) divided by the number of days in the fiscal year (365).

Hypothetical Example for Comparison Purposes

								Hypothetical
		Actual						(5% return before expenses)
		Beginning		Ending		Expenses		Beginning		Ending
	Funds’ Annualized	Account Value		Account Value		Paid During		Account Value		Account Value
	Expense Ratio	7/1/20		12/31/20		Period¹		7/1/20		12/31/20
Eventide Dividend Opportunities Fund - Class N	1.15%	$	1,000.00	$	1,272.80	$	6.59	$	1,019.41	$	5.85
Eventide Dividend Opportunities Fund – Class A	1.20%		1,000.00		1,272.90		6.87		1,019.16		6.11
Eventide Dividend Opportunities Fund – Class C	1.95%		1,000.00		1,267.10		11.14		1,015.38		9.91
Eventide Dividend Opportunities Fund – Class I	0.95%		1,000.00		1,274.30		5.45		1,020.42		4.84
Eventide Exponential Technologies Fund - Class N	1.63%		1,000.00		1,579.70		10.60		1,016.99		8.29
Eventide Exponential Technologies Fund – Class A	1.68%		1,000.00		1,579.70		10.92		1,016.74		8.54
Eventide Exponential Technologies Fund – Class C	2.43%		1,000.00		1,575.70		15.78		1,012.96		12.33
Eventide Exponential Technologies Fund – Class I	1.43%		1,000.00		1,581.70		9.31		1,018.00		7.27
Eventide Gilead Fund – Class N	1.31%		1,000.00		1,349.80		7.75		1,018.61		6.66
Eventide Gilead Fund – Class A	1.36%		1,000.00		1,349.70		8.05		1,018.36		6.91
Eventide Gilead Fund – Class C	2.11%		1,000.00		1,344.30		12.47		1,014.57		10.71	��
Eventide Gilead Fund – Class I	1.11%		1,000.00		1,351.50		6.57		1,019.62		5.64
Eventide Healthcare & Life Sciences Fund – Class N	1.45%		1,000.00		1,302.60		8.43		1,017.88		7.39
Eventide Healthcare & Life Sciences Fund – Class A	1.50%		1,000.00		1,301.90		8.72		1,017.63		7.64
Eventide Healthcare & Life Sciences Fund – Class C	2.25%		1,000.00		1,297.10		13.04		1,013.86		11.43
Eventide Healthcare & Life Sciences Fund – Class I	1.25%		1,000.00		1,303.80		7.27		1,018.89		6.37
Eventide Limited-Term Bond Fund – Class N	0.75%		1,000.00		1,010.30		3.80		1,021.42		3.82
Eventide Limited-Term Bond Fund – Class A	0.80%		1,000.00		1,010.10		4.05		1,021.17		4.08
Eventide Limited-Term Bond Fund – Class C	1.55%		1,000.00		1,006.50		7.84		1,017.39		7.88
Eventide Limited-Term Bond Fund – Class I	0.55%		1,000.00		1,010.90		2.79		1,022.43		2.80
Eventide Multi-Asset Income Fund – Class N	1.02%		1,000.00		1,172.90		5.59		1,020.06		5.19
Eventide Multi-Asset Income Fund – Class A	1.07%		1,000.00		1,172.70		5.86		1,019.81		5.45
Eventide Multi-Asset Income Fund – Class C	1.82%		1,000.00		1,168.10		9.95		1,016.03		9.25
Eventide Multi-Asset Income Fund – Class I	0.82%		1,000.00		1,173.90		4.49		1,021.07		4.18

E V E N T I D E		113

S E M I - A N N U A L R E P O R T

December 31, 2020

Eventide Funds
Additional Information (Unaudited)	December 31, 2020

Reference is made to the Prospectus and the Statement of Additional Information for more detailed descriptions of the Management Agreement, Services Agreement and Distribution and/or Service (12b-1) Plan, tax aspects of each Fund and the calculation of the net asset value of shares of each Fund.

Funds file a complete schedule of portfolio holdings with the Securities and Exchange Commission (the “SEC”) for the first and third quarters of each fiscal year as an exhibit to its reports on Form N-PORT, within sixty days after the end of the period. Form N-PORT reports are available at the SEC’s website at www.sec.gov. The information on Form N-PORT is available without charge, upon request, by calling 1-877-771-3836.

Information regarding how each Fund voted proxies relating to portfolio securities during the twelve month period ended June 30 as well as a description of the policies and procedures that each Fund uses to determine how to vote proxies relating to portfolio securities is available without charge, upon request, by calling 1-877-771-3836; and on the Commission’s website at http://www.sec.gov

E V E N T I D E		114

S E M I - A N N U A L R E P O R T

December 31, 2020

Eventide Funds
Supplemental Information (Unaudited)	December 31, 2020

The Funds have adopted and implemented a written liquidity risk management program as required by Rule 22e-4 (the “Liquidity Rule”) under the Investment Company Act. The program is reasonably designed to assess and manage the Funds’ liquidity risk, taking into consideration, among other factors, the Funds’ investment strategies and the liquidity of their portfolio investments during normal and reasonably foreseeable stressed conditions; its short and long-term cash flow projections; and its cash holdings and access to other funding sources.

During the six months ended December 31, 2020, the Board and the Trust’s Liquidity Risk Management Program Committee (the “Committee”) reviewed the Funds’ investments and they determined that the Funds held adequate levels of cash and highly liquid investments to meet shareholder redemption activities in accordance with applicable requirements. Accordingly, the Board and Committee concluded that (i) the Funds’ liquidity risk management program is reasonably designed to prevent violations of the Liquidity Rule and (ii) the Funds’ liquidity risk management program has been effectively implemented.

E V E N T I D E		115

S E M I - A N N U A L R E P O R T

December 31, 2020

Privacy Notice
Mutual Fund Series Trust Revised July 2017	1 of 2

FACTS

WHAT DOES MUTUAL FUND SERIES TRUST DO WITH YOUR PERSONAL INFORMATION?

Why?

Financial companies choose how they share your personal information. Federal law gives consumers the right to limit some, but not all sharing. Federal law also requires us to tell you how we collect, share, and protect your personal information. Please read this notice carefully to understand what we do.

What?

The types of personal information we collect and share depends on the product or service that you have with us. This information can include:

■ Social Security number and wire transfer instructions

■ account transactions and transaction history

■ investment experience and purchase history

When you are no longer our customer, we continue to share your information as described in this notice.

How?

All financial companies need to share customers’ personal information to run their everyday business. In the section below, we list the reasons financial companies can share their customers’ personal information; the reasons Mutual Fund Series Trust chooses to share; and whether you can limit this sharing.

Reasons we can share your personal information:	Does Mutual Fund Series Trust share information?	Can you limit this sharing?

For our everyday business purposes such as to process your transactions, maintain your account(s), respond to court orders and legal investigations, or report to credit bureaus.	YES	NO

For our marketing purposes to offer our products and services to you.	NO	We don’t share

For joint marketing with other financial companies.	NO	We don’t share

For our affiliates’ everyday business purposes - information about your transactions and records.	NO	We don’t share

For our affiliates’ everyday business purposes - information about your credit worthiness.	NO	We don’t share

For our affiliates to market to you	NO	We don’t share

For non-affiliates to market to you	NO	We don’t share

E V E N T I D E		116

S E M I - A N N U A L R E P O R T

December 31, 2020

Privacy Notice
Mutual Fund Series Trust Revised July 2017	2 of 2

What we do:
How does Mutual Fund Series Trust protect my personal information?	To protect your personal information from unauthorized access and use, we use security measures that comply with federal law. These measures include computer safeguards and secured files and buildings. Our service providers are held accountable for adhering to strict policies and procedures to prevent any misuse of your nonpublic personal information.
How does Mutual Fund Series Trust collect my personal information?	We collect your personal information, for example, when you ■ open an account or deposit money ■ direct us to buy securities or direct us to sell your securities ■ seek advice about your investments We also collect your personal information from others, such as credit bureaus, affiliates, or other companies.
Why can’t I limit all sharing?	Federal law gives you the right to limit only: ■ sharing for affiliates’ everyday business purposes – information about your creditworthiness. ■ affiliates from using your information to market to you. ■ sharing for non-affiliates to market to you. State laws and individual companies may give you additional rights to limit sharing.

Definitions
Affiliates	Companies related by common ownership or control. They can be financial and non-financial companies. ■ Mutual Fund Series Trust does not share with affiliates.

Non-affiliates	Companies not related by common ownership or control. They can be financial and non-financial companies. ■ Mutual Fund Series Trust doesn’t share with non-affiliates so they can market to you.

Joint marketing	A formal agreement between nonaffiliated financial companies that together market financial products or services to you. ■ Mutual Fund Series Trust doesn’t jointly market.

QUESTIONS?	Call 1-844-223-8637

E V E N T I D E		117

S E M I - A N N U A L R E P O R T

December 31, 2020

MUTUAL FUND SERIES TRUST

4221 North 203rd Street, Suite 100

Elkhorn, NE 68022

MANAGER

Eventide Asset Management, LLC

One International Place

Suite 4210

Boston, MA 02110

ADMINISTRATOR

Gemini Fund Services, LLC

4221 North 203rd Street, Suite 100

Elkhorn, NE 68022

TRANSFER AGENT

Gemini Fund Services, LLC

4221 North 203rd Street, Suite 100

Elkhorn, NE 68022

INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

BBD, LLP

1835 Market Street

3rd Floor

Philadelphia, PA 19103

LEGAL COUNSEL

Thompson Hine LLP

41 South High Street

Suite 1700

Columbus, OH 43215

CUSTODIAN BANK

U.S. Bank

1555 N. Rivercenter Drive.

Suite 302

Milwaukee, WI 53212

E V E N T I D E		118

Item 2. Code of Ethics.

Not applicable for semi-annual reports.

Item 3. Audit Committee Financial Expert.

Not applicable for semi-annual reports.

Item 4. Principal Accountant Fees and Services.

Not applicable for semi-annual reports.

Item 5. Audit Committee of Listed Companies. Not applicable to open-end investment companies.

Item 6. Schedule of Investments. See Item 1.

Item 7. Disclosure of Proxy Voting Policies and Procedures for Closed-End Funds. Not applicable to open-end investment companies.

Item 8. Purchases of Equity Securities by Closed-End Management Investment Company and Affiliated Purchasers. Not applicable to open-end investment companies.

Item 9. Submission of Matters to a Vote of Security Holder. None.

Item 10. Submission of Matters to a Vote of Security Holder. None.

Item 11. Controls and Procedures.

(a)

The registrant's principal executive and principal financial officers, or persons performing similar functions, have concluded that the registrant's disclosure controls and procedures (as defined in Rule 30a-3(c) under the 1940 Act, are effective, as of a date within 90 days of the filing date of this report, based on the evaluation of these controls and procedures required by Rule 30a-3(b) under the 1940 Act and Rule 15d-15(b) under the Securities Exchange Act of 1934, as amended.

(b)

There were no changes in the registrant's internal control over financial reporting (as defined in Rule 30a-3(d) under the 1940 Act) that occurred during the period covered by this report that have materially affected, or are reasonably likely to materially affect, the registrant's internal control over financial reporting.

Item 12. Disclosure of Securities Lending Activities For Closed-End Management Investment Companies. Not applicable to open-end investment companies.

Item 13. Exhibits

Code of Ethics for Principal Executive and Senior Financial Officers is attached hereto.

Certifications pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 are filed herewith.

Certifications pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 are filed herewith.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934 and the Investment Company Act of 1940, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Mutual Fund Series Trust

By Jerry Szilagyi	/s/ Jerry Szilagyi
President,
Date: 3/10/2021

Pursuant to the requirements of the Securities Exchange Act of 1934 and the Investment Company Act of 1940, this report has been signed below by the following person on behalf of the registrant and in the capacities and on the date indicated.

By Jerry Szilagyi	/s/ Jerry Szilagyi ___________
President
Date: 3/10/2021

By Erik Naviloff	/s/ Erik Naviloff_____________
Treasurer
Date: 3/10/2021

Mutual Fund Series Trust N-CSRSCertified semi-annual shareholder report (management investment company)